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Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease predominantly 
affecting adult women with a male to female ratio of 1:9. In the general population, the 
incidence of pSS is estimated at 3-11 per 100.000 individuals and the prevalence at 0.01% 
- 0.72%1-4 The disease is characterized by chronic lymphocytic inflammation of the exocrine 
glands, particularly the salivary and lacrimal glands. This chronic inflammation with 
concomitant destruction and loss of functional glandular tissue leads to sicca complaints 
pSS patients most present with. Besides these characteristic dryness complaints of the 
eyes and mouth, pSS regularly affects other organ systems leading to a diversity of other 
signs and symptoms. Fatigue is one of the most important disabling complaint affecting 
the majority (70%) of pSS patients.5,6 Primary Sjögren differs from secondary Sjögren (sSS). 
In sSS another autoimmune disease is present, most commonly rheumatoid arthritis or 
systemic lupus erythematosus.7 
Histopathology
Histopathologically, the chronic inflammation is seen as a focal lymphocytic sialadenitis. 
This pattern involves foci (clusters of ≥50 lymphocytes, Figure 1A) which are predominantly 
located around the striated ducts. A salivary gland biopsy is considered positive for pSS 
if the focus score (FS), calculated by the number of foci per 4mm2 glandular parenchyma, 
is equal to or greater than 1.8,9 The strong association of the lymphocytes with the ductal 
epithelium is further emphasized by the formation of lymphoepithelial lesions (LELs). LELs 
are currently defined as a cross section of a striated duct with infiltration of lymphocytes 
within the contour of the basement membrane with additional hyperplasia of the epithelial 
cell lining (Figure 1B).10 These LELs are a characteristic feature in the salivary gland biopsies 
of pSS patients.9,11 
Besides foci and LELs, a relative increase in IgG expressing plasma cells and thus 
a relative decrease in IgA expressing plasma cells is a distinctive feature of pSS related 
histopathology. The relative decrease of IgA expressing plasma cells is due to the influx 
or local production of mainly IgG and to a lesser extend IgM expressing plasma cells 
(Figure 1C).12,13 The threshold value for pSS was set by Bodeutsch et al.14 at ≤70% IgA 
expressing plasma cells in labial gland biopsies. This relative decrease in IgA expressing 
plasma cells appeared to be more sensitive and more disease specific than the FS in 
labial gland biopsies.14-16 In parotid gland biopsies, routinely taken at the University 
Medical Center Groningen (UMCG), the percentages of IgA, IgG and IgM expressing 
plasma cells are examined (besides FS and LELs) as well. Although not validated yet, 
the same threshold value of ≤70% IgA expressing plasma cells is used for parotid gland 
biopsies.
14
Another histopathological feature which can be found in about a quarter of the 
salivary gland biopsies of pSS patients are germinal centers (GCs), developing within the 
lymphoid infiltrates.17 Although GCs are not considered a diagnostic feature,9 pSS patients 
who exhibit GCs in their labial salivary gland biopsy are characterized by a more active 
disease as reflected by higher FS, more frequent expression of auto-antibodies and the 
presence of higher levels of pro-inflammatory cytokines and chemokines.17 
A B C 
Figure 1: Histopathological changes in parotid gland biopsies of pSS patients.
The examples are all from parotid gland tissue. A) Periductal focus surrounded by unaffected parenchyma. B) 
Centrally located duct forming a lymphoepithelial lesion (LEL) within a focus. C) Dual staining for IgA and IgG 
expressing plasma cells, showing a decrease of <70%IgA expressing plasma cells. Figure from Kroese, Haacke 
et al.9
B-cell hyperactivity 
The immunopathogenesis of pSS is complex and not fully elucidated. The assumption is 
that (T-cell dependent) B-cell hyperactivity plays a major role in pSS development. This 
B-cell hyperactivity is amongst others reflected in pSS by elevated serum levels of IgG, 
the presence of autoantibodies (SSA/Ro, SSB/La, rheumatoid factor) and increased levels 
of B-cell associated cytokines and chemokines.18 The many pathways involved in B-cell 
hyperactivity of pSS patients are all possible targets for treatment. 
The initial trigger for the auto-immune inflammatory response seen in pSS is not 
known, although it is presumed that activation of the ductal epithelial cells (through 
Toll-like receptors, by virus particles19) leads to the production of type I interferons (IFN), 
IL6, BAFF and pro-inflammatory cytokines and chemokines, eventually leading to B-cell 
activation and proliferation.20,21 
The inflammation of salivary glands starts with an influx of (predominantly activated 
CD4+) T-cells. The cells are mainly attracted through their CXCR3 receptor towards the 
glands by the chemokine CXCL10. The expression of CXCL10 by the epithelial cells, 
fibroblasts and monocytes is driven by IFN.22 Indeed, early pSS patients show the highest 
levels of CXCL10 in their saliva.23 As (activated and memory) B-cells and plasma cells also 
15
1can express CXCR3, a portion of B-cells can be attracted towards the salivary gland by this pathway.24 At later stages, other (non-CXCR3-expressing) B-cells are also recruited 
to the salivary glands of pSS patients by the chemokine CXCL13 through binding to their 
chemokine receptor CXCR5. Also this chemokine is increased in the salivary glands, saliva 
and tears of pSS patients.25 In addition to T- and B-cells, also non-lymphoid cells (myeloid 
and plasmacytoid dendritic cells and FDCs) are found in the glandular infiltrates. Thus, all 
components for the formation of ectopic lymphoid tissue are present. 
MALT lymphoma 
The B-cell hyperactivity is further illustrated by the presence of clonally expanded B-cells 
and plasma cells within the salivary glands of pSS patients.26,27 Neoplastic transformation 
of these clonal B-cells can occur, leading to malignant non-Hodgkin’s lymphomas (NHL). 
This serious complication of pSS develops in 5-10% of pSS patients. The lymphomas that 
develop are predominantly of the mucosa-associated lymphoid tissue (MALT) type.18,28-30 
The preferential location of these lymphomas is the parotid gland. These parotid MALT 
lymphomas are considered to be indolent neoplasia, but progression to an aggressive 
diffuse large B-cell lymphoma (DLBCL) may occur.31 Clinical and laboratory markers 
to identify pSS patients at risk for lymphoma development are, amongst others, high 
disease activity, purpura, lymphoadenopathy, persistent parotid enlargement, Raynaud 
phenomenon, low C4, anti-SSA and/or rheumatoid factor positivity and the presence of 
cryoglobulin and aberrant free κ/λ light chain ratio’s.32-37 Nevertheless, a substantial portion 
(31%) of the pSS associated MALT lymphomas is detected by a parotid gland biopsy during 
the standard diagnostic work-up for pSS at the UMCG, without any clinical suspicion.38 
Currently, there are discrepant data whether GCs in labial gland biopsies are also a risk 
factor for non-Hodgkin’s lymphoma (NHL) development in pSS patients.9,39,40
Diagnosis of pSS 
The most common and classic complaints in pSS are keratoconjunctivitis and xerostomia.41 
In about half of the pSS patients extra glandular manifestations are also present, which 
can affect most organ systems.42 Disease activity of pSS patients can be assessed by the 
EULAR-Sjögren’s Syndrome Disease Activity Index (ESSDAI). The ESSDAI encompasses 12 
domains (cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, 
central nervous system, hematological, glandular, constitutional, lymphadenopathic, 
biological) which are scored separately. The sum of this score distinguishes pSS patients 
with a low disease activity (ESSDAI<5), moderate disease activity (5≤ESSDAI≤13) and a high 
disease activity (ESSDAI≥14).43,44 
Furthermore, the majority of pSS patients experience fatigue besides sicca complaints, 
which reduces their quality of life.45,46 The wide variety of complaints in pSS patients makes 
the diagnosis of pSS challenging. For classifying patients as pSS or non-pSS, the American 
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College of Rheumatology/European League Against Rheumatology (ACR-EULAR) criteria are 
currently leading (Table 1).47 In these classification criteria, the presence of auto-antibodies 
against SSA and/or a positive salivary gland biopsy (FS≥1) are major items. The prominent 
position of the salivary gland biopsy makes uniform and precise histopathological evaluation 
crucial. Without a positive biopsy or auto-antibodies against SSA, a patient cannot be 
classified as pSS. One should keep in mind that these criteria are classification criteria and 
that each individual patient should be carefully and thoroughly examined by an experienced 
rheumatologist and other specialists such as ophthalmologists, specialists in oral medicine, 
and oral and maxillofacial surgeons to give a correct diagnosis of pSS. In other words, a 
patient cannot match classification criteria, but can clinically still be diagnosed as suffering 
from pSS. The diversity of the symptoms in pSS patients combined with the slow onset of 
complaints may cause delay in the diagnosis of pSS. An early diagnosis is important for pSS 
patients to start early treatment to prevent complications of the disease.48 
Treatment of pSS 
Until recently, therapy with traditional disease-modifying anti-rheumatic drugs (DMARDs) 
showed limited results and treatment of pSS patients was mainly focused upon reducing 
dryness complaints.49,50 With the progress of knowledge of the immunopathogenesis of pSS, 
new targets for treatment and intervention have emerged. Today, there are many specific 
drugs influencing the pathogenesis of pSS and most (experimental) medications target the 
B-cells or signaling pathways involved in the formation, activation and expansion of (auto-
reactive) B-cells. Various biological DMARDs are currently tested and numerous trials are 
running.51 For the primary endpoints of these biological therapeutics in pSS patients, the 
ESSDAI or the Sjögren’s Syndrome Response Index (SSRI) are frequently used.52-55 
An open label study with Epratuzumab (anti-CD22) showed an improvement in fatigue 
VAS, Schirmer test and stimulated whole saliva flow.56 CD22 is a receptor on B-cells, 
and binding of Epratuzumab to these receptors could lead to less B-cell activation and 
downregulation of the B-cell receptor. Belimumab targets the B-cells by binding to soluble 
BAFF (BLyS) preventing the interaction of BAFF to its receptors on B-cells. In this manner 
the survival of B-cells, their maturation and differentiation towards immunoglobulin 
secreting plasma is hindered.57,58 BAFF is amongst others expressed by salivary gland 
ductal cells, B- and T-cells, dendritic cells and levels of BAFF in serum of pSS patients 
correlate with auto-antibody production.59-62 Treatment of patients with anti-BAFF (BELISS 
open-label phase II study) showed a response in 60% (18/30) of pSS patients based upon 
the SSRI-30 (Sjögren’s Syndrome Responder Index-30) and 15/30 (50%) upon ESSDAI ≥3 
points at week 28.63 Directly targeting B-cells and as a consequence B-cell hyperactivity 
is rituximab (anti-CD20). Rituximab binds to CD20+ pre- and mature B-cells resulting in 
depletion of B-cells. Plasma cells are not targeted due to their lack of CD20 expression.64 
In pSS patients treatment with rituximab showed variability in efficacy. Although minor 
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1trials were successful,
65,66 two major placebo-controlled randomized controlled trials 
(RCT) with rituximab did not meet their primary endpoint.67,68 However, these negative 
results cannot disregard that treatment with rituximab showed beneficial effects on B-cell 
activity, fatigue, extra glandular symptoms and restoration of the glandular epithelium in 
the parotid glands.69,70 
Table 1: ACR-EULAR classification criteria for pSS 
American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) classification criteria for 
primary Sjögren’s syndrome: The classification of primary Sjögren’s syndrome (SS) applies to any individual who 
meets the inclusion criteria,* does not have any of the conditions listed as exclusion criteria,† and has a score 
of ≥4 when the weights from the five criteria items below are summed. From the publication of Shiboski et al.47
Item Weight /score
Labial salivary gland with focal lymphocytic sialadenitis and focus score of ≥1 foci/4 mm2‡ 3
Anti-SSA/Ro-positive 3
Ocular Staining Score ≥5 (or van Bijsterveld score ≥4) in at least one eye§¶ 1
Schirmer’s test ≤5 mm/5 min in at least one eye§ 1
Unstimulated whole saliva flow rate ≤0.1 mL/min§** 1
*These inclusion criteria are applicable to any patient with at least one symptom of ocular or oral dryness, defined 
as a positive response to at least one of the following questions:
1) Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2) Do you have a recurrent sensation of sand or gravel in the eyes? 
3) Do you use tear substitutes more than three times a day? 
4) Have you had a daily feeling of dry mouth for more than 3 months? 
5) Do you frequently drink liquids to aid in swallowing dry food? 
Or in whom there is suspicion of Sjögren’s syndrome (SS) from the European League Against Rheumatism SS 
Disease Activity Index (ESSDAI) questionnaire (at least one domain with a positive item).
†Exclusion criteria include prior diagnosis of any of the following conditions, which would exclude diagnosis of 
SS and participation in SS studies or therapeutic trials because of overlapping clinical features or interference 
with criteria tests: 
1) History of head and neck radiation treatment, 




6) Graft-versus-host disease, 
7) IgG4-related disease.
‡The histopathologic examination should be performed by a pathologist with expertise in the diagnosis of focal 
lymphocytic sialadenitis and focus score count, using the protocol described by Daniels et al.74
§Patients who are normally taking anticholinergic drugs should be evaluated for objective signs of salivary 
hypofunction and ocular dryness after a sufficient interval without these medications in order for these 
components to be a valid measure of oral and ocular dryness.
¶Ocular Staining Score described by Whitcher et al.75 van Bijsterveld score described by van Bijsterveld.76
**Unstimulated whole saliva flow rate measurement described by Navazesh and Kumar.77
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Another biological DMARD is abatacept, which blocks CD28-mediated co-stimulation 
of T-cells. In a phase II open label trial of 15 pSS patients, abatacept showed clinical efficacy 
based upon decline in ESSDAI of 3 or more points.66 Machado et al.71 confirmed a decline 
in ESSDAI after 24 months of abatacept treatment in a prospective observational study. 
Unfortunately, a placebo-controlled RCT showed no significant change in ESSDAI was seen 
after 24 weeks of treatment, although a significant change in ESSDAI was present at week 
12 (van Nimwegen et al., manuscript accepted for publication in Rheumatology). A second 
multicenter trial showed similar results, no significant decrease was seen in ESSDAI at day 
169 (±24 weeks).72 
Although B-cell hyperactivity is a hallmark in pSS pathogenesis, the described B-cell 
targeted therapies do not fully resolve pSS related complaints in all pSS patients. The 
population of pSS patients is diverse and within clinical trials subgroups of pSS do 
benefit from the given therapy. The focus should therefore not be solely on pSS patients 
in general, but more on personalized medicine: which pSS patients benefit from which 
specific treatment options. 
Regardless whether the primary endpoint of a clinical trial is reached, pre,- and 
post-treatment salivary gland biopsies may provide insight in the pathogenesis of pSS. 
Furthermore, standardized histopathological evaluation of biopsies may provide rationale 
for effectiveness based treatment decisions, which may eventually lead to personalized 
treatment of pSS patients.
Scope of the thesis 
The overall theme of this thesis is salivary gland histopathology in pSS patients. 
Part 1: Salivary gland histopathology
To diagnose pSS, a salivary gland biopsy is routinely taken. Traditionally a labial gland 
biopsy is performed and this is still common practice in most hospitals these days. In 
chapter 2 we present the parotid gland biopsy as an alternative to the labial gland biopsy. 
The histopathological evaluation is the same for the labial and parotid gland biopsy. For 
both these biopsies, there is disagreement in the literature on how to detect glandular 
GCs. In chapters 3a, 3b and 3c the optimal method for GC detection is assessed. The 
recognition of GCs can be difficult on general HE-stained sections. GCs can be easily 
overlooked and occluded LELs can be mistaken for GCs. We investigated whether 
additional immunohistochemical markers, such as BCl6, can aid in the correct detection 
of GCs. Furthermore, it is advocated in these chapters that uniformity of the detection of 
GCs is needed to assess their clinical relevance. 
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1Part 2: Germinal centers and MALT lymphoma in biopsies of primary Sjögren’s syndrome patients 
Patients with pSS are at risk for developing NHL, especially low grade MALT lymphomas 
located within the parotid glands. Falini et al.73 demonstrated that marginal zone 
lymphomas and a subset of DLBCL express FcRL4. In chapter 4 we investigated whether 
also pSS associated parotid MALT lymphomas express FcRL4. The expression of FcRL4 
within the salivary gland tissue (parotid and labial) of non-lymphomas pSS patients 
was further examined and the hypothesis that FcRL4+ B-cells play a major part in pSS 
lymphomagenesis is discussed. 
In chapter 5 the association of intra-epithelial B-lymphocytes in the formation of LELs 
is explored. In this study the number of B-cells and B-cell/T-cell ratio in the striated ducts 
of labial and parotid gland biopsies taken from pSS and non-pSS sicca patients is scored 
and correlated with the severity of the LELs. 
The predictive value of GCs in labial gland biopsies, specifically for parotid MALT 
lymphoma development, is examined in chapter 6a. In this study the presence of GCs 
in diagnostic biopsies taken prior to lymphoma development are compared with the 
presence of GCs in a matched control cohort with a long lymphoma free follow-up. In 
chapter 6b the occurrence of GCs in biopsies taken prior to NHL in general, including 
MALT lymphomas is further explored in relation to disease activity of pSS patients. 
Part 3: Histopathological changes after biological treatment 
Treatment of pSS patients with biological DMARDs shows promising clinical effects. As 
the salivary glands are the prime targets of the autoimmune inflammatory process, 
the changes within the glandular tissue are important in assessing the results of these 
treatment options. In chapter 7a the effect of rituximab treatment on the glandular 
tissue of the parotid gland is analyzed, and possible histopathological markers to predict 
responsiveness to rituximab treatment are presented. In chapter 7b the use of different 
clinical outcome measures (ESSDAI vs SSRI) and different methods of histopathological 
assessment in clinical trials with rituximab in pSS patients are analyzed. In chapter 8, the 
effect of blocking T-cell dependent B-cell activation by abatacept treatment on the parotid 
gland histopathology in pSS patients is assessed.
General discussion 
The importance of salivary gland histopathology in pSS patients is discussed in 
chapter 9. This chapter describes the role of histopathology as a diagnostic tool, the 
role of histopathology as predictor of disease severity and lymphomagenesis with special 
emphasis on GCs, and the role of histopathology in evaluating clinical trials. 
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Salivary gland biopsy is a technique broadly applied for the diagnosis of Sjögren’s syndrome 
(SS), lymphoma in SS, and connective tissue disorders (sarcoidosis, amyloidosis). In SS 
characteristic histology findings are found including lymphocytic infiltration surrounding 
the excretory ducts in combination with destruction of acinar tissue. In this article the 
main techniques are described for taking labial and parotid salivary gland biopsies with 
respect to their advantages, postoperative complications and usefulness for diagnostic 
procedures, monitoring disease progression and evaluation of treatment.
KEY POINTS
•	 In Sjögren’s diagnostics, parotid gland incision biopsies can overcome most 
disadvantages of minor salivary gland excision biopsies.
•	 Sensitivity and specificity of parotid and minor salivary gland biopsies for diagnosing 
Sjögren’s syndrome are comparable.
•	 Lymphoepithelial lesions and early stage lymphomas are easier to detect in parotid 
gland tissue of patients with Sjögren’s syndrome.
•	 In contrast to minor salivary glands, repeated biopsies of the same parotid gland are 
possible, which is an important asset in monitoring disease progression as well as in 
studying the efficacy of treatment at a glandular tissue level.
•	 Histopathologic results from the parotid gland can be compared with other diagnostic 
results derived from the same gland (sialometry sialochemistry, sialography, 




Salivary gland biopsy is a technique broadly applied in the diagnostic work-up of 
Sjögren’s syndrome (SS) as well as lymphoma accompanying SS, sarcoidosis, amyloidosis 
and other connective tissue disorders. A focus score ≥1 per 4 mm2 labial salivary 
gland tissue is considered as one of the four objective European-American Consensus 
Group classification criteria (AECG)1 and one of the three objective American College of 
Rheumatology provisional classification criteria (ACR)2 for SS. The focus scores reflects the 
number of infiltrates of ≥50 mononuclear inflammatory cells, predominantly lymphocytes, 
in a perivascular or periductal location, typically adjacent to normal acini, per 4 mm2 
salivary gland tissue.3,4 Also in the under construction consensus classification criteria of 
European League against Rheumatism (EULAR) and ACR, a labial focus score ≥1 will be 
maintained as a leading classification criterion.5 
Moreover, there are views that besides being of diagnostic value, labial salivary gland 
biopsies also may play a role in predicting lymphoma development6 as well as in monitoring 
disease and treatment efficacy.7-9 Recently, Fisher et al10 reviewed the labial salivary gland 
pathology that characterizes SS. They concluded that labial salivary gland biopsies offer 
a distinct potential as a biomarker in primary SS (pSS), particularly relevant to glandular 
involvement, and offer additional prognostic, stratification and mechanistic insights. They 
also added that precise value of a labial salivary gland biopsy is yet hard to determine in 
the absence of proven immunomodulatory therapies in pSS as well as that further work 
on validation and understanding the natural history is needed. 
In their review, Fisher et al10 briefly mentioned parotid biopsies as an alternative to 
labial salivary gland biopsies, but did not further state the advantages and disadvantages 
of parotid biopsies compared to labial salivary biopsies (Table 1).11,12 In this contribution we 
discuss the potential of parotid salivary gland biopsies as an alternative way to diagnose 
SS and also with emphasis of its added value in lymphoma diagnostics and rating disease 
progression and treatment efficacy.
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Ellipse of oral mucous membrane down to the muscle layer. Harvest of 6-8 
glands. Wound closure with 04 gauge silk sutures, which must be removed after 
four-five days. 
•	 Widely distributed glands
•	 Easily accessible glands
•	 Minimal chance of bleeding
•	 Germinal center like structures can be identified
•	 Localized, 6 – 10 % permanent, sensory alteration 
of the lips and skin in the mental region
•	 Internal scarring and cheloid formation
•	 Suture failingGreenspan et al,13 1974 1.5-2 cm linear incision of mucosa, parallel to the vermillion border and lateral to 
the midline
Marx et al,18 1988 Mucosal incision of 3x0.75 cm
Delgado and Moscueda,19 
1989
Longitudinal incision of 1 cm in the labial mucosa in front of the mandibular 
cuspids
Guevara-Gutierrez et al,58 
2001
Punch biopsy
Mahlsted et al,20 2002 1-1.5 cm wedge-shaped incision between the midline and commissure
Gorson and Ropper,59 
2003
1 cm vertical incision just behind the wet line through the mucosa and 
submucosa
Berquin et al,21 2006 Oblique incision, starting 1.5 cm from the midline and proceeding latero-inferiorly, 
avoiding the glandular free zone in the center of the lower lip
Caporali et al,22 2007 Small incision of 2-3 mm on the inner surface of the lower lip
Parotid gland 
Kraaijenhagen,25 1975
Markx et al,18 1988
McGuirt et al,60 2002
Baurmash et al,61 2005
Pijpe et al,11 2007
1-2 cm incision just below and behind the earlobe near the posterior angle 
of the mandible. The skin is incised and the parotid capsule is exposed by 
blunt dissection. The capsule of the gland is opened and adequate amount of 
superficial parotid tissue is removed, approximately 5 x 5 mm. The procedure is 
completed with a 2 to 3-layered closure 
•	 Presence of germinal centers
•	 Presence of LELs
•	 (Early) identification of MALT
•	 The same gland can be repeatable harvested
•	 Direct comparison with other diagnostic results 
derived from the same gland (e.g., secretory 
function, sialography, scintigrapy, ultrasound)
•	 Temporary change in sensory sensation of the skin 
in the area of the incision
•	 More demanding surgical expertise
Adam et al,62 1992
Berquin et al,21 2006
Mucosal incision 1 cm anterolarerally from the Whartonian duct to 1 cm 
anteroposteriorly. Blunt dissection and harvest of 0.5 cm3 of glandular tissue. The 
wound edges are joined with 1-2 resorbable stiches
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MINOR SALIVARY GLAND BIOPSY
Minor salivary glands are widely distributed in the labial, buccal and palatal mucosa of the 
oral cavity. Since pathognomonic changes are seen in minor salivary glands, labial salivary 
gland biopsy is largely used for assisting the diagnosis of SS.4,13,14
Surgical considerations 
Minor salivary glands, and labial salivary glands in particular, are easily accessible. The 
labial salivary glands lie above the muscle layer and branches of the mental nerve (labial 
sensory nerves), and are separated from the oral mucous membrane by a thin layer of 
fibrous connective tissue. Although the chance of excessive bleeding is minimal, since 
the arterial supply to the lip lies deep, there is a serious hazard of sensory nerve injury, 
as the labial sensory nerves are closely associated to the minor salivary glands (Figure 1). 
Figure 1: Association of the labial and parotid salivary glands with, respectively, the mental and facial nerve (after 
Delli et al 2015). 
A) The mental nerve has three branches: one branch supplying the skin of the chin and two branches supplying 
the skin and mucous membrane of the lower lip. The branch that supplies the mucous membrane usually has two 
sub-branches of which the vertical one has an ascending course toward the vermillion border and is in close relation 
to the labial salivary glands. B) The facial nerve enters the parotid gland forming a characteristic branching pattern 
that resembles a goose foot and is known as the pes anserinus. The parotid gland is divided into a superficial and 
deep lobe based on the course of the facial nerve as it passes through. In the area of the incisional biopsy of the 
parotid gland the distance between the surface of the parotid gland and the facial nerve is approximately 1.5 – 2 cm.
Labial salivary gland biopsies in the diagnosis of SS were introduced by Chisholm and 
Mason.3 The biopsies involve oral preparation of the patient with local anesthetic infiltration 
followed by excising an ellipse of oral mucous membrane down to the muscle layer. The 
wound was closed with 4-0 gauge silk sutures, which were removed after 4-5 days. Ideally 
6 to 8 minor glands are harvested and sent for histopathologic examination. 
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Several clinicians have revised the Chisholm and Mason technique. Currently, 
the approach of Greenspan et al13 and Daniels14 is mostly applied (Figure 2). This 
approach is described in detail on the SICCA website.15 In short, the biopsy has to be 
performed through the mucosa of the lower lip that appears normal clinically. After 
applying local anesthetics, the lip is everted to expose the mucosa. Next, a 1.0-1.5 
cm horizontal incision will be made to the right or left of the midline, approximately 
halfway between the vestibule and the vermilion border and halfway between the 
midline and the labial commissure. The lamina propria is bluntly dissected to release 
the minor salivary glands from lamina propria beyond the incision and to bring them 
into the operating field. Approximately 7 minor salivary glands should be removed to 
provide a minimum gland section area of 8-12 mm2 for microscopic focus scoring.10 
Finally, the mucosal incision margins are repositioned and sutured with 5-0 rapid 
absorbable (polyglactin/L-lactide acid) sutures (Figure 2).
Figure 2: Technique for harvesting labial salivary glands after infiltration of local anesthesia. 
A) A horizontal incision of approximately 1.0-1.5 cm is made on the mucosal site of the lip. Just the epithelium 
is incised. B) About 6 -8 labial salivary glands are harvested avoiding damage to the branches of the mental 
nerve. C) Wound closure with 5-0 rapid absorbable (polyglactin/L-lactide acid) sutures; inverted buried notches.
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Histologic grading 
The first grading system for salivary gland biopsies was employed by Chisholm and 
Mason3 in an attempt to standardize the examined area and record the degree of 
histopathological change. At present, according to the revised AECG and provisional 
ACR classification criteria for SS (and also in the recent ACR-EULAR classification under 
construction), a labial salivary gland biopsy is considered positive if the glands (obtained 
through normal appearing mucosa) demonstrate focal lymphocytic sialadenitis, evaluated 
by an expert histopathologist, with a focus score ≥1 (Figure 3). Diagnosis of nonspecific 
chronic sialadenitis, sclerosing chronic sialadenitis and granulamatous inflammation need 
to be excluded. A sufficient area of labial salivary gland tissue has to be examined as El-
Hashimi et al16 showed that focus score might differ on multiple sections taken from the 
same labial glands specimen.
Figure 3: Histopathology of the labial salivary glands of a patient with Sjögren’s syndrome which is characterized 
by lymphocytic infiltration (*) of the excretory ducts and destruction of the acini, and fulfilling the criterion of a 
focus score ≥1.
Complications
Complications of labial salivary gland biopsies include localized (permanent) sensory 
alteration of the lip, external haematoma, local swelling, formation of granulomas, internal 
scarring and cheloid formation, failing sutures and local pain.11,13,14,17-24 The localized sensory 
alterations are frequently described with the terms anesthesia, reduced or partial loss of 
sensation, transitory numbness and hypoesthesia. These localized sensory alterations 
of the vermillion border of the lower lip mucosa may last for a few months, but can be 





The parotid gland is divided into a superficial and deep lobe based on the course of the 
facial nerve as it passes through (Figure 1). The technique of the parotid gland biopsy was 
initially described by Kraaijenhagen25 and modified by Pijpe et al11 (Figure 4). The parotid 
biopsy is performed in the superficial lobe area where the facial nerve is 1.5-2 cm below 
the surface of the gland. 
Figure 4: Technique of a parotid biopsy.
A) The skin below the ear lobe is infiltrated with local anesthesia. B) With a No 15 blade a small 1-2 cm incision 
is made just below and behind the earlobe near the posterior border of the ascending ramus of the mandible. 
C) The parotid capsule is exposed by blunt dissection after the skin incision. The capsule of the gland is carefully 
opened and a small amount of 5 x 5 x 5 mm superficial parotid tissue is removed. D) The procedure is completed 
with a 2 to 3-layered closure with 4-0 gauge absorbable sutures (polyglycolic acid), while the skin layer is closed 
with 5-0 nylon sutures. 
Surgical considerations
In short, the area in the region of the earlobe is anesthetized (auriculotemporal nerve) with 
0.5 ml local infiltration anesthesia followed by skin disinfection and standard preparation. 
With a No 15 knife-blade, a small 1-2 cm incision is made just below the earlobe near 
the posterior border of the mandible. The skin is incised and after blunt dissection of 
the subdermal tissue the parotid capsule is exposed, followed by carefully opening of 
36
the capsule and excision of the required amount of superficial parotid gland tissue for 
histopathologic review. The capsule of the parotid gland and subcutaneous layer is closed 
with 5-0 absorbable (polyglycolic acid) sutures, whereas the skin is closed with 5-0 nylon 
sutures (Figure 4). With this surgical approach there are no reports on development on 
sialoceles or fistula. For details see the instructional film. 
Histologic grading
Pijpe et al11 established a new set of validated histopathological criteria for diagnosing 
Sjögren’s syndrome in accordance with the AECG classification criteria based on biopsy of 
the parotid gland (Figure 5). A parotid biopsy is considered positive when it has a focus score 
of ≥1, defined as the number of lymphocytic foci (which are adjacent to normal-appearing 
acini and contain >50 lymphocytes) per 4  mm2 of glandular parotid tissue (including fat 
tissue; Figure 5A), irrespective of the presence of benign lymphoepithelial lesions (LEL; 
Figure 5B). LELs are a characteristic histological feature of the salivary, predominantly 
parotid, glands of SS patients. LELs form through basal cell hyperplasia forming a multi-
layered epithelium. Between these reactive ductal epithelial cells, lymphocytes are present. 
Figure 5: Histopathology of the parotid salivary glands of a patient with Sjögren’s syndrome. 
A) Focus B) Lymphoepithelial lesion
Complications
Potential complications of parotid salivary gland biopsies include the development of 
sialoceles and salivary fistulae, and a temporary change in sensation in the skin area of the 
incision,11,18 which are obvious due to the surgical opening of the skin and superficial gland 
area. As mentioned before, development on sialoceles or fistula has not yet been observed 
by us and is neither reported in the literature. The often mentioned potential risk of facial 
nerve damage is based on lack knowledge of anatomic and surgical skills as this nerve, 
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as also mentioned before, is 1.5-2 cm below the surface of the gland. The only reported 
complications are a temporary change in sensation in the skin area of the incision. No 
permanent complications are, however, documented in the literature.11,18,26 The level of 
post-operative pain accompanying a parotid gland biopsy is comparable to a lip biopsy.11
SUITABILITY OF SALIVARY GLAND BIOPSIES
Diagnostic 
As mentioned before, a labial salivary gland biopsy is considered as positive for SS when focal 
lymphocytic sialadenitis with a focus score ≥1 per 4 mm2 glandular tissue is present (Figure 
3). However, for proper interpretation of the biopsy specimens broad experience is needed 
as focal lymphocytic sialadenitis may occur in conjunction with other autoimmune diseases 
and even in healthy subjects, in particular in the elderly.27 Typically for pSS, the lymphocytic foci 
have to be adjacent to normal-appearing mucous acini and contain no more than a minority 
proportion of plasma cells. Furthermore, above a focus score of 10, foci are typical confluent 
and an arbitrary score of 12 is often applied for such biopsies.13,14 Other difficulties that may 
interfere with the interpretation of the biopsies are features more usually associated with 
non-specific chronic sialadenitis, such as acinar atrophy, interstitial fibrosis and duct dilatation. 
These features are relatively common and increase with age and may also coexist with pSS 
related focal lymphocytic sialadenitis.10,28 Replacement of glandular tissue with fibrotic tissue 
as a result of age and chronic salivary gland inflammation may lower the focus score and lead 
to a ‘burnt-out’ appearance.10,29 Moreover, it may be difficult to harvest a sufficient number of 
labial salivary glands in atrophic submucosa of patients with longstanding SS.30 
In contrast to labial glands, parotid salivary biopsies allow the clinician to monitor 
disease progression and to assess the effect of an intervention treatment in SS. This 
is feasible due to the fact that parotid tissue can be harvested relative easily, repeated 
biopsies from the same parotid gland are possible, and the histopathological results can 
be compared with other diagnostic results derived from the same gland (e.g., secretory 
function, sialographic appearance, scintigraphy, ultrasound, CT, MRI).31 Additionally, by 
performing parotid biopsies as a routine diagnostic procedure for SS, LELs and lymphomas 
located in the parotid gland can identified (see section on lymphoma).18,32 So, the question 
remains as to what biopsy should be preferred for diagnostics and/or monitoring disease 
progression and treatment efficacy.
Disease progression
There are only few studies that compared the diagnostic characteristics of major and 
minor salivary gland biopsies and even none that compared the ability of both biopsy 
types to monitor disease progression and treatment efficacy. Pijpe et al11 compared the 
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diagnostic ability of labial and parotid salivary gland biopsies in diagnosing pSS as well 
as compared their morbidity. They showed that the diagnostic sensitivity and specificity 
were identical. Moreover, the presence of characteristic benign LELs in the parotid 
gland can aid the diagnosis of SS. The observation that LELs are commonly present 
in parotid biopsies and are virtually absent in labial salivary gland biopsies was earlier 
confirmed by Pennec et al33 and Carbone et al.34 The incidence of germinal centers in 
the major and minor salivary gland biopsies is comparable.11 There is a need for larger 
studies comparing the diagnostic utility of labial and parotid salivary gland biopsies in 
the diagnostic work-up of SS emphasizing whether these procedures are exchangeable 
or that a specific biopsy type is preferred for a specific diagnostic issue regarding SS or 
SS-associated diseases.
Treatment evaluation purposes 
EULAR has developed a disease activity index (ESSDAI) and a patient reported index 
(ESSPRI) as validated outcome measures for SS.35-38 Although the development is an 
important advantage, ESSDAI focuses on systemic disease features and is so less 
relevant to patients with predominantly glandular features. The ESSPRI addresses the 
symptomatic components of dryness, pain and fatigue. The latter has an important 
impact on the quality of life, but might be susceptible to placebo effects or the impact of 
concomitant disorders leading to important implications for sample size. Thus, as posed 
by Fisher et al,10 an objective biomarker of glandular inflammation would therefore be 
desirable, and salivary gland biopsy has added advantage that it may offer insights into 
the mechanism of action of a novel agent, or more importantly, reasons for failure in a 
negative study. 
When comparing the potential application of labial and parotid salivary gland biopsies 
with regard to disease activity and progression, studies involving repeated labial salivary 
gland biopsies revealed that in patients presenting with sicca symptoms, a focus score 
≥1 was associated with antibodies to Ro and La, rheumatoid factor, antinuclear antibody 
and a lower unstimulated whole salivary flow rate.4,39,40 It also was shown that a higher 
focus score is accompanied by a larger decrease in unstimulated41 and stimulated42 whole 
salivary flow rate over time. Repeated labial salivary gland biopsies might have some value 
in assessing the effect of biologicals on the glandular level as labial salivary gland biopsies 
seems to be of added value in rating the efficacy of treatment with rituximab7, abatacept8 
or belimumab.9 It has to be mentioned, however, that not the same labial salivary glands 
are examined as a function of time, but a new sample of glands collected from the same 
patient bringing the hazard of the reproducibility of, e.g., a focus score in repeated sections 
from even the same labial salivary glands into mind.16 However, Kapsogeorgou et al43 
showed that the infiltration grade and prevalence of the major infiltrating cell types (T 
and B cells, macrophages, dendritic cells, natural killer cells) remained largely unchanged 
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during a median 55 month biopsy time interval follow-up (quartiles 42-81) indicating that 
the labial salivary gland histopathology is rather stable with time and probably does not 
readily reflects disease progression and/or disease activity. 
In contrast to labial salivary glands, repeated biopsies from the same parotid gland 
are possible, which is probably an important asset in studies assessing the efficacy of a 
treatment in SS patients or monitoring disease progression. Another important advantage 
is that the histopathological results can be compared with other diagnostic results derived 
from the same gland (secretory function, sialographic appearance, scintigraphy, ultrasound, 
CT, MRI). Moreover, as mentioned before, LELs are often observed in parotid gland 
tissue of SS patients and rarely in labial salivary gland tissue. These LELs, a characteristic 
histological feature of the major salivary glands in SS44, develop as a result of basal cell 
hyperplasia forming a multi-layered epithelium. Between these reactive ductal epithelial 
cells, lymphocytes are present.44
While features of labial salivary gland pathology have been associated with a variety of 
serological, clinical and imaging parameters, features of parotid salivary gland tissue are not 
yet associated with such parameters. However, currently a number of studies is underway 
assessing whether histopathologic features reflect changes in whole and glandular salivary 
flow, serum and salivary gland ultrasonography. First results will become available shortly 
indicating whether disease progression and disease activity are indeed accompanied 
by characteristic features at the level of parotid gland histopathology. With regard of 
parotid salivary gland tissue as a monitor of treatment efficacy more progress has been 
made. Pijpe et al31 showed in an open label trial that sequential parotid biopsy specimens 
obtained from patients with pSS before and after rituximab treatment demonstrated 
histopathologic evidence of reduced glandular inflammation and redifferentiation of 
lymphoepithelial duct lesions to regular striated ducts as a putative morphologic correlate 
of increased parotid flow and normalization of the salivary sodium content. Next, Delli 
et al45 assessed the prognostic value of parotid gland immunopathology with regard to 
responsiveness of patients with pSS to rituximab treatment in a randomized placebo 
controlled study. These investigators found a significant reduction in the number of CD20+ 
B-cells/mm2 parenchyma, while no reduction was observed in placebo-treated patients. 
Furthermore, the relative number and severity of LELs and germinal centers significantly 
reduced after rituximab treatment. Moreover, when comparing the baseline characteristics 
of clinical responders with non-responders to rituximab treatment, number of CD20+ 
B-cells/mm2 parenchyma was significantly higher in responders, which might predict the 
responsiveness of pSS patients to rituximab treatment. In addition, an open label study 
with abatacept46 showed that treatment did not affect focus score, area of lymphocytic 
infiltrate, and number of LELs, infiltrating B- and T-cells. Abatacept reduced, however, 
the presence of germinal centers (GC), which was associated with an improvement in 
the glandular domain (reduction in swelling) of the ESSDAI. Thus, abatacept appears to 
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inhibit local T-cell dependent B-cell activation in parotid gland tissue of pSS patients as 
witnessed by the decline in GC/mm2 after treatment. Furthermore the presence of GC at 
baseline predicts response in ESSDAI glandular domain after abatacept treatment. These 
observations have to be confirmed in a placebo controlled study, a study that is currently 
in progress.
SALIVARY GLAND BIOPSIES AND LYMPHOMAS 
Five to ten per cent of patients with SS develop malignant B cell lymphoma,47-49 48%–75% 
of which are of the MALT-type. These MALT B cell lymphomas are most frequently located 
in the parotid gland.50-52 Theander et al6 suggested that the presence of GC-like structures 
in pSS diagnostic labial salivary biopsies is highly predictive and easy-to-obtain marker for 
non-Hodgkin lymphoma development. They even posed that presence of these GC-like 
structures allows for risk stratification of patients and the possibility to initiate preventive 
B-cell-directed therapy. Later on, however, Johnsen et al53 were unable to detect a clear 
association between cellular infiltrates, B cell clonality, and lymphoma development in 
labial salivary gland biopsies. Our recent data indicate that presence of germinal centers 
in diagnostic (labial) biopsies is not a risk factor for the development of MALT lymphoma 
in the parotid glands.54 Since lymphomas in pSS patients mainly develop in parotid glands, 
taking parotid gland biopsies may be a great asset in both diagnosing pSS associated 
lymphomas as well as in titrating which therapy is needed.32 Quintana et al55 and De Vita 
et al56 mentioned that LELs and reactive lymphoid follicles, features that are common place 
in parotid salivary gland pathology of pSS patients, are indicative of malignant lymphoma, 
and thus benign LELs must be discriminated from (pre)malignant lesions. Haacke et al54 
looked with more detail into salivary gland biopsies of pSS patients with regard to LELs 
and observed that FcRL4+ B cells are in close association with LELs and that these FcRL4+ 
B cells are significantly increased when comparing the parotid gland to the labial gland. As 
MALT lymphomas, and a small subset of diffuse B cell lymphomas, express FcRL4,57 this 
observation might explain why lymphomas in pSS patients commonly develop in parotid 
and not in minor salivary glands and thus favors taking a parotid and not a labial salivary 





Early diagnosis and objective treatment evaluation of costly therapies based on biologicals 
are of high importance in SS. Unfortunately, so far there is not a single test capable 
of confirming the diagnosis of SS. A positive salivary gland biopsy is strong evidence, 
which in correlation with additional diagnostic tests can establish a definite conclusion. 
Parotid gland biopsy is a relatively simple technique with no permanent morbidity reported 
compared to a relative high morbidity rate of labial salivary gland biopsies due to the 
rather high hazard of permanent damage to the sensory nerve supply of the lower lip in 
the latter biopsies. Parotid biopsies are able to overcome most of these disadvantages.
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We have read with great interest the letter to the editor by van Roon et al.1 commenting 
to our paper ‘Towards personalised treatment in primary Sjögren’s syndrome: baseline 
parotid histopathology predicts responsiveness to rituximab treatment’.2 The authors 
argue that there is a need for standardisation of the histopathological characteristics of 
salivary gland tissue of patients with primary Sjögren’s syndrome (pSS), in general, and of 
the presence of germinal centres (GCs), in particular. 
We fully agree with van Roon et al.1 and other authors about the need for consensus 
guidelines to standardise the histopathological evaluation of salivary gland biopsies in 
patients with pSS.3 A standardised scoring system may facilitate prognostication and 
stratification of patients with pSS and is needed for a valid evaluation of various clinical 
trials.3 In particular, histological definition of GCs in salivary gland tissue is warranted, 
since these structures can be difficult to detect in diagnostic H&E-stained tissue sections. 
Detection of GCs in the periductal lymphoid infiltrates of the salivary glands is clinically 
relevant, because the presence of these structures is associated with more severe 
disease.4 Importantly, the presence of GCs in minor salivary gland biopsies has been 
postulated to be a predictor of patients who are at risk of lymphoma development.5,6 It 
has to be mentioned, however, that recently, we were not able to confirm these findings 
for a larger number of mucosa-associated lymphoid tissue (MALT) lymphomas in parotid 
glands of patients with pSS (Haacke et al., unpublished data). 
In our study, we defined GCs in H&E stained sections as lighter areas within the 
lymphoid infiltrate composed of both lymphoid cells (centrocytes, centroblasts) and cells 
with a non-lymphoid nature (macrophages and follicular dendritic cells (FDCs)) (Figure 
1a).1 Furthermore, the GCs were scored independently by two experienced pathologists. 
For the inexperienced eye, GCs may be overlooked, because of their small size, or 
lighter areas within the infiltrate may erroneously be scored as GCs, while in fact they 
represent lymphoepithelial lesions. For proper and easy detection of GCs, also by less-
trained persons, additional immunohistochemical staining might be helpful. Therefore, 
we propose to stain for B-cell lymphoma 6 (Bcl-6) to define and identify GCs. Bcl-6 is a 
transcription factor expressed at high levels by GC B-cells. Like GCs in peripheral lymphoid 
organs, GCs in salivary glands of patients with pSS are also consistently positive for Bcl-6.5 
As shown in Figure 1b, staining for Bcl-6 allows the easy and unequivocal detection and 
scoring of GCs in salivary gland biopsies, both in minor and major (parotid) salivary glands. 
Implementation of Bcl-6 staining is relatively easy, since it is routinely used in pathology 
laboratories worldwide for the diagnosis of lymphomas.7 Other markers, as proposed 
by Fisher et al.3 and van Roon et al.,1 are less specific and less suitable to detect GCs in 
routine diagnostics. For example, activation-induced deaminase, an enzyme essential for 
the function of GCs B-cells, is expressed only by a minority of GCs B-cells in minor salivary 
glands of patients with pSS,5 which may make GCs harder to detect. The long isoform 
of CD21 (CD21L) has also been suggested for detection of GCs. CD21L is expressed by 
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follicular dendritic cells (FDCs). However, although FDCs are a prerequisite for GC function 
and development, the presence of these cells does not necessarily imply that GCs are 
present. Indeed, ectopic lymphoid infiltrates in salivary gland tissue of patients with pSS 
can contain FDC networks in the absence of GCs.8,9 Staining for the CD21L may therefore 
result in an overestimation of the number of GCs present in salivary gland tissue. 
Figure 1: Images showing serial paraffin sections of a parotid gland biopsy of a patient with primary Sjögren’s 
syndrome (pSS) stained with A) H&E and B) for Bcl-6. A clearly visible germinal centre (GC) (indicated with an 
arrow) is seen in the periductal infiltrate. Asterisks indicate lymphoepithelial lesions.
In our study we observed that a relative high proportion of the parotid salivary gland 
biopsies presented with GCs at baseline; 67% and 68% of patients in the placebo-treated 
and rituximab-treated groups, respectively.2 These are relatively high percentages 
compared with the general pSS population, in which approximately one-quarter of the 
minor salivary gland biopsies exhibit GCs.4 The reason for this high baseline characteristic 
can be attributed to the inclusion criteria of our study. In our study the patients with pSS 
were all positive for anti-SSA antibodies and had high systemic activity, as indicated by the 
relatively high European League against Rheumatism Sjogren’s Syndrome Disease Activity 
Index scores.10 Indeed, presence of GCs in minor salivary glands has been associated 
with more severe disease, including systemic proinflammatory mediators and anti-SSA 
antibodies.4 A second explanation for the high number of GCs at baseline might be related 
to histopathological differences between minor and parotid salivary gland biopsies. 
Although a previous study in a small cohort of patients with pSS (n=30) did not report 
a difference in numbers of GCs,11 it remains possible that there are more and/or larger 
GCs in parotid gland biopsies compared to minor salivary glands. Apparently, there is a 
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petition for larger studies focusing on the inherent differences in the histopathological 
characteristics of parotid and minor salivary gland tissue in both pSS patients and healthy 
controls. 
In summary, in agreement with van Roon et al.1 we would also like to emphasise 
that there is a need for consensus guidelines to standardise the evaluation of ectopic 
lymphoid infiltrates and GCs in salivary gland tissue of patients with pSS. The various 
methods used for automated analysis of several parameters should also be taken into 
account.12 Consensus guidelines will assist the pathologist to correctly identify and quantify 
histopathological parameters in pSS and contribute to a more accurate prediction of 
disease progression and personalised treatment, as well as allowing the comparison 
between study cohorts and different clinical trials.
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We thank Alunno et al.1 for their comments, as a response to our recent publication2 
in which we describe that, in contrast to the prevailing view, germinal centres in 
diagnostic labial gland biopsies are not predictive for the development of mucosa-
associated lymphoid tissue (MALT) lymphoma in parotid salivary glands in patients with 
(primary) Sjögren’s syndrome (pSS). As we2 and others also noted before,3-6 Alunno 
et al.1 underpin in their comments the need for standardisation of the detection 
method of germinal centres in salivary gland biopsies in patients with pSS. Germinal 
centres are structures that arise in B-cell follicles of secondary lymphoid organs as 
a response to antigenic stimulation. In these structures, high-affinity memory B-cells 
are generated, as a consequence of an intimate interplay between B-cells, follicular 
helper T cells (TFH) and immune-complex presenting follicular dendritic cells (FDCs). 
Germinal centres can also be found within B-cell areas of ectopic (tertiary) lymphoid 
tissue that develops in target tissues of various rheumatic autoimmune diseases, 
including pSS.7 While detection in secondary lymphoid tissue is usually relatively 
simple, recognition of these structures in salivary gland biopsies of patients with 
pSS is generally more difficult. In particular in H&E stained sections, striated ducts 
infiltrated with lymphocytes (lymphoepithelial lesions), can erroneously be mistaken 
for germinal centres (see Figure 1). As discussed before,5 we proposed for this reason 
to use staining for transcription factor B-cell lymphoma (Bcl)-6 to identify germinal 
centres (Figure 1). Bcl-6 is consistently expressed at high levels by germinal centre 
B-cells and is commonly applied by pathology laboratories for lymphoma subtyping. 
In our study2 we observed slightly more germinal centres in Bcl-6 stained sections of 
pSS salivary gland biopsies compared with H&E stained sections, which was due to the 
fact that also small germinal centres (defined as clusters of > 5 Bcl-6+ B-cells) could 
easily be detected. Larger cohorts of salivary gland biopsies are obviously needed to 
establish the higher sensitivity and specificity of Bcl-6 stained sections, compared to 
H&E salivary gland stained sections. 
FDCs are not only essential for the generation and function of germinal centres 
but are, as CXCL13 producing cells, also critically involved in the maintenance of the 
spatial organisation of the ectopic lymphoid tissue into segregated B-cell and T-cell 
areas.8 Indeed, the mere presence of FDC networks, as revealed by CD21 staining, 
in salivary gland lymphoid tissue of patients with pSS does not imply that germinal 
centres are also present.9 Staining for (the long isoform of) CD21 is thus not appropriate 
for identification of germinal centres. Nevertheless, CD21 staining may be useful to 
discriminate unorganised infiltrates from organised ectopic lymphoid tissue. Besides 
proper detection of structures, we like to stress here that the proper nomenclature 
should be used in all histopathological studies and that ectopic lymphoid tissue is not 
equivalent with ectopic germinal centres. We propose the following levels of organisation 
of the infiltrating lymphoid cells: (1) unorganised lymphocytic focus (CD21-Bcl-6-), 
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(2) organised lymphocytic focus (ectopic lymphoid tissue) without germinal centres 
(CD21+Bcl-6-) and (3) organised lymphocytic focus (ectopic lymphoid tissue) with 
germinal centres (CD21+Bcl-6+). 
Figure 1: Histopathological evaluation of germinal centers in parotid salivary glands of pSS patients. 
Consecutive formalin fixed-paraffin embedded parotid gland sections from two pSS patients were stained for 
H&E, Bcl-6, CD21 and for CD20 (brown) plus cytokeratin (CK) 8+18 (red). The CK staining was used to identify 
epithelial cells. Lymphoepithelial lesions (composed of epithelial cells and lymphoid cells) are marked by an * and 
can be mistaken for germinal centers in H&E stained sections. The H&E stained and the Bcl6 stained micrographs 
of the lower panels are from our reference.5
An important question is whether identification of germinal centres is clinically relevant and 
has an additional value over the already collected serological and clinical data. Germinal 
centres are observed in diagnostic (minor) salivary gland biopsies of approximately 25% 
of the patients with pSS.10 Patients with germinal centres in their diagnostic biopsies seem 
to have more severe disease as witnessed by the presence of autoantibodies (rheumatoid 
factor, anti-SSA, anti-SSB), hypergammaglobulineamia, increased levels of local and 
systemic proinflammatory cytokines and extraglandular manifestations.10,11 Presence of 
germinal centres has also been associated with a higher risk of non-Hodgkin’s lymphoma 
development.12 This latter association has been used frequently to justify the evaluation 
of germinal centres in minor salivary gland biopsies. However, importantly, only one of the 
seven non-Hodgkin lymphomas observed in the pSS cohort of the study of Theander et 
al.12 was a parotid MALT lymphoma, that is. the type of lymphoma that is characteristically 
associated with pSS. In our retrospective study2 we could not demonstrate that the 
presence of well-defined germinal centres in diagnostic minor salivary gland biopsies 
(both H&E and Bcl-6-defined) was also predictive for the development of parotid MALT 
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lymphoma. We agree with Alunno et al.1 that histopathological analysis of salivary gland 
biopsies from larger cohorts of patients scored using standardised protocols and with 
well-defined definitions are needed to assess the clinical relevance of the presence of 
germinal centres in salivary gland biopsies of patients with pSS. 
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Histopathological assessment of salivary gland biopsies is an important element of the 
diagnostic work-up of Sjögren’s syndrome (SS).1,2 Microscopic evaluation of salivary glands of 
primary SS (pSS) patients reveals characteristic periductal lymphocytic infiltrates (foci), which 
mainly consist of T- and B-lymphocytes, as well as a variety of non-lymphoid cells, including 
dendritic cells and macrophages. Over time, these infiltrates may become organised to 
ectopic lymphoid tissue with T/B cell compartmentalisation, presence of CD21+follicular 
dendritic cell (FDC) networks and high endothelial venules.2-5 Germinal centres (GCs) are 
present within this ectopic lymphoid tissue in roughly one-quarter of the salivary gland 
biopsies of pSS patients and their presence is associated with more severe disease compared 
to GC-negative pSS patients.6 These glandular ectopic GCs express mRNA encoding for 
activation-induced deaminase, an enzyme critical for the induction of somatic hypermutation 
and essential for the main function of GCs, the generation of high-affinity memory B-cells.7-9 
Presence of GCs in biopsies taken for the diagnosis of pSS has been suggested to 
be a risk factor for lymphoma development,10-12 a finding recently disputed by us.13,14 
Detection of GCs in routine haematoxylin and eosin (H&E) stained sections can be 
challenging because small GCs may be overlooked and distinction between GCs and 
lymphoepithelial lesions may be difficult.3,15 Therefore, immunohistochemical identification 
using antibodies directed against CD21, expressed by FDCs (but also by B-cells) or Bcl6, a 
transcription factor highly expressed by GC-B cells, have been used, 7,15,16 but consensus 
criteria regarding identification of GCs are lacking.17 Hence, the aim of this study was to 
asses which staining is most suitable to unequivocally identify GCs in diagnostic salivary 
gland biopsies of pSS patients by comparing H&E, CD21 and Bcl6 stainings. 
In our study we restricted ourselves to these three markers, which can be easily 
applied in an automated fashion in diagnostic pathology laboratories. For this reason, we 
did not consider staining for other GC-associated markers, such as activation-induced 
deaminase, as potential candidates for identification of GCs in biopsies. 
MATERIALS AND METHODS 
Patients and evaluation of salivary gland biopsies 
From 42 pSS patients, classified according to American College of Rheumatology (ACR)-
European League Against Rheumatism (EULAR) classification criteria,18 both a labial and 
a parotid salivary gland biopsy were obtained (see Table 1). Four μm thick serial sections 
of salivary gland biopsies were stained with H&E and immunohistochemically for CD21 
and Bcl6. For detailed ethical approval information, staining characteristics and statistical 
analysis see supplementary methods.
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RF positive, n (%)
ANA positive, n (%)
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Histopathological parameters of the labial gland
Focus score 
≤70% IgA plasma cells, n (%)
Lymphoepithelial lesions, n (%)





Histopathologic parameters of the parotid gland
Focus score
≤70% IgA plasma cells, n (%)
Lymphoepithelial lesions, n (%)





Note: Patients were classified according to the ACR-EULAR criteria. Data are represented as mean ± SD, median 
[95% CI] or number (%). * % of area of lymphocytic infiltrate in salivary gland parenchyma (Aperio ImageScope 
v12.0). Abbreviations: ANA, antinuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
ESSDAI, European League Against Rheumatism SS Disease Activity Index; n, number of patients; pSS, primary 
Sjögren’s syndrome; RF, rheumatoid factor; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen 
B; UWS, unstimulated whole saliva.
In H&E stained sections, a GC was defined as a clearly visible lighter area in a lymphocytic 
infiltrate containing centrocytes, centroblasts, FDCs and macrophages. In CD21-stained 
sections, a network of positive staining within a focus was classified as a FDC-network. In 
Bcl6-stained sections a cluster of ≥5 adjacent positive cells within a focus was classified 
as a GC.15 Even though Bcl6 is also expressed by follicular helper T-cells, this expression 
does not interfere with detection of GCs as these cells are not organised in clusters as 




Six labial and eleven parotid salivary gland biopsies did not contain any H&E defined 
periductal foci. For the remaining biopsies, 36 labial and 31 parotid glands, all individual 
H&E-defined foci (210 labial, 141 parotid) were analysed on serial sections. This staining 
revealed that 1% (3/210) of labial gland foci and 6% (9/141) of parotid gland foci contained 
H&E-defined GCs. Immunohistochemical staining for CD21, revealed that 24% (50/210) 
of the foci in the labial gland and 49% (69/141) of the foci in the parotid gland contained 
CD21+FDC-networks (Table 2). Importantly, after staining for Bcl6, we showed that only 
18% (9/50) of the labial gland foci with CD21+FDC-networks and 32% (22/69) of the 
parotid gland foci with CD21+FDC-networks also comprised Bcl6+GCs. Apparently, not all 
foci contain CD21+FDC-networks and not all foci with CD21+FDC-networks also harbour 
Bcl6+GCs. This was confirmed by dual CD21/Bcl6 staining (Figure 1A). Consequently, the 
number of CD21+FDC-networks/mm2 was significantly higher than the number of H&E+- 
and Bcl6+-defined GCs/mm2 in both labial and parotid salivary glands (Figures 1B and 
1C). We observed a significant correlation between CD21+FDC-networks/mm2 in parotid 
and labial salivary gland biopsies (Figure 1D, r=0.60, p=0.001), indicating comparability in 
lymphoid organisation at these two anatomical sites. Such a correlation was not seen for 
the presence of H&E- or Bcl6-defined GCs. 
Table 2: Comparison between the number of germinal centres in labial and parotid salivary gland biopsies of 
primary Sjögren’s syndrome patients.
Labial salivary gland Parotid salivary gland
Number of biopsies with foci 36 31
Number of foci 210 141
% H&E+GCs 1.4 (3/210) 6.4 (9/141)
% Bcl6+GCs 4.3(9/210) 15.6 (22/141)
% CD21+FDC networks 23.8 (50/210) 48.9 (69/141)
Note FDC, follicular dendritic cell; GCs, germinal centres; H&E, haematoxylin & eosin.
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Figure 1: Presence of germinal centres and follicular dendritic cell networks in salivary gland biopsies of patients 
with primary Sjögren’s syndrome.
A) Histopathological identification of germinal centres. Paraffin embedded parotid gland biopsy of a patient 
with primary Sjögren’s syndrome stained with H&E (left panel) and by double immunohistochemistry for CD21 
(red) and Bcl6 (brown) (middle and right panel). The left panel shows a periductal focus with a H&E stained GC, 
(indicated by a dotted line, magnification 10x); the middle panel a CD21+FDC-network with a Bcl6+GC (indicated by 
a dotted line, magnification 20x), and the right panel a CD21+FDC-network (indicated by an asterisk, magnification 
20x) without a GC. B) Number of GCs or FDC-networks/mm2 in labial (n=36) salivary gland tissue after staining 
with H&E and immunohistochemically for Bcl6 or CD21. C) Number of GCs or FDC-networks/mm2 parotid (n=31) 
salivary gland tissue after staining with H&E and immunohistochemically for Bcl6 or CD21. D) Spearman’s rank 
order correlation revealed a significant positive association between CD21+FDC-networks/mm2 in parotid and 
labial salivary gland biopsies (Figure 1D r=0.60, p=0.001). Red lines in




In a recent study Carubbi et al. analysed the usage of CD3/CD20 as well as CD21 and Bcl6 
as markers for the detection of GCs.16 While they conclude that combination of CD3/CD20 
and CD21 should be recommended for assessment of GCs, we clearly show here that 
usage of CD21 as surrogate marker for GCs significantly overestimates GC counts. The 
reason for this is that formation of B-cell follicles and presence of CD21+FDC-networks 
(which are also present in primary B-cell follicles), does not imply also presence of GCs.19 
On the other hand, staining with H&E revealed fewer GCs compared to staining for Bcl6, 
most likely because small GCs can easily be overlooked on H&E. 
Although staining for CD21 is thus less appropriate for detection of GCs, staining 
for CD21 is still valuable. FDCs play an essential role in the spatial orientation and B/T-
cell compartmentalisation in ectopic lymphoid tissues due to their CXCL13 producing 
property. Presence of FDC-networks suggests a more advanced stage of ectopic lymphoid 
development and may therefore be a useful marker for classification of the organisation 
of glandular tissue.20 
CONCLUSION
In conclusion, we propose to use Bcl6 as a simple, sensitive and specific marker for 
unequivocal identification of GCs in salivary gland biopsies of (suspected) pSS patients. 
Large prospective studies are now needed to evaluate whether presence of GCs in 
diagnostic salivary gland biopsies for pSS is a risk factor for non-Hodgkin lymphomas 
or not, and whether it can be used for stratification of pSS patients for personalised 
medicine.2,21
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Study information: Biopsies for this retrospective observational study were collected 
from 2014 until 2016. Inclusion and exclusion criteria are shown in supplementary table 1. 
All labial and parotid salivary gland biopsies were performed by one Oral and Maxillofacial 
surgeon (FKLS) at the University Medical Center Groningen. 
Ethical approval information: The study was approved by the Medical Research Ethics 
Committee of the UMCG, the Netherlands (METc2013.066). All participants gave consent 
according to the declaration of Helsinki. 
Immunohistological staining and histopathological assessment 
CD21 staining: Sections were deparaffinised and antigen retrieval was performed (EDTA, pH 
8). Endogenous peroxidase activity was blocked using H2O2 and PBS. Slides were incubated 
with CD21 antibodies (2G9; Cell Marque Corporation, USA) for 75 min. After rinsing, 
sections were treated with horse radish peroxidase (HRP) polymer (goat anti-mouse IgG) 
for 40 min. Staining was visualised with DAB and the sections were counterstained with 
haemotoxylin. This staining procedure was optimized for the detection of FDC networks. 
Bcl6 staining and CD21/Bcl6 double staining: Bcl-6 (GI19E/A8; Ventana Medical systems, 
USA, pre-diluted by supplier) staining and CD21/Bcl6 double staining was performed after 
deparaffinisation, pre-treatment with Ultra CC1 (Ventana Medical Systems, USA), antigen 
retrieval and endogenous peroxidase blocking using the Benchmark automated staining 
platform (Ventana Medical Systems, USA). The double staining was performed serially. 
All foci in labial and parotid salivary gland parenchyma were analysed for the 
presence of CD21+FDC-networks and for H&E+- or Bcl6+GCs by a trained researcher 
(UN), an experienced pathology resident (EH) and a head and neck pathologist (BvdV). 
Discrepancies between observers were resolved in a consensus meeting. 
Statistical analysis 
Data were analysed using SPSS version 23 statistical software (SPSS Inc., Chicago, IL). 
Differences between groups were tested with Mann-Whitney U test. Correlation analysis 
was performed using the Spearman’s rank order correlation. P-values <0.05 were 
considered statistically significant. 
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Supplementary Table 1: Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
§	Ability to give informed consent.
§	Male or female patients 18 years of age or older.
§	Patients, classified according to ACR-EULAR 
classification criteria.
§	Must be willing to have a standard physical exam 
as part of standard clinical care and a complete 
diagnostic work-up according to the ACR criteria 
for ocular staining, labial salivary gland biopsy and 
serology.
§	Must be willing to have a standard physical exam 
and complete AECG diagnostic tests as part of 
standard clinical care (including eye exam, oral 
exam, salivary gland exam and biopsy).
§	Must be willing to donate 1ml of stimulated, whole 
saliva in 30 minutes or less. If a participant cannot 
produce 1ml during a 30 min collection period, 
subject will be unavailable and will be considered a 
screen failure and withdrawn from the study.
§	Subjects must be willing have a labial salivary gland 
biopsy in addition to a parotid biopsy.
§	Must be willing and able to give approximately 8 ml 
of blood. 
§	Previous radiation to the head and neck.
§	Confirmed hepatitis C virus infection, which may 
cause SS-like signs and symptoms.
§	Known HIV infection, which can cause salivary gland 
infiltrates and enlargements similar to SS.
§	Sarcoidosis, which may causes-like signs and 
symptoms.
§	Graft-versus-host disease, which may cause SS-like 
signs and symptoms.
§	Oral cancer or history of oral cancer.
§	Presence of MALT lymphoma.
§	Pregnancy based on self-report.
§	Previously confirmed diagnosis of autoimmune 
disease known to be associated with sSS (RA, SLE, 
CREST, scleroderma, mixed connective tissue 
disease, polymyositis). 
§	Insufficient biopsy material harvested from either 
labial or parotid salivary gland.
§	Absence of any focus in the labial and parotid gland.
Note: Abbreviations: ACR, American College of Rheumatology; AECG, American-European Consensus Group; 
EULAR, European League Against Rheumatism; CREST, Calcinosis, Raynaud’s syndrome, Esophageal dysmotility, 
Sclerodactylyl, Telangiectasia; MALT, Mucosa associated lymphoid tissue; RA, Rheumatoid arthritis; SLE, Systemic 
Lupus Erythematosus; sSS, secondary Sjögren’s syndrome. 
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Fc receptor-like protein 4 (FcRL4) is normally expressed on a small subset of mucosa-
associated B-cells, as well as on mucosa-associated lymphoid tissue (MALT) lymphoma 
B-cells. Primary Sjögren’s syndrome (pSS) patients have an increased risk of developing 
MALT lymphomas, preferentially in the parotid glands. For this reason we studied here by 
immunohistochemistry and mRNA analysis whether FcRL4 expressing B-cells are present 
in salivary gland tissue (labial and parotid) of pSS patients (n=54) and non-pSS sicca 
patients (n=16) and whether parotid gland MALT lymphomas in pSS patients (n=49) also 
express this receptor. We also studied the effect of treatment (rituximab and abatacept) 
on the presence of FcRL4+ B-cells, and whether numbers in labial gland biopsies at time of 
diagnosis of pSS can predict whether patients are at risk for MALT lymphoma development. 
We demonstrate that FcRL4+ cells are present in salivary gland tissue of pSS patients where 
they are closely associated with ductal epithelial cells forming lymphoepithelial lesions. 
The glandular FcRL4+ cells are highly proliferative, genuine PAX5+ B-cells. These FcRL4+ 
B-cells are far more frequent in parotid gland than in labial gland tissue (p=0.003). We 
further show that expression of FcRL4 is present in pSS-related parotid MALT lymphomas. 
The FcRL4 mRNA expression level in parotid MALT lymphoma is increased compared to 
parotid gland tissue of pSS patients without lymphoma (p=0.017). However, numbers of 
FcRL4+ B-cells in labial gland biopsies taken at the time of pSS diagnosis, are not predictive 
for later development of MALT lymphoma. Reduction of parotid gland FcRL4+ B-cells by 
rituximab, but not abatacept is accompanied by restoration of the glandular epithelium, 
illustrating the crosstalk between these B-cells with the ductal cells. 
In conclusion, intraepithelial FcRL4+ B-cells are present in the salivary glands of 
pSS patients. These cells are likely involved in the epithelial changes seen in pSS. 
Their enrichment in parotid glands may explain why MALT lymphomas in pSS patients 
preferentially develop at this specific location. 
HIGHLIGHTS
•	 Highly proliferative FcRL4+ B-cells are present in salivary glands of pSS patients 
•	 FcRL4+ B-cells are associated with salivary gland ductal epithelium and are enriched 
in parotid glands 
•	 FcRL4+ B-cells can effectively be targeted by rituximab




Primary Sjögren’s syndrome (pSS) is an autoimmune disease affecting exocrine glands 
leading to dryness of mouth and eyes.1 Histologically, salivary glands of pSS patients 
harbor lymphocytic infiltrates that are arranged around striated ducts. The interaction 
of lymphocytes and the ductal epithelial cells is further emphasized by the formation 
of lymphoepithelial lesions (LELs), formerly called epimyoepithelial islands. These LELs 
are composed of proliferative metaplastic epithelial cells and intraepithelial lymphocytes. 
Interestingly, LELs are more pronounced in parotid glands than in labial glands.2-4
A hallmark of pSS pathogenesis is hyperactivity of B-cells, which is amongst others 
reflected by the elevated risk of non-Hodgkin lymphoma development. This serious 
complication occurs in 5-10% of pSS patients.5,6 These lymphomas are almost exclusively 
B-cell lymphomas, mostly of the mucosa-associated lymphoid tissue (MALT) type (>60%) 
and preferentially develop in the parotid gland.6-8 It is not clear why MALT lymphomas arise 
predominantly at this location, since all minor and major salivary glands are affected in pSS.
Parotid MALT lymphomas often contain distinct LELs that are infiltrated and 
surrounded by neoplastic B-cells with a centrocyte-like or monocytoid appearance, 
sometimes admixed with neoplastic plasma cells.9,10 Falini et al. demonstrated that 
exclusively marginal zone lymphomas, including major salivary gland MALT lymphomas 
and a subset of DLBCL (diffuse large B-cell lymphoma) express the inhibitory Fc receptor-
like protein 4 (FcRL4/IRTA1/CD307d).11 DLBCL can develop, occasionally as transformation 
from MALT lymphoma in pSS patients as well.9,12 In healthy individuals, FcRL4 is expressed 
on a small subset of highly proliferative memory B-cells in mucosal tissues (tonsils, Peyer’s 
patches), where they are concentrated near and within the epithelial surfaces. FcRL4+ 
B-cells are rarely found in blood, spleen and peripheral lymph nodes.13,14 This association 
with the epithelium at mucosal sites is in concordance with the notion that FcRL4 is a 
receptor for IgA and strongly argues that FcRL4+ B-cells exert an important role in mucosal 
immune responses.15 In response to chronic antigen stimulation FcRL4 dampens activation 
by the B-cell receptor (BCR) and enhances innate Toll-like receptor (TLR) activation.15,16 
Upon differentiation from FcRL4+ B-cells towards plasma cells, FcRL4 expression is 
lost. An increased number of FcRL4+ B-cells is found in reactive lymphadenitis caused 
amongst others by toxoplasmosis, HIV and mononucleosis.13,14 In the autoimmune disease 
rheumatoid arthritis, FcRL4+ B-cells are found in synovial fluid and synovial tissue, where 
they are located beneath the synovial lining and around blood vessels.17 In this study we 
assessed the presence and localization of FcRL4+ B-cells in salivary gland tissue of pSS 




Salivary gland biopsies were collected from 54 patients diagnosed with pSS. All patients 
fulfilled the American-European Consensus Group (AECG) criteria for pSS and were 
selected because they had not developed a malignant lymphoma during follow up (median 
9.2 year, IQR 4.4–12.6 year). Thirty biopsies were taken from the parotid gland and 24 
from the minor salivary (labial) glands. As controls served parotid gland biopsies (n=8) and 
labial gland biopsies (n=8) obtained from non-pSS sicca patients (complaints of dryness, 
not fulfilling the AECG criteria). Clinical data of the pSS patients and sicca patients are 
presented in table 1. Furthermore, 5 parotid glands from individuals with no complaints 
of dryness were included in this study. Of these five patients, who had undergone surgery 
for pleomorph adenoma (n=3) or warthin tumor (n=2) the resection margins of the parotid 
gland were used. To explore whether FcRL4+ cells are affected by rituximab or abatacept, 
parotid gland biopsies from pSS patients enrolled in the placebo-controlled rituximab trial 
(18 rituximab, 9 placebo)18,19 and open label abatacept study (n=15)20,21 were also analyzed. 
In addition, tissue samples from the parotid gland of 49 pSS patients diagnosed with 
parotid MALT lymphomas were obtained. These pSS patients were either diagnosed 
or referred for parotid MALT lymphoma at the University Medical Center Groningen 
(supplementary Figure 1). Biopsy material stored at other hospitals was requested for 
re-evaluation. Clinical data at time of diagnosis of MALT lymphoma are presented in table 
1. From 10 parotid MALT lymphoma patients, a diagnostic labial salivary gland biopsy (for 
the diagnosis of pSS) prior to lymphoma development was available for analysis as well.
Histological evaluation of salivary gland biopsies
Hematoxylin and eosin (HE) stained sections were used to assess focus score (FS) and 
presence of LELs. FS was based on the number of periductal infiltrates of ≥50 lymphocytes 
(foci)/4 mm2 parenchyma. In case of multiple large confluent foci an arbitrary maximal FS 
of 12 was used (1 pSS patient).22 LELs were defined as a cross section of a striated duct 
with infiltration of lymphocytes within the contour of the basement membrane combined 
with hyperplasia of the ductal epithelium.19
Immunohistochemical staining for FcRL4 
Formalin fixed (4%), paraffin embedded tissue samples were sectioned at 4 µm thickness 
and deparaffinized. After antigen retrieval in 1mM EDTA pH8.0, 98°C, 15 minutes and 
blocking of endogenous peroxidase (0.3% H2O2) slides were incubated for 75 minutes 
with a culture supernatant of monoclonal mouse-anti-human FcRL4 antibody produced 
and generously provided by Profs. Pileri and Falini (Bologna and Perugia, Italy)13 diluted 
in PBS/1%BSA. After incubation with a horseradish peroxidase (HRP) labeled secondary 
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antibody (Real™EnVision™ Detection System, DAKO) FcRL4 was visualized with DAB (3,3’ 
diaminobenzidine). As negative (isotype) control an irrelevant IgG2a mouse monoclonal 
antibody (clone C1.18.4, BD Biosciences) was used (Supplementary Figure 2). Parotid MALT 
lymphomas were considered positive if there was detectable FcRL4, expressed by at least 
5% of the lymphoma B-cells. To quantify FcRL4 expression in salivary gland biopsies, the 
relative area of FcRL4 staining was measured with Aperio ImageScope software (algorithm 
positive pixel count v9 (v12.0)). Thresholds of negative and positive pixels were manually 
corrected for each slide minimizing false positive pixels from non-specific background 
staining. FcRL4 staining was evaluated in the glandular parenchyma only excluding 
interparenchymal connective- and fatty tissue. 
Phenotype and proliferative capacity of FcRL4+ cells
Dual staining for FcRL4 in combination with transcription factors Pax5, Bcl6, Blimp1 
(PRDM1) and Mum1 (IRF4) or proliferation marker Ki-67 (supplementary table 1) was 
performed using the MultiVision Polymer Detection System (ThermoScientific) according 
to manufacturers manual. After deparaffinization, antigen retrieval and endogenous 
peroxidase blocking (see before) Ultra-V-block was applied. After incubation with primary 
antibodies in PBS/1%BSA for 75 minutes, MultiVision Polymer Cocktail was used. Staining 
for FcRL4 was visualized by LVRed (HRP congugated anti-mouse IgG) and the transcription 
factor or proliferation marker by LVBlue (alkaline phosphatase conjugated anti-rabbit IgG). 
mRNA-isolation and qPCR of FcRL4
From 11 pSS patients with parotid MALT lymphomas, 9 pSS patients without a lymphoma 
and 8 non-pSS sicca patients frozen parotid biopsies were available. Total mRNA was 
extracted using the Absolutely RNA Microprep Kit (Agilent Technologies) according to 
instructions of the manufacturer. After DNAse treatment, cDNA was synthesized using 
Oligo dT12-18’s and M-MLV Reverse Transcriptase (Thermo-Fisher Scientific). A qPCR 
for FcRL4 expression was carried out on the CFX384 Touch Real-Time PCR detection 
system (BioRad) using SYBR green supermix (BioRad) using primer sets for β-actin: 5’ 
GAGCGGGAAATCGTGCGTGAC-3’ (forward), 5’ AGGAAGGAAGGCTGGAAGAGTGC-3’ (reverse) 
and FcRL4: 5’-GGGCGTCCTTGCTGGCCTTT-3’ (forward), 5’ GGGTGTTTCCTGGGGTCAGGGT-3’ 
(reverse). Experiments were carried out in duplicate. Gene expression was normalised to 
β-actin expression. 
Statistical analysis
Wilcoxon Signed Rank, Mann-Whitney U were used when appropriate to test differences 
between parameters. Spearman’s correlation coefficient was calculated for testing 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FcRL4+ cells are present in salivary gland tissue of pSS patients 
FcRL4 positive (FcRL4+) cells were clearly present in nearly all parotid gland biopsies (29/30, 
97%) and in the majority of labial (17/24, 71%) gland biopsies of pSS patients at the time of 
pSS diagnosis (Figure 1 and Supplementary Figure 2). Compared to the overall lymphocyte 
population in the glandular tissue of pSS patients, the numbers of FcRL4+ cells (as expressed by 
relative surface areas stained by the antibody) were relatively low but varied between patients. 
Remarkably, in pSS patients the numbers of FcRL4+ cells were significantly higher in parotid 
gland tissue than in labial gland tissues (p=0.003, Figure 1H). Furthermore, the intensity of 
the FcRL4 staining was higher in parotid gland tissue compared to labial gland tissue. In pSS 
patients, the majority of FcRL4+ cells was located within LELs of the salivary glands and a smaller 
fraction in the periductal infiltrate, mostly in close proximity to the epithelium. FcRL4 staining 
intensity was highest within the LELs. All LELs contained FcRL4+ cells, even if LELs were very 
small, i.e., LELs with only few infiltrating lymphocytes and minimal reactive epithelial changes. 
FcRL4+ cells were absent from parotid gland tissue of patients without sicca complaints (n=5, 
data not shown). They could also not be observed in labial gland biopsies and in the majority 
of parotid gland biopsies of non-pSS sicca patients. 
Measurement of FcRL4 transcript levels by qRT-PCR confirmed the expression of FcRL4 
protein in salivary gland biopsies of pSS patients and their virtual absence in non-pSS sicca 
patients (Figure 2). 
As shown in Figure 1H there is a wide variety in numbers of FcRL4+ cells in parotid glands of 
pSS patients and there are patients with high levels and patients with low levels of FcRL4+ cells. 
There is a tendency that patients with autoantibodies (anti-SSA, anti-SSB, RF, ANA) have higher 
levels of FcRL4+ cells compared to patients with lower levels of FcRL4+ cells (supplementary 
Figure 3). 
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Figure 1: FcRL4+ cells in pSS patients: parotid gland, labial gland and parotid MALT lymphoma.
A) Parotid gland biopsy of a pSS patient with a lymphoepithelial lesion (LEL) and germinal center (GC), HE stain. B) 
FcRL4+ cells in the same parotid gland. FcRL4+ cells are in close association with the ductal epithelium. Less FcRL4+ 
cells are found in the infiltrate with lower intensity of the FcRL4 stain. C) Labial gland biopsy of a pSS patient, HE 
stain. D) FcRL4+ cells in the same labial gland. E) MALT lymphoma in the parotid gland of a pSS patient, HE stain. 
F) FcRL4 stain same MALT lymphoma. The FcRL4+ cells cluster in and around LELs and in the marginal zone. Few 
FcRL4+ B-cells with low intensity are found despite the presence of a periductal infiltrate. G) High magnification 
of FcRL4+ cells in the parotid gland. H) Quantification of FcRL4+ cells, by measuring relative surface of FcRL4 
staining. Amount of FcRL4 staining is higher in pSS patients compared to non-pSS sicca patients. In the parotid 
glands of pSS patients significantly more FcRL4 positivity is present compared to labial glands of pSS patients. In 
diagnostic labial gland biopsies from pSS patients who developed a parotid MALT lymphoma and pSS patients 
who did not, FcRL4 staining was similar. *Mann-Whitney U, p<0.05.
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Figure 2: Increased mRNA expression of FcRL4 in pSS patients and pSS parotid MALT lymphomas. 
A) Quantitative PCR analysis of FcRL4 in parotid gland biopsies showed an increase of FcRL4 mRNA expression 
in pSS patients and pSS parotid MALT lymphoma patients compared to sicca patients. The MALT lymphoma that 
was negative for FcRL4 by immunohistochemistry is indicated. B) FcRL4 staining of the parotid gland from a pSS 
patient with an expansive MALT lymphoma. Difference in FcRL4 staining between glandular tissue (pSS, left side) 
and MALT lymphoma (MALT, right side) is clearly visible. Counterstain with hematoxylin. *Mann-Whitney U, p<0.05.
FcRL4+ cells are proliferative B-cells without signs of plasma cell differentiation
Dual staining for FcRL4 and the B-cell associated transcription factor Pax5 revealed that 
virtually all FcRL4+ cells express Pax5, and thus represent B-cells. Dual staining with FcRL4 
and other transcription factors expressed during B-cell differentiation showed that FcRL4+ 
cells did not express Bcl6, a transcription factor highly expressed by GC B-cells, nor PRDM1 
and IRF4 which are both associated with plasma cell differentiation (Figure 3). Transcription 
factor expression profiles of the FcRL4+ cells were similar in both parotid and labial salivary 
gland tissue. 
A high percentage of FcRL4+ B-cells in the LELs of the parotid gland (mean 20.5%, 
±7.7%) and labial gland (mean 15.4 ±8.2%) express Ki-67, a marker expressed by cells 
that are not in the G0 phase of the cell cycle. In the periductal infiltrate lower percentage 
of FcRL4+ B-cells express Ki-67 (parotid gland; mean 13.8%, ±4.6% and labial gland; mean 
10.5%, ±3.8%, Figure 3). Thus, a significant proportion of the FcRL4+ B-cells are actively 
dividing cells, especially within LELs. 
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Figure 3: FcRL4+ cells are proliferative B-cells without signs of plasma cell differentiation.
Double staining for FcRL4 (brown) versus other proteins (blue). FcRL4+ B-cells in the parotid gland and the labial 
gland have a similar phenotype. A,B) FcRL4+ cells express Pax5. C,D) FcRL4+ cells do not express the germinal 
center B-cell associated transcription factor Bcl6. E,F) The transcription factor Mum1 is not expressed by FcRL4+ 
B-cells G,H) nor the transcription factor Blimp1, both associated with terminally differentiated plasma cells. 
I,J) FcRL4+ cells are proliferative cells. FcRL4+ Ki-67+ B-cells in the parotid and labial gland are found within the 
lymphoepithelial lesions and fewer in the parenchymal infiltrate.
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FcRL4+ B-cells correlate with presence of LELs and CD20+ B-cells
Histopathological analysis of parotid and labial salivary gland biopsies of pSS patients 
revealed that the focus score (FS) is comparable between these two types of salivary 
glands, but that the number of LELs is higher in parotid glands than in labial glands (Table 
1). Accordingly and as noted before, also the numbers of FcRL4+ B-cells, which are mostly 
located in or near LELs were higher in parotid glands. When we divided parotid and labial 
salivary gland biopsies each into two groups, one group with LELs and the other without 
LELs, significantly more FcRL4+ cells were present in salivary gland biopsies with LELs 
(Figure 4A, 4B).
Previously, we evaluated (i.e., pre-treatment) baseline numbers of LELs/mm2 and 
CD20+ B-cells/mm2 in parotid gland biopsies of pSS patients enrolled in the rituximab 
and abatacept studies.19,21 As we show here, there was a strong correlation between 
FcRL4 expression and number of LELs/mm2 (Spearman ρ=0.559, p<0.001) and between 
FcRL4 expression and number of CD20+ B-cells/mm2 (Spearman ρ=0.588, p<0.001, Figure 
4C, 4D) in the pre-treatment biopsies of these patients (n=42). In contrast, there was no 
correlation between FcRL4 expression and FS (Figure 4E).
FcRL4+ B-cells are reduced after rituximab, not by abatacept
To study the effect of in-vivo B-cell depletion and blocking of T-cell co-stimulation on FcRL4+ 
B-cells, we compared pre-treatment and post-treatment parotid gland biopsies in the 
rituximab (n=18 rituximab and n=9 placebo) and abatacept (n=15) studies. Rituximab but not 
placebo, not only effectively reduced the number of CD20+ B-cells and LELs in parotid gland 
biopsies 12 weeks after treatment19 but also the numbers of FcRL4+ B-cells (p=0.001, Figure 
5). Similar to the absence of any effect on the numbers of B-cells or LELs, FcRL4+ B-cells were 
not reduced by abatacept treatment (p=0.163, Figure 5) 24 weeks after treatment.21
FcRL4 expression is preserved in pSS associated parotid MALT lymphomas 
Immunohistochemistry revealed that 47/49 (96%) of pSS-associated parotid MALT 
lymphomas expressed FcRL4. This is similar to other extra-nodal marginal zone lymphomas 
in general.11 The FcRL4+ cells cluster in and around LELs and in the marginal zone (Figure 1). 
Both the number of FcRL4+ cells and the intensity of FcRL4 staining varied between cases. 
Quantitative RT-PCR (qRT-PCR) analysis of the 11 parotid MALT lymphomas from which 
frozen material was available, including one specimen that did not exhibit detectable levels 
of FcRL4 by immunohistochemistry, revealed that, in contrast to sicca control patients 
(n=8) and pSS patients (n=9), FcRL4 transcripts were detectable in all lymphomas. The 
lowest mRNA level was found in the pSS patient with the immunohistochemical FcRL4 
negative MALT lymphoma. As expected, FcRL4 transcript levels were significantly higher 
in parotid glands from pSS patients with MALT lymphoma compared to parotid biopsies 
obtained from pSS patients without lymphoma (p=0.017, Figure 2). 
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Figure 4: FcRL4+ B-cells are associated with LELs.
A) FcRL4+ B-cells in labial gland biopsies (n=24) are enriched in biopsies harboring LELs (33%). B) In parotid 
gland biopsies FcRL4+ B-cells are also significantly increased in biopsies harboring LELs (n=72, including baseline 
biopsies of the rituximab and abatacept trials). In total 83% of the parotid gland biopsies were positive for LELs. 
C-E) FcRL4 positivity in parotid gland biopsies (n=42, baseline rituximab and abatacept trials) is correlated with 
number of LELs/mm2 (ρ =0.559) and numbers of CD20+ B-cells/mm2 (ρ = 0.588) glandular parenchyma. Focus 
score did not correlate with FcRL4. *Mann-Whitney U, p<0.05.
FcRL4 expression in pre-lymphoma labial gland biopsies 
The 10 labial gland biopsies from pSS patients taken at time of pSS diagnosis, but prior (mean 
5.3 ±1.5 years) to parotid MALT lymphoma development, did not differ in numbers of FcRL4+ 
cells (as reflected by the relative surface area of FcRL4 staining) compared to labial biopsies 
of pSS patient without lymphoma development (p=0.360, Figure 1). Although at the group 
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level there was thus no significant difference, two pre-lymphoma pSS patients clearly had an 
elevated expression of FcRL4 in their diagnostic labial gland biopsy. Time between labial biopsy 
and parotid MALT lymphoma was 73 months and 4 months respectively in these patients. 
Figure 5: FcRL4+ B-cells are targeted by rituximab, not by abatacept.
Amount of FcRL4 staining is reduced after rituximab therapy in pSS patients. FcRL4+ B-cells located within the 
ductal epithelium and those located in the infiltrates that surrounds the ducts were depleted. The placebo 
group remained stable. As indicated, one placebo treated patient developed a lymphoma. Abatacept treatment 
of pSS patients did not affect the amount of FcRL4 staining. There was no significant difference in FcRL4 staining 
between baseline biopsies (BL) of abatacept trial and rituximab trial. All biopsies were taken from the parotid 
gland. Of note, follow up time of post-treatment biopsies varies between the studies since mode of action of 
these therapeutic biologicals differs.18,20 *Wilcoxon Signed Rank, p<0.05. 
DISCUSSION
In this study we show for the first time that FcRL4+ cells are present in the inflamed salivary 
glands of pSS patients. They are associated with the ductal epithelium forming LELs. Within 
these structures FcRL4+ cells are actively dividing. Strikingly, the number of FcRL4+ cells 
is much higher in parotid gland tissue than labial gland tissue. The transcription factor 
profile of FcRL4+ cells in both types of salivary glands reveals that these cells express Pax5, 
but not Blimp1, Mum1 or Bcl6. Thus, FcRL4+ cells in salivary gland tissue of pSS patients 
are highly proliferative genuine B-cells that have not differentiated towards plasma cells. 
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In healthy individuals the FcRL4+ B-cells are mostly found at mucosal sites within or in 
close proximity of epithelial linings.13 These cells have also been found in the target tissues 
of patients with autoimmune disease. In rheumatoid arthritis patients FcRL4+ B-cells were 
present in the synovia, beneath the synovial lining and around blood vessels.17 Our study 
shows that also in the salivary glands of pSS patients FcRL4+ B-cells have a clear association 
with the epithelium. This association is maintained in pSS-associated parotid MALT 
lymphomas, emphasizing the importance of the interaction of ductal epithelial cells and 
FcRL4+ B-cells. The ductal epithelial cells in pSS salivary gland parenchyma produce a wide 
variety of chemokines including CCL3/MIP-1α and CCL5/RANTES.23 These chemokines are 
ligands for the chemokine receptors CCR1 and CCR5 respectively, which are expressed at 
elevated levels by FcRL4+ B-cells present in the peripheral blood of healthy individuals.14,17 
These, and other not yet identified chemokine-chemokine receptor interactions can 
contribute to homing and retention of FcRL4+ B-cells to inflamed salivary glands, and more 
specifically to the ductal epithelium. Differences in chemokine expression levels between 
ductal epithelial cells of labial and parotid glands may account for the higher numbers of 
FcRL4+ B-cells seen in parotid glands compared to labial glands of pSS patients. 
Labeling with Ki-67 indicates that FcRL4+ B-cells of the salivary glands are highly 
proliferating cells. Approximately 15-20% of FcRL4+ B-cells in LELs of pSS patients are in cell 
cycle as determined immunohistochemical by Ki-67. In line with our findings in salivary glands 
of pSS patients, previous studies demonstrated (using immunofluorescence staining for Ki67, 
FACs and transcriptome analysis for Ki67) that a relative high fraction (5-43%) of tonsillar 
FcRL4+ (memory) B-cells are not in G0 phase.
13,24 In comparison, only a few percent of tonsillar 
memory cells not expressing FcRL4, are actively dividing.24 Gene expression profiling studies 
further revealed that tonsillar FcRL4+ B-cells indeed overexpress several genes involved in the 
regulation of entry and progression through the cell cycle including Ki-67.24
FcRL4+ B-cells fail to proliferate in response to BCR signaling, whereas signaling 
through innate pathways, for instance by TLRs, is enhanced.14,16,25 Sohn et al, observed 
that BCR signaling was attenuated and TLR9 activation by unmethylated CpG was 
enhanced in FcRL4+ transfected Ramos B-cells.16 Based upon these findings they 
speculated that FcRL4 signaling may act as a molecular switch to dampen adaptive 
signaling and enhance innate signaling in response to chronic (antigenic) stimulation. 
Zheng et al, reported that lymphocytes residing within LELs of parotid gland tissue from 
pSS patients express more TLR9 as compared to controls.26 As epithelial cells in pSS are 
intrinsically more sensitive for cell death27 they may deliver ligands for TLR activation 
such as nucleic acids containing particles. In addition, in pSS, ductal cells produce a 
wide variety of cytokines,28 which can contribute to the activation of the FcRL4+ B-cells, 
particularly intraepithelial FcRL4+ B-cells expressing the highest levels of FcRL4. In this 
manner, ductal epithelial cells might be responsible for signals that lead to sustained 
activation and proliferation of FcRL4+ B-cells. 
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The epithelium may not only influence activation of FcRL4+ B-cells, but in turn the 
epithelium may also be affected by FcRL4+ B-cells. Indeed, the higher number (and severity 
of LELs) seen in parotid gland tissue compared to the labial gland tissue may be attributed 
to the higher number of infiltrating FcRL4+ B-cells. After appropriate stimulation, B-cells are 
able to secrete a wide variety of cytokines29 and these cytokines may affect the epithelium. 
Intestinal epithelial cells, for example, are stimulated to proliferate by pro-inflammatory 
cytokines such as IL-6 derived from intraepithelial lymphocytes.5,30 Similarly, cytokines 
produced by FcRL4+ B-cells, may induce proliferation and differentiation of the epithelium, 
subsequently leading to formation of LELs. The impact of FcRL4+ B-cells on the ductal cells 
is further substantiated by our findings in parotid gland tissue of pSS patients treated with 
rituximab. FcRL4+ B-cells have strong expression of CD20 making them highly susceptible 
targets for rituximab therapy.13,14,17 Treatment with rituximab did not only reduce the total 
number of B-cells, but also reduced intraepithelial FcRL4+ B-cells. This resulted not only 
in a significant decrease in the number of LELs, but also normalization of the epithelial 
lining.19,31 Apparently, when FcRL4+ B-cells are depleted from the epithelium, stimulation 
of ductal cells by FcRL4+ B-cells is no longer present, enabling restoration of epithelium. 
Of note, blocking the CD28 mediated co-stimulation with abatacept did not affect the 
presence of (intraepithelial) FcRL4+ B-cells, and concomitantly also not the numbers and 
severity of LELs.21 Thus, in pSS patients a crosstalk between ductal epithelial cells and 
FcRL4+ B-cells is likely to exist and play a significant role in the formation of LELs. 
In line with previous reports on extra-nodal marginal zone lymphomas in general,11 we 
showed that the vast majority, if not all, of the parotid MALT lymphomas of pSS patients 
express FcRL4. FcRL4 mRNA expression in parotid MALT lymphomas is clearly increased 
as compared to pSS patients without MALT lymphoma indicating an expansion of FcRL4+ 
B-cells. Similar to the association of non-malignant FcRL4+ B-cells with the ductal epithelium 
of the glandular tissue of pSS patients, the majority of malignant FcRL4+ B-cells of parotid 
MALT lymphomas is located within or in close proximity with the ductal epithelium that 
forms LELs. The region of these LELs is also the region in which early expansion of 
neoplastic cells takes place in MALT lymphomas.9 Apparently, neoplastic FcRL4+ B-cells 
maintain their association with epithelium in parotid MALT lymphomas, emphasizing the 
importance of the interaction between epithelial cells and FcRL4+ B-cells. 
In pSS patients MALT lymphomas preferentially develop in parotid salivary glands, and 
less frequent in other major and labial salivary glands.32 Presently, we do not know the 
lymphoma stem cells from which the clonal expansion derives. One possibility is that they 
reside within the compartment of mature B-cells from which the FcRL4+ B-cells derive and 
that the expansion of these FcRL4+ B-cells is due to the interaction with specific epithelial 
features within the parotid glands. Another possibility might be that the FcRL4+ B-cells 
themselves are directly targeted and become neoplastic. The high proliferative capacity of 
FcRL4+ B-cells in the ductal epithelium makes them prone for malignant transformation. 
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Moreover, tonsillar FcRL4+ B-cells exhibit an increased gene expression of activation 
induced deaminase (AID) compared to FcRL4 negative B-cells.24 This gene encodes for an 
enzyme that converts C to U in DNA and is typically expressed in germinal center B-cells 
for initiation of both class switch recombination and somatic hypermutation but can also 
target non-immunoglobulin genes.33 AID is therefore potentially mutagenic and may cause 
genomic instability.34
Numbers of FcRL4+ B-cells vary between pSS patients, and part of the pSS patients 
appears to have higher numbers of these cells. As shown, pSS patients with autoantibodies 
appear to have higher levels of these cells in the glandular tissue. Further analysis in 
prospective studies is needed to see whether patients with the higher numbers of parotid 
gland FcRL4+ B-cells represent a distinct subgroup of patients and/or are the result of 
higher disease activity. However, at the group level the number of FcRL4+ cells in pre-
lymphoma labial gland biopsies did not differ from the numbers seen in biopsies from 
pSS patients that did not develop lymphoma. In two pre-lymphoma labial gland biopsies 
high numbers of FcRL4+ cells were present. Whether these elevated numbers of FcRL4+ 
cells are clonally expanded B-cells with neoplastic potential, seeding from the parotids 
glands to the labial glands or vice versa, remains to be seen. Since high expression of 
FcRL4 was not seen in any of the labial gland biopsies of pSS patients without lymphoma 
development, increased FcRL4 expression in the labial gland biopsy might indicate that a 
pSS patient is at risk for parotid MALT lymphoma development.
In summary, FcRL4+ B-cells are present in pSS salivary glands in close association 
with the ductal epithelium forming LELs. Herewith these cells may play an important role 
in the pathogenesis of pSS, reduced saliva production and destruction of the glands. 
Furthermore, enrichment of parotid gland tissue with highly proliferative intraepithelial 
FcRL4+ B-cells provides a plausible explanation why MALT lymphomas predominantly 
develop in parotid glands rather than labial glands. Treatment with rituximab reduces 
FcRL4+ B-cells, interrupting the interaction between these cells and ductal cells enabling 
the epithelium to restore. Targeting of FcRL4+ B-cells in pSS patients might be explored 
for treatment of pSS patients in general, and more specifically for the treatment of pSS 
patients who are at risk for the development for parotid MALT lymphomas. 
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Supplementary Table 1: Antibodies used for immunohistochemistry.
Antigen Clone Host Company
PAX5 SP34 Rabbit Ventana Roche
BCL6 EPR11410-43 Rabbit DAKO
BLIMP1 EPR16655 Rabbit Abcam
MUM1 MRQ-43 Rabbit Ventana Roche
Ki-67 SP6 Rabbit Abcam
Supplementary Figure 1: Selection of pSS patients with parotid MALT lymphoma
A Pathology-Anatomy Nationwide Digital Archive (*PALGA) search was performed to identify all pSS patients 
diagnosed or revised with a parotid MALT lymphoma at the UMCG. Residual parotid MALT lymphoma biopsy 
material of pSS patients (n=49) from the following pathology departments was used; Pathology dept. University 
Medical Center Groningen, Groningen (n=36), Pathology dept. Friesland, Leeuwarden (n=7), Pathology dept. 
Isala Clinics, Zwolle (n=2), Laboratory Pathology dept. Eastern-Netherlands, Hengelo (n=1), Pathology dept. Onze 
Lieve Vrouwe Gasthuis, Amsterdam (n=1), Pathology dept. Martini Hospital, Groningen (n=1) and Pathology 
dept. University Medical Center Utrecht, Utrecht (n=1). *PALGA: Pathology-Anatomy Nationwide Digital Archive. 
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Supplementary Figure 2: Validity of the immunohistochemical FcRL4 staining.
Serial sections of a parotid gland biopsy from a pSS patient showing A) FcRL4+ cells in and surrounding a striated 
duct forming a lymphoepithelial lesion and B) negative IgG2a isotype control (clone C1.18.4, BD Biosciences). C,D) 
Serial sections of a labial gland biopsy from a pSS patient showing C) FcRL4+ cells in and surrounding a striated 
duct forming a small lymphoepithelial lesion and D) negative IgG2a isotype control. 
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Supplementary Figure 3: PSS patients with auto-antibodies tend to have high numbers of FcRL4+ B-cells in 
their salivary gland biopsy.
In pSS patients with autoantibodies (anti-SSA, anti-SSB, RF, ANA) tend to have higher numbers of FcRL4+ B-cells 




Martha S van Ginkel1 
Erlin A Haacke1,2 
Hendrika Bootsma1 
Suzanne Arends1 
Jolien F van Nimwegen1 
Gwenny M Verstappen1 
Fred KL Spijkervet3 
Arjan Vissink3 
Bert van der Vegt2 
Frans GM Kroese1 
Departments of 1Rheumatology and Clinical Immunology, 2Pathology and Medical 
Biology, and 3Oral and Maxillofacial Surgery, University of Groningen, University 
Medical Center Groningen, the Netherlands
Modified version of: Clin Exp Rheumatol. 2019;37:42-48
Presence of intraepithelial 
B-lymphocytes is associated with 
the formation of lymphoepithelial 





Objective: Lymphoepithelial lesions (LELs) in salivary glands are associated with primary 
Sjögren’s syndrome (pSS). LELs are composed of hyperplastic epithelium infiltrated with 
lymphocytes. The objective of this study was obtaining insight in the relative roles of 
intraepithelial B- and T-lymphocytes in the formation of LELs in salivary glands of pSS 
patients.
Methods: Parotid and labial salivary gland biopsies of pSS patients (n=15), non-SS sicca 
patients (n=5) and non-sicca controls (n=5) were analysed. Serial sections were stained 
with H&E and for cytokeratin, CD20 and CD3. Striated ducts with lymphocytes, but without 
hyperplasia, and striated ducts with LELs were identified in H&E and cytokeratin stained 
sections. LELs were classified in successive stages of severity based on the amount of 
hyperplasia (stage1-3). Numbers of B- and T-lymphocytes within striated ducts and LELs 
were counted in CD20 and CD3 stained sections. 
Results: Lymphocyte-containing striated ducts of both salivary glands of all pSS and 
control patients harboured T-lymphocytes, scattered throughout the ductal epithelium. 
In contrast, B-lymphocytes were exclusively found in a small fraction (21%) of striated 
ducts without hyperplasia and in nearly all striated ducts with LELs of pSS patients, but 
not in controls. In striated ducts with LELs B-lymphocytes were mostly located in the 
areas of proliferating epithelium. Numbers of B-lymphocytes and B/T-ratios increased 
significantly with higher severity of LELs. This was even more pronounced in the parotid 
than in the labial gland. 
Conclusion: We conclude there is an association between presence of intraepithelial 




Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by 
sicca complaints and lymphocytic infiltration of the lacrimal and salivary glands.1 These 
infiltrates are mostly situated around the striated ducts, forming periductal foci. The major 
role of the salivary gland in the pathogenesis of the disease is illustrated by the prominent 
role of histopathology of the salivary gland in the 2016 ACR-EULAR classification criteria.2 
These criteria require either a positive salivary gland biopsy or presence of anti-Ro/SSA 
antibodies to classify a patient as pSS. A biopsy is suggestive for pSS when the focus 
score (FS) ≥1. FS is defined as the number of foci (clusters of ≥50 lymphocytes) in 4 
mm2 glandular tissue.3 However, the FS has some important limitations and additional 
histopathological features may be helpful for diagnosis and classification of pSS.4 One of 
the features associated with pSS is the formation of lymphoepithelial lesions (LELs) within 
the foci.5 Ihrler et al. postulated that LELs develop in a stepwise manner: lymphocytic 
infiltration within the ductal epithelium with subsequent hyperplasia of ductal basal 
cells, causing differentiation into a multi-layered stratified epithelium, or even complete 
obstruction of the striated ducts.5 Interestingly, a serious complication of the disease 
is the development of non-Hodgkin lymphoma in 5-10% of the patients, mostly of the 
mucosa associated lymphoid tissue (MALT) type.6 These lymphomas most commonly 
develop in the parotid gland and are consistently associated with the presence of LELs in 
the glandular tissue. Both B- and T-lymphocytes may be present in LELs.4,7 However, the 
exact roles of B- and T- lymphocytes in LEL formation are unknown. 
The aim of the work described here was to quantify the number of B- and 
T-lymphocytes within striated ducts without hyperplasia and striated ducts with LELs in 
both labial and parotid gland biopsies of pSS patients and controls, in order to get insight 
in the role of lymphocyte subtypes in LEL formation. 
MATERIALS AND METHODS 
Patients 
Both parotid and labial salivary gland biopsies were collected of 15 pSS patients and 
5 non-SS sicca patients, without MALT lymphoma, non-specific chronic sialadenitis 
(NSCS), sclerosing chronic sialadenitis (SCS) or other autoimmune diseases. Patient 
characteristics are provided in Table 1. PSS patients fulfilled the 2016 ACR-EULAR 
criteria. Non-SS sicca patients were defined as patients having sicca complaints, 
without serum anti-Ro/SSA antibodies and without foci (FS=0) in neither parotid nor 
labial salivary glands, and who did not use medication that is known to induce sicca 
symptoms. Furthermore, biopsy material of non-sicca control patients was obtained 
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from diagnostic redundant material. For parotid gland tissue of non-sicca controls 
(n=5), resection margins from parotidectomies of patients with a Warthin tumor (n=2) 
or pleiomorphic adenoma (n=3) were used. For non-sicca labial gland tissue (n=5), 
samples from benign retention cyst (mucocele) resections were taken. The study 
of pSS patients and non-SS sicca patients was approved by the Medical Research 
Ethics Committee of the University Medical Centre Groningen (METc2013.066). All 
pSS and non-SS sicca patients provided informed consent. For the non-sicca controls, 
informed consent was not required by Dutch Law for Medical Research and by 
institutional guidelines. No objection against use of redundant tissue was recorded 
from these non-sicca controls in the institutional record of objection. Patient material 
was handled according to the ‘Code of conduct for health research’ of the Dutch 
Federation of Biomedical Scientific Societies.8












Age* 49.1 (±14.2) 46.7 (±13.5) 59.2 (±12.2) 24.8 (±17.0)
Female 14 (93) 4 (80) 2 (40) 2 (40)
Anti-SSA-positivity 14 (93) 0 (0) N.D. N.D.
FS parotid gland 1.3 (0.6 – 1.9) 0 (0-0) N.D. N.D.
FS labial gland 1.6 (0.8 – 2.3) 0 (0-0) N.D. N.D.
UWS ≤0.1ml/min 10 (67) 4 (80) N.D. N.D.
OSS ≥5 8 (62) 0 (0) N.D. N.D.
Schirmer’s test ≤5 mm 13 (87) 2 (40) N.D. N.D.
Data are given as mean (±SD), number (%) or median (IQR). FS: Focus Score; UWS: Unstimulated Whole Saliva; 
OSS: Ocular Staining Score; N.D.: not determined. * Age at the time of diagnosis.
Histochemical and immunohistochemical staining
Formalin fixed (4%), paraffin embedded tissue samples were serially sectioned at 3 
µm thickness and deparaffinized. Tissue samples were automatically stained with 
hematoxylin and eosin (H&E) and manually stained for CD20 (clone L-26, Ventana 
Roche), CD3 (clone 2GV6, Ventana Roche) and high molecular weight cytokeratin 
(hmwCK, clone 34βE12, Ventana Roche). For the immunohistochemical staining 
antigen retrieval was performed (15 minutes, 98 ˚C in EDTA buffer pH 8.0) and 
endogenous peroxidase was blocked. Primary antibodies were used at a pre-fixed 
dilutions in 1% BSA-PBS (Ventana Roche) for 75 minutes. After incubation with a poly-
HRP-labelled secondary antibody (Thermo Scientific), the primary antibodies were 
visualised by using DAB (3,3’diaminobenzidine). The typical spatial distribution of CD3, 
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CD20 and hmwCK staining within tonsillar tissue was used as both a positive and 
negative control, as the tonsillar epithelium expresses hmwCK and does not express 
CD3 and CD20 and the tonsillar lymphoid tissue expresses CD3 and CD20, but does 
not express hmwCK. 
Histological analysis 
The FS and severity of LELs was scored on H&E stained sections. HmwCK staining was 
used to identify the ductal epithelium, and to detect “occluded LELs” (Figure 1), which 
are otherwise very difficult to detect unequivocally. Only striated ducts with lymphocytes 
within the epithelium were analysed. Ducts were divided into two groups: striated ducts 
with lymphocytes, but without epithelial hyperplasia and striated ducts with lymphocytes 
with epithelial hyperplasia (i.e. LELs). LELs were subdivided into three stages, according 
to the amount of hyperplasia (Figure 1). In all biopsies, the 10 most severe LELs were 
selected for further analysis. In case less than 10 striated ducts with LELs were present, 
striated ducts without hyperplasia, but with intraepithelial lymphocytes, identified by H&E 
staining, were selected to complete the total of 10 ducts. If the total number of striated 
ducts with lymphocytes in the salivary gland tissue was still less than 10, the maximum 
number of striated ducts with intraepithelial lymphocytes and LELs was analysed. 
Numbers of B- and T-lymphocytes within each of the striated ducts and LELs were 
manually scored by using Image J cell counter in serial CD20 and CD3 stained sections. 
Figure 1: Scoring of severity of LELs. 
Striated ducts with lymphocytes were divided into two groups: striated ducts without epithelial hyperplasia (SD 
w/o H) and striated ducts with epithelial hyperplasia (stage 1-3 LELs). Stage 1 LEL: Lymphocytic ductal infiltration 
and hyperplasia affecting less than 50 percent of the epithelium. Stage 2 LEL: Lymphocytic ductal infiltration and 
hyperplasia affecting between 50 and 100 percent of the epithelium. Stage 3 LEL: Lymphocytic ductal infiltration 
and fully circumferentially hyperplastic epithelium without lumen. Arrows point at lymphocytes and the star 
marks the area of proliferation. Dotted lines mark the ductal border, identified on hmwCK staining.
Statistical analysis 
Statistical analyses were performed in IBM SPSS Statistics 23. Generalized estimating 
equations (GEE) were used to analyse the numbers of B-, T-lymphocytes and B/T-ratio’s 
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within LELs of pSS patients over the different stages of severity, within striated ducts 
without hyperplasia of pSS versus control patients, and within LELs of parotid versus 
labial glands of pSS patients. Spearman’s correlation coefficient was used to analyse 
correlations between parotid and labial glands of individual pSS patients and to analyse 
associations between severity of LELs, FS and clinical features of pSS patients. 
RESULTS
Histological analysis
Of the total number of 50 biopsies (25 parotid and 25 labial glands), six biopsies (5 parotid 
and 1 labial gland) were excluded from the analysis due to insufficient biopsy material (< 
4 mm2), or because slides were not stored in a consecutive order. For pSS patients, 11 
parotid and 14 labial gland biopsies were analysed, of which 97 and 137 striated ducts 
were selected for the parotid and labial glands, respectively (median value 10 for both 
types of glands). For the control group (non-SS sicca patients and non-sicca controls), 9 
parotid and 10 labial gland biopsies were analysed, of which 41 and 65 striated ducts 
were selected (median value 4 and 7, respectively). 
Severity of LELs
In pSS patients, striated ducts with LELs were found in 81% of parotid and 86% of labial 
glands, and they were consistently located in association with periductal infiltrates. This 
is in contrast to striated ducts with intraepithelial lymphocytes, but without hyperplasia, 
which were not always associated with periductal infiltrates. Striated ducts with LELs were 
completely absent in non-SS sicca patients and non-sicca controls; in these patients only 
striated ducts without epithelial hyperplasia were present. Numbers of analysed striated 
ducts without hyperplasia and striated ducts with LELs, including frequencies of stages 
of LELs, are shown in Table 2. The number of stage 3 LELs is relatively small in both types 
of glands, due to the small study population. Stage 2 LELs dominated in parotid glands 
of pSS patients, whereas stage 1 LELs were most frequent in labial glands. Mean severity 
of LELs (stage 1-3) of pSS patients was, however, not significantly different between 
parotid and labials glands (1.38±0.78 and 1.08±0.56, respectively). In the parotid gland 
of pSS patients, a higher FS was associated with presence of more severe LELs (rs 0.540, 
p=0.038). 
B- and T-lymphocytes within striated ducts and LELs 
T-lymphocytes were detected in all striated ducts without hyperplasia and striated ducts 
with LELs (stage 1-3) of pSS patients as well as in all striated ducts without hyperplasia 
of the non-SS sicca patients and non-sicca controls. In contrast, B-lymphocytes were 
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exclusively found in striated ducts without hyperplasia and striated ducts with LELs of 
pSS patients, and were completely absent in the striated ducts of non-SS sicca and non-
sicca controls. B-lymphocytes were nearly always found in striated ducts with LELs of 
pSS patients, namely in 100% of parotid and 87% of labial gland stage 1-3 LELs. The 
remaining 13% of LELs without B-lymphocytes in labial glands, were all scored as stage 1 
LELs. Interestingly, B-lymphocytes in striated ducts with LELs were mostly concentrated 
in the areas where the epithelium was proliferating, whereas T-lymphocytes were 
scattered through the whole ductal epithelium (Figure 2). Although B-lymphocytes were 
consistently found in striated ducts with LELs, they were also present in 21% of striated 
ducts without hyperplasia of pSS patients; these striated ducts were also associated with 
a periductal focus.
Table 2: Numbers and frequencies of analysed striated ducts without hyperplasia and LELs. 
Parotid gland Labial gland
pSS patients
N = 99 ducts
Controls
N = 41 ducts
pSS patients
N = 137 ducts
Controls
N = 65 ducts
SD w/o H 63 41 92 65
LELs 36 0 45 0
Stage 1 LELs 13 (36) - 33 (73) -
Stage 2 LELs 21 (58) - 9 (20) -
Stage 3 LELs 2 (6) - 3 (7) -
Data are given as number or number (%). SD w/o H: striated duct without hyperplasia; LELs: lymphoepithelial 
lesions. Controls: non-SS sicca patients and non-sicca controls.
In the parotid and labial gland of pSS patients, the absolute numbers of B-lymphocytes 
in the striated ducts with LELs increased significantly with higher severity of LELs (overall 
increase p<0.001). For T-lymphocytes such an association was only seen in the parotid 
gland (p=0.042). Absolute numbers of B-lymphocytes showed a higher increase compared 
to T-lymphocytes, resulting in a significant increase of the B/T-ratio with higher severity of 
LELs in both glands (overall increase p<0.001) (figure 3). In both parotid and labial salivary 
glands of pSS patients, there was a predominance of T-lymphocytes in striated ducts 
without hyperplasia as well as in stage 1 LELs (B/T-ratio <1). In the more severe stages 
of LELs (stage 2-3), B-lymphocytes outnumbered the T-lymphocytes (B/T-ratio >1) (figure 
3). The fact that B-lymphocytes were present in striated ducts without hyperplasia of pSS 
patients, but not in control patients, was also reflected by a significantly higher number of 
B-lymphocytes and higher B/T-ratio in striated ducts without hyperplasia of pSS patients 
than in non-SS sicca and non-sicca controls in both salivary glands (p<0.001)(Figure 3). 
Numbers of B-lymphocytes, T-lymphocytes and B/T-ratios within LELs (stage 1-3) were 
significantly higher in the parotid gland than in the labial gland (p=0.001, p=0.021 and 
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p=0.007 respectively). To compare parotid and labial glands of individual pSS patients, 
the highest number of B-lymphocytes, T-lymphocytes and the highest B/T-ratio within 
LELs of each gland was taken. A correlation was found between the highest number 
of T-lymphocytes (rs 0.659, p=0.038). No concordance was found between the highest 
number of B-lymphocytes, highest B/T-ratio and most severe stage of LEL within parotid 
and labial gland biopsies of individual pSS patients.
Figure 2: B-lymphocytes are located in the hyperplastic area of the striated duct. 
Serial sections were stained with H&E, and for hmwCK, CD3 and CD20. A) Stage 1 LEL with infiltrating lymphocytes 
and ductal hyperplasia (star) after H&E staining. B) Positive hmwCK staining marks the ductal epithelium. C) 
CD3+ T-lymphocytes are scattered throughout the whole ductal epithelium, whereas D) CD20+ B-lymphocytes 
are located in the hyperplastic area.
Clinical correlations
In order to further explore the role of LELs in disease development, severity of LELs was 
correlated to clinical findings of pSS patients. Positive correlations were found between 
the highest B/T-ratio in the parotid gland and IgG-levels and rheumatoid factor (RF) levels 
in plasma of pSS patients (rs 0.790, p=0.004 and rs 0.696, p=0.017, respectively). A positive 
correlation was also found between the most severe stage of LEL within labial glands and 
the flow rate of unstimulated whole saliva (UWS) (rs 0.563, p=0.029). No correlations with 
ESSDAI scores or other clinical parameters were found in this small study population. 
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Figure 3: B-lymphocytes are exclusively present in striated ducts of pSS patients, and their absolute numbers 
increase with higher severity of LELs.
Numbers of B- and T-lymphocytes, as well as B/T-ratios were assessed in striated ducts without hyperplasia (SD 
w/o H) and striated ducts with hyperplasia (LELs) of pSS and control patients. LELs were only present in pSS 
patients. Striated ducts without hyperplasia of non-sicca controls (con), non-SS sicca patients (non-SS) and pSS 
patients (pSS) are listed on the left side of each graph. Striated ducts with LELs (stage 1-3) of pSS patients are 
listed on the right side of the graphs. Bars represent medians. GEE analyses were used to analyse differences in 
numbers of B-lymphocytes (A,B), T-lymphocytes (C,D) and B/T ratios (E,F) between SD w/o H of pSS and control 
patients (left side of graphs) and between the different LEL stages of pSS patients (right side of graphs) in both 




The main aim of this study was to gain insight in the formation of LELs by quantification of 
the numbers of B- and T-lymphocytes within striated ducts without hyperplasia and within 
different stages of LELs in the parotid and labial salivary gland of pSS patients, compared 
to salivary glands of non-SS sicca patients and non-sicca controls. We found that all 
analysed striated ducts with lymphocytes consistently harbored T-lymphocytes, scattered 
throughout the whole epithelium. In contrast, B-lymphocytes were exclusively seen in 
striated ducts without hyperplasia and in striated ducts with LELs of pSS patients, and 
were mostly located in areas of proliferating epithelium. B-lymphocytes were completely 
absent in the striated ducts of non-SS sicca and non-sicca controls. Absolute numbers of 
B-lymphocytes increased with higher severity of LELs in both glands, leading to a significant 
increase in B/T-ratio over the stages of LELs. This was even more pronounced in the 
parotid gland, than in the labial gland. 
Our observation that in non-SS sicca patients (in this study defined as patients 
without anti-SSA antibodies and FS=0) and in non-sicca controls (all without periductal 
foci), the ductal epithelium only contains T-lymphocytes, indicates that these cells are a 
normal component of the salivary gland epithelium. On the other hand, B-lymphocytes 
were only present in a small proportion of striated ducts without hyperplasia and in all 
(parotid gland) or nearly all (labial glands) of the striated ducts with LELs of pSS patients. 
These B-lymphocytes are predominantly located at the sites where the epithelium is 
hyperplastic. These findings strongly argue that intraepithelial B-lymphocytes are involved 
in proliferation of the epithelial cells and the generation of LELs. Strong support for this 
notion also comes from studies of pSS patients treated with B-lymphocyte depletion 
therapy (rituximab). These studies showed that this therapy not only results in depletion of 
intraepithelial B-lymphocytes of the ducts but concomitantly also in downstaging of LELs.9 
In this study, the possible contribution of hyperactive B-lymphocytes in salivary gland 
dysfunction was also reflected by positive correlations between B/T-ratios and severity of 
LELs with serological parameters and salivary secretion. However, our study population 
was quite small and correlations with clinical parameters should be further explored in a 
larger cohort of pSS patients. 
Based upon the results of the current study, it seems plausible that influx of 
B-lymphocytes precedes the hyperplastic reaction of the epithelium, since 21% of striated 
ducts with lymphocytes, but without hyperplasia of pSS patients (but not of controls), 
already contain B-lymphocytes. A major chemokine produced by the ductal epithelium of 
pSS patients that can attract CXCR3-expressing B- and T-lymphocytes, is the inflammatory 
chemokine CXCL10, which is induced by IFN.10 Strongly elevated levels of this chemokine 
are detected in saliva, tears and serum of pSS patients.11,12 We have previously observed 
that the vast majority of B-lymphocytes within the LELs express FcRL4.13 A high proportion 
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of these intra-epithelial B-lymphocytes is proliferative in both the parotid (mean 20.5±7.7%) 
and labial gland (mean 15.4±8.2%), as revealed by Ki67 staining.13 Thus after the initial influx 
into the epithelium, these cells may proliferate locally. The reason for the proliferation of 
the B-lymphocytes (and possibly to some extent also intraepithelial T-lymphocytes) is not 
known. The epithelial cells in the inflamed salivary glands of the pSS patients produce a 
wide variety of cytokines, including BAFF and APRIL,14 which may support the intraepithelial 
proliferation of the B-lymphocytes. Verstappen et al.15 revealed expression of IL-21 
within the parotid ductal epithelium. This cytokine, important for B-lymphocyte activation 
and differentiation, is a signature cytokine for follicular helper T-lymphocytes (TFH). This 
observation opens the possibility that TFH play a role in the activation of intraepithelial 
B-lymphocytes. 
Interestingly, also the MALT lymphomas in the parotid gland of pSS patients express 
FcRL4 and the neoplastic B-lymphocytes are characteristically associated with LELs. We 
therefore hypothesized that the neoplastic B-lymphocytes arise from this small subset 
of FcRL4-expressing B-lymphocytes.13 In line with the observation that MALT lymphomas 
preferentially develop in the parotid glands of pSS patients we observed in this study 
that B/T ratios are higher in striated ducts with LELs of parotid glands compared to labial 
glands.
We speculate that after homing into the epithelium, the (FcRL4+) B-lymphocytes 
activate the ductal epithelial (stem) cells, after which they start to proliferate. How these 
B-lymphocytes exert their possible effects on the epithelium remains to be shown, but 
cytokines secreted by activated B-lymphocytes are possible candidates. It is already known 
that intestinal intraepithelial lymphocytes can secrete pro-inflammatory cytokines like IL-
2, IL-4 and IL-6, which can cause epithelial cell proliferation.16 Vice versa, epithelial stem 
cells derived from the parotid glands proliferate under the influence of pro-inflammatory 
cytokines in vitro.17 In RA, FcRL4+ B-lymphocytes have been found in synovial fluid, where 
they produce cytokines such as TNFα and RANKL.18 In salivary glands of pSS patients, 
FcRL4+ B-lymphocytes may possibly also secrete cytokines within the ductal epithelium 
and thereby stimulate proliferation of the epithelial cells [Verstappen et al. submitted for 
publication]. More research on the functional capabilities of the (FcRL4+) B-lymphocytes 
in pSS patients is needed, especially on the cytokines they produce.
In conclusion, LELs are a characteristic histopathological finding in salivary glands 
of pSS patients and there is a close interaction between lymphocytes and the ductal 
epithelial cells. Our results show an association between intra-epithelial B-lymphocytes 
and hyperplasia of the basal ductal epithelial cells and thereby the formation of LELs in 
salivary glands of pSS patients. 
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Objective: Patients with primary Sjögren’s syndrome (pSS) have an increased risk of 
developing non-Hodgkin’s lymphoma (NHL), particularly parotid gland mucosa-associated 
lymphoid tissue (MALT) lymphomas. Presence of germinal centres (GCs) in labial gland 
biopsies has been suggested as predictive factor for NHL. We assessed whether presence 
of GCs is increased in labial gland biopsies from patients with pSS who developed parotid 
MALT lymphoma, the dominant NHL-subtype in pSS, compared with patients with pSS 
who did not develop lymphoma.
Methods: Eleven labial gland biopsies from patients with pSS that were taken prior to 
parotid MALT lymphoma development were compared to biopsies of 22 matched pSS 
controls (1:2) who did not develop lymphoma. Biopsies were evaluated for GCs (H&E and 
Bcl6).
Results: Labial gland biopsies of pSS MALT lymphoma patients, revealed GCs in 2/11 (18%) 
H&E sections and 3/11 (27%) Bcl6 stained sections. In controls, GCs were present in 4/22 
(18%) of H&E sections and 5/22 (23%) of Bcl6 stained sections. 
Conclusion: Presence of GCs in labial gland biopsies does not differ between patients 
with pSS that develop parotid MALT lymphoma and patients with pSS who do not develop 
lymphoma. The presence of GCs in labial gland biopsies is therefore not a predictive factor 




Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, in which salivary and 
lacrimal glands are affected by a chronic inflammatory process, which leads to dryness 
of mouth and eyes.1 Histopathologically, this inflammatory process is characterised by a 
periductal lymphoid infiltrate in the glandular parenchyma.2 In roughly one quarter of the 
patients with pSS, germinal centres (GCs) can be found within these lymphoid infiltrates 
reflecting the B-cell hyperactivity that characterises the disease.3,4 Although the clinical 
significance of these GCs remains to be elucidated, the presence of GCs in the glandular 
tissue of patients with pSS is generally associated with more severe clinical disease as 
reflected by a higher focus score (FS), increased presence of anti-SSA/Ro (52 kD + 60 kD) and 
anti-SSB/La autoantibodies and elevated levels of proinflammatory cytokines in the blood.3 
A serious complication of pSS is the 5%-10% lifetime risk of developing non-Hodgkin’s 
B-cell lymphomas (NHL).5 The most common subtype NHL in pSS is the mucosa-associated 
lymphoid tissue (MALT) lymphoma.5-7 These MALT lymphomas preferentially arise in the 
parotid glands and account for >60% of the lymphomas arising in patients with pSS.6-
8 Which patients with pSS will develop NHL is largely unknown, but several predictors 
have been identified including disease activity, persistent glandular enlargement, 
lymphadenopathy, palpable purpura, anti-Ro/anti-La antibodies, rheumatoid factor (RF), 
lymphopenia, declined C3 or C4 levels, cryoglobulinaemia and a FS ≥3 in the labial gland 
biopsy.9-11 Presence of GCs in diagnostic labial gland biopsies has also been proposed 
as a predictive factor for the development of NHL. However, in the study underlying this 
assumption, all subtypes of NHL were taken into account, including NHL subtypes not 
typically associated with pSS, such as follicular lymphoma and T-cell lymphoma.12 For this 
reason, we explored the predictive role of GCs in labial gland biopsies from patients with 
pSS for parotid gland MALT lymphomas. 
MATERIALS AND METHODS
Patients
From 56 patients with pSS diagnosed with parotid MALT lymphoma we were able to 
acquire labial gland biopsies of 11 patients taken at diagnosis of pSS, before (median 
4.0, IQR 1.5-6.1 years) lymphoma diagnosis (Table1). Labial gland biopsies from 22 pSS 
patients with a NHL free follow-up (median 12.0, IQR 6.3-16.8 years) served as controls 
(Supplementary Table 1). Matching of control pSS patients (1:2) was based on age at 
diagnosis of pSS and the presence of SSA autoantibodies. Patients were frequency-
matched within three age groups: patients diagnosed with pSS at an age of ≤40, between 
40 and 60 and ≥60 years. All patients were clinically diagnosed as pSS and retrospectively 
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fulfilled the ACR-EULAR (American College of Rheumatology - European League Against 
Rheumatism classification criteria13 at time of diagnosis. Of the 33 included patients, 32 
also fulfilled the AECG-criteria at time of diagnosis. Of one patients this is uncertain due 
to missing sialometry and ocular examination.
Histopathological assessment of diagnostic salivary gland biopsies
Diagnostic labial salivary gland biopsies were formalin fixed, paraffin embedded 
and sectioned at 3 µm thickness. Serial sections were stained with H&E, and 
immunohistochemically for B-cell lymphoma six protein (Bcl6, clone 2B11+PD7/26, 
Ventana, Illkirch, France) and CD45 (clone 2B11+PD7/26, Ventana, Illkirch, France). 
Staining was performed on a Ventana Benchmark platform as previously described.14 
In H&E stained sections, FS, lymphoepithelial lesions (LELs) and GCs were assessed. FS 
was based on the number of clusters of ≥50 lymphocytes (foci)/4 mm2 parenchyma. In 
case of multiple large confluent foci an arbitrary FS of 12 was used.15 LELs were defined 
as a striated duct with lymphocytes within its basement membrane. GCs were defined as 
a clearly visible lighter area in a lymphocytic infiltrate containing cells usually present in 
classical GCs: follicular dendritic cells, centrocytes, centroblasts and macrophages. Since 
detection of GCs is difficult in H&E stained sections, and small GCs may be overlooked,16 we 
also evaluated GCs in Bcl6 stained sections. Bcl6 is a transcription factor highly expressed 
by all GC B-cells. A cluster of ≥5 adjacent Bcl6+ cells within a focus was classified as a GC.
Besides focus score, we also measured the extent of glandular inflammation as 
proposed.2 This was assessed using CD45 staining. CD45 is expressed by all lymphoid 
and non-lymphoid cells of hematopoietic origin, allowing easy quantification of the relative 
area of the infiltrate. CD45 expression was measured using ImageScope v12.0 (Aperio 
Technologies). Slides were blinded and independently scored by a trained resident (EH) 
and a dedicated head & neck pathologist (BvdV). 
Statistical analysis
Mann-Whitney U test and Fisher’s Exact test were used accordingly to test differences 
between groups (IBM-SPSS Statistics V.23).
RESULTS
Analysis of H&E stained sections from diagnostic labial gland biopsies, taken prior to 
parotid MALT lymphoma development, revealed presence of GCs in 2/11 (18%) patients 
(Table 2). Staining for Bcl6, revealed an extra (small) GC in a biopsy of one additional 
patient (Figure 1, Table 2). Thus, in pSS patients who developed parotid MALT lymphoma, 
GCs were present in 3/11 (27%) prelymphoma labial gland biopsies. In the patients with 
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pSS that did not develop parotid MALT lymphomas (nor any other type of NHL) GCs were 
detected in 4/22 (18%) diagnostic labial gland biopsies in H&E stained sections and in 5/22 
(23%) of Bcl6 stained sections (Table 2). This proportion was comparable with that seen 
in patients with pSS who did develop parotid MALT lymphoma. 
Since FS≥3 has been suggested as predictive factor for NHL development,9 we 
compared FS and relative area of CD45+ infiltrate in prelymphoma labial gland biopsies and 
biopsies from control pSS patients. FS did not differ between both groups (Mann-Whitney 
U, p=0.204). The percentage of biopsies with FS ≥3 was even higher in the control group 
(36% versus 27%). The relative area of CD45+ lymphocytic infiltrate, however, tended to be 
higher in the prelymphoma labial gland biopsies than in the controls (Table 2). 
Figure 1: GCs in diagnostic labial salivary gland biopsies of patients with pSS who developed a parotid MALT 
lymphoma later on. A) Clearly visible GC in a periductal focus of the labial gland , H&E stain. B) Bcl6 staining 
of serial section, showing the same GC. C) Suspicious GC in a periductal focus of the labial gland, H&E stain. 












































































































































































































































































































































































































































































































































































































































































































Table 2: Patient characteristics and histological results of diagnostic labial gland biopsies from pSS developing 
parotid MALT lymphomas and control labial gland biopsies.
Variable Labial biopsies prior 
to parotid MALT 
lymphoma
 (n=11)
Labial biopsies from 




Whitney U test 
(MWU) or Fisher’s 
exact test (FT) 
Female n (%) 11/11 (100%) 20/22 (91%) 0.542  (FT)
Age (year), mean (sd) 47.5 (14.0) 48.7 (17.2) 0.638  (MWU)
Anti-SSA positive, n (%) 11/11 (100%) 22/22 (100%) -
Anti-SSB positive, n (%) 7/11 (64%) 13/22 (59%) 1.000  (FT)
Anti-RF positive, n (%) 11/11 (100%) 19/22 (86%) 0.534  (FT)
Anti-ANA positive, n (%) 11/11 (100%) 21/22 (96%) 1.000  (FT)
Δ pSS-lymph (year), median (IQR)
Δ pSS-FU (year), median (IQR) 
4.0 (1.5 – 6.1)
-
-
12.0 (6.3 – 16.8) 
-
-
FS, median (IQR) 1.8 (0.8 – 4.0) 2.7 (1.4 – 3.5) 0.204  (MWU)
FS≥3, n (%) 3/11 (27%) 8/22 (36%) 1.000  (FT)
Area CD45 (%), median (IQR) 20.3 (7.4 – 27.7) 12.7 (9.4 – 19.1) 0.143  (MWU)
LELs based on H&E, n (%) 7/11 (64%) 13/22 (59%) 1.000  (FT)
GC based on H&E, n (%) 2/11 (18%) 4/22 (18%) 1.000  (FT)
GC based on Bcl6, n (%) 3/11 (27%) 5/22 (23%) 1.000  (FT)
Δ lymph-pSS: time between diagnosis of pSS and parotid MALT lymphoma, Δ pSS-FU: time between diagnosis 
of pSS and last follow up, GC: germinal center, H&E: hematoxylin and eosin, Bcl6: B-cell lymphoma 6 protein.
DISCUSSION
This study shows that the presence of GCs does not differ between diagnostic labial 
gland biopsies from patients with pSS who did develop parotid MALT lymphoma and 
patients with pSS patients who did not develop such lymphoma. In H&E stained sections 
we observed an identical percentage of GCs in both categories of patients (18%). With a 
more sensitive and specific method to identify GCs, viz. staining for the GC B-cell associated 
transcription factor Bcl6,16 a slightly higher incidence of GCs was seen in both groups: 27% 
for pre-lymphoma patients and 23% for non-lymphoma pSS patients. Although the two 
groups of patients with pSS are rather small, the percentages of GCs are similar to those 
reported for labial gland biopsies among the general pSS population.3 Based upon a large 
number of studies, Risselada et al. reported that the mean weighted percentage of GCs in 
labial gland biopsies of patients with pSS was 25.1±5.0% (range 18.3-33%) in H&E stained 
sections. Since there was no difference in the occurrence of GCs in labial gland biopsies 
of patients with pSS prior to parotid MALT lymphoma development and the matched pSS 
controls as well as with the general pSS population, we conclude that presence of GCs in 
labial biopsies is not likely predictive for parotid MALT lymphoma development. 
122
Other studies that examined the predictive value of GCs in NHL development did not 
restrict themselves to MALT lymphoma.9,12,17 In a retrospective analysis of prelymphoma 
labial gland biopsies from 13 pSS patients with unspecified NHL lymphomas, Risselada 
et al.9 found that in H&E stained sections GCs were present in only three (23%) of the 
patients. Johnsen et al.17 showed that in similarly stained labial gland biopsies of pSS NHL 
patients, 4 out of 12 biopsies (33%) exhibited GCs. The matched control group of pSS 
patients without malignant lymphoma development showed an even higher percentage 
of 46% (13/28) GCs in the biopsies. However, in Johnsen’s study, biopsies were taken prior 
to NHL development and simultaneously or even after NHL development. 
In contrast to our findings and the aforementioned reports, two earlier studies 
(Theander et al12 and Bombardieri et al18) indicated an increased incidence of GCs in 
diagnostic biopsies preceding NHL development. Theander et al, observed that 6 out of 
7 patients had GCs in diagnostic labial salivary gland biopsies, prior to NHL development. 
Besides differences in patient cohorts, the most likely explanation for the apparent 
discrepancy between Theander’s study and our findings might be the selection of patients 
with pSS that developed NHL. While Theander et al. took all NHLs into account, we restricted 
ourselves to NHLs that are typically associated with pSS, namely parotid MALT lymphomas. 
Remarkably, only one out of seven pSS lymphomas in Theander’s retrospective study 
represented a salivary gland (parotid) MALT lymphoma, making comparison with our study 
difficult. Bombardieri et al18 found ‘GC-like structures’ in six out of eight (75%) of labial 
gland biopsies from pSS and patients with secondary Sjögren’s preceding parotid MALT 
lymphoma. However, in this study, GC-like structures were determined by the presence of 
T-cells, B-cells and CD21+ FDC networks. Although CD21+ FDC networks are a prerequisite 
for GC development, their presence does not imply that GCs are indeed present. This may 
lead to a significant overestimation of the number of GCs in the tissue compared with 
Bcl6 staining.16,19
In conclusion, there are no indications that the occurrence of GCs in diagnostic labial 
gland biopsies is increased in patients with pSS who developed parotid MALT lymphoma. 
Thus, in our opinion, labial salivary gland GCs of patients with pSS are not likely a predictive 
factor for parotid MALT lymphoma development. Nevertheless, their presence might be 
of clinical relevance for stratification of pSS patients regarding treatment options. For this 
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Dear Editor, with great interest we have read the article of Sène et al.1 in which ectopic 
germinal centres (GCs) in labial gland biopsies of primary Sjögren syndrome (pSS) 
patients were found predictive for Non-Hodgkin’s lymphoma (NHL) development later 
in the disease. In the univariate analysis the presence of GCs in these biopsies was 
not significantly different between pSS patients who developed NHL or pSS patients 
who did not. However, multivariate analysis revealed that presence of GCs in biopsies 
was an independent predictor for NHL development.1 This study adds to the ongoing 
discussion about the presence of ectopic GCs in pSS diagnostic salivary gland biopsies 
as a risk factor for subsequent NHL development. The study of Theander et al.2 showed 
that GCs in diagnostic labial gland biopsies was predictive for NHL development in pSS 
patients, whereas we3 and others4,5 did not detect such an association. As discussed 
extensively,3,6 a major reason for the apparent discrepancy in the different studies was 
the variation in NHL-subtypes that were included. 
Remarkably, half of the pSS patients in the study of Sène et al.1 were male, whereas 
in the other studies that evaluated the presence of GCs as risk factor, the majority of 
patients (>81%) were females.2-5 Whether the predictive value of presence of GCs in 
diagnostic biopsies differs between males and females is not known. 
A very unusual observation in the study of Sène et al.1 was that all pSS patients 
who developed NHL, had a monoclonal gammopathy (MG). In pSS patients in general, 
the presence of MG is 4-22%.1,7,8 We observed MG at time of lymphoma diagnosis in 4/8 
(50%) pSS patients with a parotid MALT lymphoma (Haacke et al., unpublished data). 
In another recent study only 3/7 (43%) pSS patients with pulmonary MALT lymphomas 
exhibited MG.9 Presence of MG is known as a risk factor for NHL development, but 
is also associated with higher disease activity.8,10 The presence of MG in pSS pre-
lymphoma patients in the study of Sène et al.1 could thus also be a reflection of high 
disease activity (ESSDAI) which is an independent predictor for NHL development.11 
Also the presence of GCs in biopsies is associated with high disease status.12 Since 
disease activity as measured by ESSDAI can change over time,13 the time point when 
the diagnostic pSS biopsy is taken, is of crucial importance. If a labial gland biopsy is 
taken during a period of relatively low disease activity, the likelihood of presence of GCs 
might consequently be low. On the other hand, when a diagnostic pSS salivary gland 
biopsy is taken in a period of high disease activity, the chance of finding GCs is higher.
Thus, both GCs and MG are associated with higher disease status, but there is 
no clear indication that presence of ectopic GCs is a prerequisite for MALT lymphoma 
development. There are many pSS patients with GCs in their salivary gland biopsies 
that do not develop NHL. Of note, presence of GCs is usually assessed in labial salivary 
glands, which are not the sites where MALT lymphoma preferentially develop. We 
conclude that for prediction of pSS patients who are at risk for NHL development, 
clinical and laboratory factors such as low C4, RF-positivity, presence of cryoglobulin, 
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highly active disease, purpura, lymphadenopathy and especially persistent parotid 
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Objectives: The aims of this study were (1) to assess the effect of rituximab (RTX; anti-
CD20) treatment in primary Sjögren’s syndrome (pSS) patients based on sequential parotid 
biopsies obtained in a placebo-controlled, randomized clinical trial, and (2) to assess the 
prognostic value of the histological characteristics of parotid gland tissue with regard to 
responsiveness to RTX treatment.
Methods: In a double-blinded, placebo-controlled trial, sequential parotid gland biopsies 
were taken from 20 RTX-treated and 10 placebo-treated pSS patients, at baseline and 12 
weeks after treatment. The relative amount of lymphocytic infiltrate (stained for CD45), 
absolute number of T-cells and B-cells per mm2 parenchyma (stained for CD3 and CD20, 
respectively), focus score, number of germinal centers and of lymphoepithelial lesions per 
mm2 in parotid gland parenchyma were assessed. Histopathological data were compared 
between clinical responders (decrease in European League Against Rheumatism EULAR 
Sjögren’s Syndrome Disease Activity Index (ESSDAI) score of ≥3 at 12 weeks compared to 
baseline) and non-responders (change in ESSDAI <3) to RTX treatment. 
Results: In RTX-treated patients, a significant reduction in the number of CD20+ B-cells/
mm2 parenchyma was observed, while no such reduction was observed in placebo-treated 
patients. The number of CD3+ T-cells/mm2 in parenchyma did not change in either group. 
Furthermore, the number and the severity of lymphoepithelial lesions/mm2 and number 
of germinal centers/mm2 was significantly reduced in RTX-treated patients, but did not 
change in placebo-treated patients. When comparing the pre-treatment characteristics 
of clinical responders with non-responders, the median number of CD20+ B-cells/mm2 
parenchyma at baseline was significantly higher in responders (1871 versus 353 cells/
mm2, p=0.001). Other histopathological baseline characteristics were not predictive for 
response to RTX treatment. 
Conclusion: RTX treatment in pSS leads to a major reduction of lymphocytic infiltration 
and to fewer B-cells, germinal centers and lymphoepithelial lesions in parotid gland 
parenchyma. A high pre-treatment number of CD20+ B-cells/mm2 parotid gland parenchyma 
predicts better responsiveness of pSS patients to RTX treatment. Pre-treatment parotid 
gland histopathological characteristics could therefore contribute to a more personalized 




Primary Sjögren’s syndrome (pSS) is a common rheumatic disease, with a prevalence 
of 60.8 (95% CI 43.7 to 77.9) cases per 100 000 inhabitants in the total population.1 
PSS commonly affects salivary and lacrimal glands, resulting in a sensation of dry mouth 
(xerostomia) and dry eyes (keratoconjunctivitis sicca). Although the exact pathogenic 
mechanism has not been fully elucidated, in patients with pSS the minor and major 
salivary glands are characteristically infiltrated by mononuclear lymphoid cells, which 
form periductal foci. The classic glandular lesion is composed of a lymphoid infiltrate of 
T and B lymphocytes, whose distribution may vary according to lesion severity.2 A central 
role is attributed to B-cells, which to be hyperactive.3 pSS patients have an increased risk 
of developing lymhoproliferative diseases, which is about 4% during the first 5 years, 
10% at 15 years and 18% after 20 years post-diagnosis.4 Consequently, about 7.5% of 
patients with pSS develop malignant B-cell lymphoma. In 48-75% of these cases, this is 
the mucosa-associated lymphoid tissue (MALT) type of lymphoma.5-7 Most commonly, 
these lymphomas arise in the parotid glands. The assumed role of hyperactive B-cells in 
the pathogenesis of pSS is supported by the observed beneficial objective and subjective 
clinical effects of B-cell depletion by rituximab (RTX), a chimeric monoclonal antibody 
that binds to the B-cell surface antigen CD20.8-16 Significant response was observed in 
most trials, except from one large randomized clinical trial, the TEARS study.17 Posthoc 
application of the Sjögren’s syndrome response index (SSRI), showed also significant 
response rate difference between RTX and placebo in TEARS.18 Because there are some 
concerns about the efficacy of rituximab, the TRACTISS study is aiming to provide evidence 
whether rituximab improves the clinical outcomes.19 The final results of the TRACTISS 
study, including a subanalysis on responders and non-responders, are eagerly awaited. 
In a previous open-label phase II study, based on sequential parotid biopsies of 5 pSS 
patients, we showed that RTX treatment might result in restoration of secretory tissue 
at a glandular level in responding patients.20 In that study we observed a reduction of 
the lymphocytic infiltration with partial to complete loss of germinal centers (GC) and 
redifferentiation of lymphoepithelial lesions (LEL) to regular striated ducts. However, major 
limitations of the study by Pijpe et al. were the small number of patients and lack of a 
placebo group.20 Therefore, the aims of the current study were (1) to assess the effect 
of RTX treatment in pSS patients based on sequential parotid biopsies obtained in a 
placebo–controlled, randomized clinical trial, and (2) to assess the prognostic value of 





Thirty patients with pSS were treated in a randomized double-blinded placebo-controlled 
trial on days 1 and 15 with either 1000 mg RTX i.v. (Roche, Woerden, the Netherlands; n= 
20) or placebo i.v. (n= 10) at the University Medical Center Groningen, the Netherlands, 
as described before.14 All patients fulfilled the American European Consensus Group 
Criteria (AECG) criteria for pSS.21 To minimise side effects (infusion reactions, serum 
sickness), all patients, including the placebo treated patients, were pre-medicated with 
methylprednisolone (100 mg i.v.), acetaminophen (1000 mg p.o.) and clemastine (2 mg 
i.v.), and received 60 mg oral prednisone on days 1 and 2, 30 mg on days 3 and 4, and 15 
mg on day 5 after each infusion. 
An incisional biopsy was taken under local anesthesia from the same parotid gland 
before and 12 weeks after therapy.22 The European League Against Rheumatism (EULAR) 
Sjögren’s Syndrome Disease Activity Index (ESSDAI)23,24 was assessed at the same time 
points by two experienced rheumatologists, who were blinded to the treatment group, 
in order to evaluate possible systemic complications.16 With regard to response to RTX 
treatment, patients were categorized into two groups: clinical responders, if the decrease 
in ESSDAI was 3 points or more at 12 weeks after treatment compared to baseline, and 
clinical non-responders, if the change of ESSDAI was less than 3 points. The cut-off of 3 
points was chosen because this difference indicates a clinically relevant effect.25 All patients 
provided informed consent in accordance with the ethics committee of the University 
Medical Center Groningen (METC approval: 05.229). 
Histopathologic analysis
Parotid gland tissue biopsies were fixed in 4% formaldehyde, embedded in paraffin, cut 
at a thickness of 3 μm, and stained with hematoxylin and eosin. The focus score (defined 
as ≥50 lymphocytes per 4 mm2 glandular tissue), and the number of GC/mm2 parotid 
gland parenchyma were determined. GC were defined as a clearly visible lighter area 
in a lymphocytic infiltrate containing cells that are usually present in classical germinal 
centers, like follicular dendritic cells, centrocytes or centroblasts and macrophages. LEL 
are expressed in LEL/mm2 of parotid gland parenchyma, excluding intraparenchymal 
connective and fat tissue. LEL were evaluated in immunohistochemically stained tissue 
sections, stained for CD20 as B-lymphocytes predominate in the LEL. A LEL was defined 
as a cross section of a striated duct with infiltration of CD20+ B-cells within the basement 
membrane combined with hyperplasia of the epithelium. To evaluate regeneration of the 
ducts, LEL were subcategorized into three stages (Figure 1A): stage 1) LEL affecting less 
than 50% of the epithelium of the striated duct (partial LEL); stage 2) LEL affecting between 
50% and 100% of the epithelium of the striated duct (developed LEL); stage 3) LEL with fully 
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circumferentially affected epithelium without lumen (occluded LEL). For histopathological 
evaluation, biopsies were independently scored by 2 investigators (R.P.P. and S.I.) in a 
blinded setting. In case of discrepancy, a definitive score was established by consensus. 
Figure 1: A) Classification of lymphoepithelial lesions (LELs) in three stages as stained with CD20:20 (1) LEL 
affecting less than 50% of the epithelium of the striated duct ( partial LEL); (2) LEL affecting between 50% and 
100% of the epithelium of the striated duct (developed LEL); (3) LEL with fully circumferential affected epithelium 
without lumen (occluded LEL). B) Number of LELs/mm2 of parenchyma in parotid glands of patients with primary 
Sjögren’s syndrome ( pSS). Horizontal lines indicate median values. C) Presence of three stages of LELs/mm2 in 
placebo-treated and rituximab (RTX)-treated patients at week 0 and week 12; y axis indicates the total number 
of patients, while x axis the presence of different stages of LEL.
Immunohistochemical analysis 
Immunostaining was utilized for the analysis of lymphocytic infiltrate and was performed as 
follows. Parotid glands were fixed in 4% buffered formaldehyde, embedded in paraffin wax and 
sectioned into 4-μm-thick serial sections. Sections were stained after deparaffinisation, pre-
treatment with Ultra CC1 (Ventana Medical Systems, Inc, USA), antigen retrieval and endogenous 
peroxidase blocking using the Benchmark machine. Sections were immunohistochemically 
stained with anti-CD45 (dilution 1:25, Dako, Heverlee, Belgium, clone 2B11+PD7/26), anti-
CD79a (dilution 1: 100, Dako, Heverlee, Belgium, clone JCB117), anti-CD20 (dilution 1:200, Dako, 
Heverlee, Belgium, clone L-26) and anti-CD3 (dilution 1:20, Monosan, Uden, the Netherlands, 
clone PS-1) antibodies. The sections were then treated with peroxidase-labelled secondary 
antibody and visualized with the chromogen DAB (3,3’ Diaminobenzidine) solution. 
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The relative amount of CD45 positive lymphocytic infiltrates was assessed in relation to 
the total amount of tissue parenchyma by morphometry with use of ImageJ software (v1.46). 
Using HistoQuest software, version 3.5.3.0171, two markers were created, the DAB master 
marker (CD20) and the hematoxylin non-master marker (nucleus). For the master marker, 
multiple reference shade was set on 8 with a background threshold range of 5–255. Ring 
mask and identified cell mask were used. By using a color picker, the shade was chosen 
directly from a positively stained CD20 cell. One whole section was analyzed excluding 
intraparenchymal connective and fat tissue leaving multiple regions of interest (ROIs). For the 
assessment of CD20+ cells, scattergrams were created for each ROI, allowing the visualization 
of corresponding positive cells in the source ROI, using the real-time back-gating feature. To 
correct false events, a specific gate according to cell size and intensity of CD20 staining was 
defined and applied to all analyzed samples. CD20+ cells were quantified according to the 
selected marker and gate. By using the real-time back-gating feature, automatically counted 
CD20+ cells were visualized and controlled. The CD20+ cell count (number of cells/mm2) for 
each analyzed ROI was obtained. The same procedure was followed for CD3+ cell count.
Statistical analysis 
Analysis was carried out with IBM SPSS Statistics 20 (SPSS, Chicago, Illinois, USA). Mann-
Whitney U test was used to compare differences between the RTX and placebo groups 
or between clinical responders and non-responders. Wilcoxon signed-rank test was used 
to compare differences over time within groups. Spearman’s correlation coefficient was 
used to analyze the relationship between histopathology and ESSDAI. Correlations (ρ) <0.3 
were interpreted as a poor association, 0.3–0.6 as moderate, 0.6–0.8 as good and >0.8 
as excellent.15 P-values <0.05 were considered as statistically significant. Power analysis 
was performed with Statistical Power Calculator (DDS Research, Washington DC, USA). 
RESULTS
From the total group of 30 patients, five patients had to be excluded from histopathological 
analysis, due to serum sickness (n=1, RTX-group) or insufficient biopsy material (n=3, RTX-
group); one patient dropped out of the study (placebo group). Thus, complete evaluation 
could be performed of parotid gland biopsies taken from 16 RTX treated patients and 9 
placebo-treated patients. 
Lymphocytic infiltrate in parotid glands 
No differences at baseline between the RTX-treated group and the placebo-treated group 
were found regarding the focus score, relative area of CD45 staining, numbers of CD20+ 
B-cells and CD3+ T-cells and proportion of biopsies containing GC (data not shown). 
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After treatment, the focus score did not change significantly in either the RTX-treated 
group or the placebo-treated group (Table 1). However, CD45 staining demonstrated a 
significant decrease of the relative area of infiltrates at 12 weeks after RTX treatment. In 
the placebo group no change was observed between baseline values and 12-week post-
treatment values (Figure 2, Table 1). 
Figure 2: Effect of placebo (n=9) and rituximab (RTX) (n=16) treatment on relative areas of infiltrates (stained 
with CD45; %), in parotid gland parenchyma of patients with primary Sjögren’s syndrome (pSS). Horizontal lines 
indicate median values.
By counting the number of CD20+cells/mm2 of parenchyma, a significant decrease was 
observed in the number of B-cells (1172 versus 355 cells/mm2, p=0.001) in the glandular 
tissue at 12 weeks after RTX treatment compared to baseline (Figure 3, Table 1). In the 
placebo-treated group the number of CD20+/mm2 of parenchyma of the parotid glands at 
week 12 was not statistically different from the number of CD20+ cells at baseline (Table 1). 
The number of CD3+cells/mm2 of parenchyma remained unaffected after 12 weeks both 
in the placebo and RTX-treated group (Table 1). 
GC were present at baseline in 67% and 68% of the parotid glands of the placebo 
and RTX-treated patients, respectively. RTX treatment resulted in a significant decrease 
in the total number of GC/mm2 (Figure 4, Table 1). Twelve out of 16 parotid glands (75%) 
were completely devoid of GC 12 weeks after treatment with RTX. In the placebo group, 
no significant difference was observed in the number of GC/mm2 between baseline levels 
and 12 weeks after treatment. 
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Table 1: Histopathological and immunohistochemical data [median values and interquartile range (Q1-Q3)] 
before and after RTX or placebo therapy. 
Placebo (n=9) RTX-treated (n=16)
Baseline Week 12 p Baseline Week 12 p
Focus score 1.63 (0.84-3.27) 1.97 (1.47-2.88) 0.678 1.7 (0.87-2.5) 1.19 (0.59-1.23) 0.179
LELs/mm2 0.77 (0.38-1.05) 1.11 (0.67-1.23) 0.310 0.48 (0.24-0.91) 0.18 (0-0.42) 0.011
GCs/mm2 0.06 (0-0.23) 0.09 (0.03-0.15) 0.735 0.07 (0-0.28) 0 (0-0.1) 0.004
CD45 (%) 15.2 (5.86-16.92) 14.8 (5.2-28.06) 0.374 7.45 (1.85-22.35) 3.96 (0.48-7.71) 0.011
CD20+cells/mm2 2709 (1469-4395) 3664 (2256-7979) 0.173 1172 (389-5278) 355 (51-743) 0.001
CD3+cells/mm2 863 (359-1483) 1712 (725-2878) 0.953 315 (124-2157) 180 (91-570) 0.535
Figure 3: Effect of placebo (n=9) and rituximab (RTX) (n=16) treatment on number of CD20+ cells/mm2 of 
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LELs/mm2 0.77 (0.38-1.05) 1.11 (0.67-1.23) 0.310 0.48 (0.24-0.91) 0.18 (0-0.42) 0.011
GCs/mm2 0.06 (0-0.23) 0.09 (0.03-0.15) 0.735 0.07 (0-0.28) 0 (0-0.1) 0.004
CD45 (%) 15.2 (5.86-16.92) 14.8 (5.2-28.06) 0.374 7.45 (1.85-22.35) 3.96 (0.48-7.71) 0.011
CD20+cells/mm2 2709 (1469-4395) 3664 (2256-7979) 0.173 1172 (389-5278) 355 (51-743) 0.001
CD3+cells/mm2 863 (359-1483) 1712 (725-2878) 0.953 315 (124-2157) 180 (91-570) 0.535
Figure 3: Effect of placebo (n=9) and rituximab (RTX) (n=16) treatment on number of CD20+ cells/mm2 of 
parenchyma in parotid glands of patients with primary Sjögren’s syndrome ( pSS). Horizontal lines indicate 
median values.
Figure 4: Number of germinal centres (GCs)/mm2 of parenchyma in parotid glands of patients with primary 
Sjögren’s syndrome ( pSS). Horizontal lines indicate median values.
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Lymphoepithelial lesions 
At baseline, no differences were observed in the presence of LEL in the parotid gland 
parenchyma between the group of RTX-treated patients and the placebo treated patients 
(data not shown). In the RTX-treated group, a significant decrease in the total number of 
LEL/mm2 was observed after 12 weeks of treatment (Figure 1B, Table 1). In 6 out of 16 
patients (38%), LEL were completely absent after RTX treatment. In the placebo group, 
no significant change was observed in the amount of LEL/mm2 after 12 weeks (Figure 
1B, Table 1). Besides the number of LEL/mm2, the severity of the lesions also appeared 
to decrease; all stages of LEL seemed to transform to a less severe stage. Detailed data 
regarding the presence of all stages of LEL/mm2 in placebo and RTX-treated patients at 
week 0 and week 12 is presented in Figure 1C. 
Histopathology and ESSDAI 
Of the 16 patients that were treated with RTX, 11 patients (69%) improved by 3 or more 
ESSDAI points and were therefore considered to be clinical responders .25 The other 5 
were considered to be non-responders. The supplementary table shows the number (%) 
of patients having any degree of activity per ESSDAI domain (score at least 1) before and 
after RTX therapy, stratified for responders and non-responders. 
The baseline (pre-treatment) histopathological parameters (CD20+ cells/mm2, 
CD3+ cells/mm2, CD45+ relative infiltrate, GC/mm2, LELs/mm2 and focus score) as well 
as CD19-positive B-cell subsets determined by flow-cytometry in the peripheral blood 
(i.e., CD38Low CD27-, CD38High CD27-, CD27 Low CD38-, CD27High CD38-, CD38Low 
CD27Low, CD38High CD27High, CD27Low CD38High, CD27High CD38Low, CD38- CD27-
) of responders and non-responders to RTX treatment were subjected to additional 
statistical analysis. In responders, the baseline number of CD20+ cells/mm2 was significantly 
higher in comparison to non-responders [1871 (Q1-Q3=801-4310) cells/mm2 versus 353 
(Q1-Q3=35-2102) cells/mm2; Figure 5]. At an alpha level of 5% it was calculated that the 
number of responders and non-responders would give us a power of 94.2% to assume 
that their baseline number of CD20+ cells/mm2 could serve as potentially prognostic 
factor with regard to responsiveness to RTX treatment. The other baseline histological 
characteristics, as well as baseline B-cell subsets determined by flow-cytometry in the 
peripheral blood, did not differ significantly between responders and non-responders. 
Of note, there was no correlation between the absolute numbers of CD20+ B-cells/mm2 
of parenchyma and ESSDAI or between B-cell subsets in peripheral blood and ESSDAI. 
Furthermore, in RTX treated patients the change in ESSDAI correlated with the 
change in the number of CD20+ cells/mm2 of parenchyma (ρ=0.706 and p<0.05). No other 
statistically and clinically significant correlations were found for the changes between 
baseline and 12 weeks. 
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Figure 5: Number of baseline CD20+ cells/mm2 in clinical responders (n=11) and non-responders (n=5), p<0.05. 
Horizontal lines indicate median values.
DISCUSSION
We demonstrated that RTX treatment significantly reduced the overall lymphocytic 
infiltrate with a major loss of the B-cell component and number of GC/mm2 of parotid 
gland parenchyma in pSS patients. In addition, a major reduction of the quantity and 
severity of LEL was apparent, reflecting significant restoration of the striated ducts. 
RTX treatment results in a considerable decrease in the number of B-cells in the 
parotid gland tissue. Although this is reflected by a decrease in the amount of infiltrate, 
as measured by staining for CD45, this is not manifested by a decrease in the focus 
score. This apparent discrepancy can be explained by the fact that the foci also contain 
high numbers of T-cells, which may outnumber the number of B-cells2, and which are 
not affected in significant numbers by RTX treatment. The focus score is therefore not 
an appropriate criterion to measure the local effect of RTX on the periductal lymphocytic 
infiltration. Although RTX treatment results in the almost complete absence of B-cells in 
the peripheral blood of patients with pSS26, this is thus not accompanied by a complete 
loss of B-cells in parotid salivary gland tissue. These results are in line with other studies 
in pSS20,28 and rheumatoid arthritis29-31 showing a certain degree of persistence of B-cells 
in the local tissue after RTX treatment. In contrast, Devauchelle-Pensec et al. reported a 
total depletion in B-cells in labial salivary glands of pSS patients after RTX treatment.10 
However, in that study only a very low number of the pSS patients (6 out of 15) showed 
significant numbers of B-cells in the periductal infiltrates at baseline. This is remarkable, 
since B-cells usually make up to 20-60% of the lymphocytes in the infiltrates of the labial 
glands of pSS patients, depending upon the grade of the lesion.2 
148
In this study at baseline the included patients had high systemic activity, as indicated by 
the relatively high ESSDAI scores, and the high numbers of GC/mm2.32 We observed a strong 
reduction of GCs in the parotid tissue after RTX treatment; in several patients we even observed 
a complete absence of GCs. This is striking, since not all B-cells are depleted in the parotid 
glands, and GC B-cells may be relatively more resistant for anti-CD20 therapy compared to 
other B-cells, as shown by Gong et al. in a murine model for human CD20 expression.33 A 
possible explanation for the strong depletion of GCs in the parotid tissue might be that RTX 
treatment also results in a significant reduction of follicular helper T cells (TFH), as indicated 
by analysis of peripheral blood samples (Verstappen et al. 2015, manuscript in preparation). 
TFH cells are essential for the development of GCs at local sites. These cells are present in the 
salivary gland tissue of pSS patients34, where they may drive GC formation and generation of 
plasma cells. It is therefore possible that the relative absence of TFH in the salivary gland tissue 
after RTX treatment contributes to the loss of GC activity in these pSS patients. 
LEL develop in striated ducts in pSS patients, particularly in the parotid glands. The 
epitheliotropic autoimmune inflammation of the intraepithelial lymphocytes results in the 
reaction of the epithelium and induction of these lesions.35 RTX treatment not only results in 
a significant reduction of the number CD20+ B-cells in the periductal infiltrates, but also in a 
recovery of the LEL, as revealed by a considerable reduction of the severity of the lesions at 
all stages (Figure 1C). Such a restoration/redifferentiation of LEL was also observed in the 
small RTX treatment study (5 patients) described by Pijpe et al.20 Apparently, RTX treatment 
also results in depletion of B-cells within the basement membrane of striated ducts. To 
explain this, we have hypothesized that the trigger for LEL formation is diminished, and 
as a result less epithelial reaction takes place leading to reduced proliferation and finally 
anatomical restoration of the striated ducts. The trigger for LEL formation is unknown, but 
B-cell derived cytokines may possibly be responsible for this. This notion is in line with the 
finding of Pollard et al., who showed in the same cohort of RTX-treated patients that the 
serum levels of pro-inflammatory cytokines (e.g. IL-6) decreased significantly.36 
Patients with pSS have different genetic backgrounds, demographic features and 
prognosis and exhibit a wide variety of clinical manifestations, involving a number of 
pathophysiological pathways.37 Personalized treatment, i.e. providing ‘the right patient with 
the right drug at the right dose at the right time’38, will therefore be the key to treating pSS. 
An important finding in our study was that clinical responders to RTX treatment had a 
higher number of CD20+ B-cells/mm2 of parenchyma parotid gland tissue at pre-treatment 
(baseline) compared to non-responders. Furthermore, we also observed a correlation 
between the change in the number of CD20+ cells/mm2 of parenchyma and the change in 
ESSDAI. When higher numbers of B-cells are present in the parotid gland parenchyma, it is 
therefore possible that RTX treatment may result in depletion of more absolute numbers of 
B-cells responsible for the disease activity (measured by ESSDAI) than when lower numbers 
of B-cells are present in the tissue. The baseline number of B-cells/mm2 of parenchyma of 
149
7a
parotid gland may therefore determine patients’ response to treatment with RTX and may be 
considered as a biomarker for a more personalized treatment approach to pSS patients. The 
nature of these disease-associated B-cells that are reduced after RTX treatment needs to be 
elucidated. These cells are probably not antibody-producing cells, since antibody producing 
cells persist in the parotid salivary glands after RTX treatment.28 Alternatively, these cells may 
represent cytokine-producing B-cells.36 
Although the change in number of B-cells in the infiltrates of the salivary glands 
correlated to the change in ESSDAI after RTX treatment, the absolute number of B-cells 
at baseline did not correlate to the ESSDAI. Furthermore, the focus score of the salivary 
glands did not correlate to the ESSDAI. However, Risselada et al. showed a significant 
correlation at baseline between the focus score and the cumulative ESSDAI in labial salivary 
glands of 174 pSS patients (ρ=0.166-0.284, p≤0.04).39 This discrepancy could be ascribed 
to the fact that the study by Riselada et al. was retrospective, where ESSDAI was assessed 
at any time point during disease (not necessarily at diagnosis and biopsy), that 21% of 
patients used immunomodulating medication at the time of the biopsy and correlations 
were considered to be significant even if ρ was as low as 0.166-0.284. Moreover, the size 
of the focus (as we assessed by CD45 staining) is probably more relevant than the absolute 
number of present foci in the salivary gland tissue. 
In conclusion, we demonstrated that in parotid gland tissue of pSS patients: 
1.  RTX treatment leads to major reduction of B-cells, and a significant reduction in the 
number of GCs and LEL. This reduction in the LEL may be the consequence of a major 
decrease of local B-cell infiltration and may result in structural regeneration of the 
glands, especially the striated ducts. 
2.  The baseline number of CD20+B-cells/mm2 of parenchyma may serve as a prognostic 
biomarker to predict response to RTX treatment. As a result, baseline histopathological 
characteristics of a parotid biopsy may strongly contribute to a more personalized 
treatment approach to pSS patients.
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SUPPLEMENTARY MATERIALS
Supplementary Table 1: Number (%) of patients having any degree of activity per ESSDAI domain (score at least 
1) before and after RTX therapy, stratified for clinical responders and non-responders.
Responders Non-responders 
Before After Before After
Cutaneous 1 (9) 0 (0) 0 (0) 0 (0)
Pulmonary 5 (45) 0 (0) 0 (0) 0 (0)
Renal 0 (0) 0 (0) 0 (0) 0 (0)
Articular 8 (73) 2 (18) 5 (100) 5 (100)
Muscular 0 (0) 0 (0) 0 (0) 0 (0)
Peripheral nervus system 0 (0) 0 (0) 0 (0) 0 (0)
Central nervus sytem 0 (0) 0 (0) 0 (0) 0 (0)
Hematological 6 (55) 5 (45) 2 (40) 2 (40)
Glandular 9 (82) 4 (36) 4 (80) 4 (80)
Constitutional 1 (9) 0 (0) 0 (0) 0 (0)
Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0)
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In primary Sjögren’s syndrome high 
absolute numbers and proportions 
of B-cells in parotid glands predict 
responsiveness to rituximab as 





With great interest we have read the article by Cornec et al1 regarding our paper 
‘Towards personalised treatment in primary Sjögren’s syndrome (pSS): baseline parotid 
histopathology predicts responsiveness to rituximab treatment’.2 In essence we showed 
in our paper that absolute numbers of CD20+ cells/mm2 of parenchyma of parotid gland 
tissue are predictive for the responsiveness of patients with primary Sjögren’s syndrome 
(pSS) to rituximab (RTX) treatment. Cornec et al. argue that there is a discrepancy in 
outcomes presented in their study and our study,1 as they observed that a high proportion 
of minor salivary gland B cells predict absence of a clinical response to RTX.3 As we will 
show and explain here, there is no inconsistency between the two studies and most of 
the apparent discrepancy is likely the result of differences in how the tissues are analyzed 
and how the disease activity is established. 
Absolute numbers versus proportions of B cells and technique applied
A major difference in the two studies is how B cells are assessed in tissue sections of salivary 
gland biopsies of pSS patients before (and after) RTX treatment. We measured absolute 
numbers of CD20+ B cells/mm2 of parenchyma, while Cornec et al. assessed the proportion 
of B cells.1,3 Obviously, even when there is a change in absolute numbers of B cells in the 
tissue, the B/T cell ratio still can remain the same. Thus, although higher numbers of B 
cells, do not need to be reflected per se in higher proportions of B cells, we also found 
in our study that patients with higher absolute numbers of B cells in the glandular tissue, 
had a higher B/B+T cell ratio. Furthermore, responders to RTX, as defined by a decrease in 
European League Against Rheumatism EULAR Sjögren’s Syndrome Disease Activity Index 
(ESSDAI) score of ≥3 (ΔESSDAI≥3) at 12 weeks after treatment compared to baseline,4 had 
a higher B/B+T cell ratio compared to non-responders (Figure 1).
Figure 1: Proportions of baseline CD20+ cells in clinical responders (n=11) and non-responders (n=5) as defined 
by ESSDAI, p<0.05. Horizontal lines indicate median values.
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Nevertheless, there are some technical differences between the two studies that warrant 
some attention. We counted the absolute number of cells with HistoQuest software 
(version 3.5.3.0171, Tissuegnostics, Vienna, Austria), a well-known and widely used image 
analysis software package within pathology. Since parotid gland biopsies include areas 
of fat and fibrous tissue and intra parenchymal lymph nodes, we excluded these areas 
manually from the analysis, in order to increase the accuracy of the data. We would like to 
emphasize that, as stated in the section on ‘Immunohistochemical analysis’ in the materials 
and methods of our article,2 the whole slide (except from fat and fibrous tissue) was 
evaluated and areas of interest were not electively chosen, as implied by Cornec et al.1 The 
methodology used by Cornec et al. is based on digital pixel counting procedure developed 
by Costa et al.1,3,5 We have some concerns about this method. First, with the method of 
Costa et al. extra-glandular areas are not excluded from the tissue specimen studied,5 
which has the risk to include in the counting infiltrating cells located in areas of non-interest, 
e.g., intraparenchymal fat tissue, fibrous tissue, perineural tissue, etc. Second, although 
the number of pixels is reported to correlate to the manually counted cells,5 the exact 
number of pixels corresponding to one cell remains unknown. Moreover, although the 
B-cell proportions assessed with the method of Costa et al. correlate moderately to focus 
scores,5 the focus score does not give an indication about the severity of inflammation, as 
discussed in our paper.2 As a consequence, when the area covered by a single focus at 
baseline is rather large, a clinically relevant decrease in the inflamed area is not necessary 
reflected by a decrease in focus score. Apparently the HistoQuest method of counting the 
absolute number of cells is more precise in these aspects. Thus, it would be interesting to 
know whether the results reported by Cornec et al. change if biopsies would have been 
analyzed with the HistoQuest software approach.3
ESSDAI versus SSRI
Another factor that contributes significantly to the apparent difference between the two 
studies concerns the way disease activity has been defined. Cornec et al. pose that the 
discrepancy in outcomes can partially be attributed to ineffectiveness of RTX in improving 
systemic involvement as measured by ESSDAI.1 This prompted them to develop and use 
the Sjögren’s Syndrome Response Index (SSRI), an index reflecting mainly the objective and 
subjective sicca symptoms.6 When we applied the SSRI to classify patients as responder 
or non-responder, we were unable to detect any difference in our data in baseline CD20+ 
B-cells/mm2 parenchyma between responders and non-responders (Figure 2). Importantly, 
the agreement between ESSDAI and SSRI in defining responders in our study was rather 
poor (κ=0.25, percentage of agreement 64%; data not shown). Based on these findings we 
conclude that it is evident that ESSDAI and SSRI measure different outcomes; the ESSDAI 
focuses on systemic disease activity and the SSRI mainly on sicca related complaints. In this 
respect it is also worth mentioning that in our placebo treated patients, SSRI characterized 
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40% of the patients as responders, while ESSDAI only 11%. ESSDAI has been proven to 
be sensitive to measure the change in disease activity after therapeutic interventions and 
also showed that RTX was effective in our double-blind placebo-controlled RTX trial.4,7-10 
Thus, further validation is necessary for the SSRI.
Figure 2: Numbers of baseline CD20+ cells/mm2 in clinical responders (n=8) and non-responders (n=6) as defined 
by SSRI. Horizontal lines indicate median values, ns: non-significant.
Differences in general features
In addition to these two main aspects that result in the apparent discrepancies between the 
two studies, there are also some other differences that may influence differences in outcomes. 
Baseline ESSDAI: Although the baseline ESSDAI scores were rather similar between the 
two studies (8 in our study and 10 in the TEARS study) only in our study the ESSDAI was 
prospectively evaluated.11,12 In the TEARS study the ESSDAI was retrospectively evaluated. 
Baseline salivary gland positivity: Another major difference between the two studies 
is the positivity of salivary gland biopsy of the included patients; all patients in our study 
had a positive parotid gland biopsy at baseline, while only 64% of the patients included 
in the study by Cornec et al. had a positive minor salivary gland biopsy.1 When excluding 
patients with a negative minor salivary gland biopsy from the study by Cornec et al., the 
median proportion of B-cells in responders would have been probably higher than in 
non-responders, which is in agreement with the conclusion of our study. 
Parotid versus minor salivary gland biopsy: The different histopathological 
characteristics observed in parotid and minor salivary gland biopsies complicate the 
comparison as, e.g., the B/T-cell ratio differs greatly. Minor salivary glands of healthy controls 
may have a physiological infiltrate that consists mainly of T-lymphocytes (and plasma cells), 
while parotid salivary gland tissue of healthy controls shows rarely a lymphocytic infiltrate. 
Although those differences have been shown by Pijpe et al.,13 there is still a need for larger 
studies focusing on the inherent differences in the histopathological characteristics of 
parotid and minor salivary gland tissue in both pSS patients and healthy controls.
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Salivary gland ultrasound 
Like Cornec et al., we also feel that ultrasound has merit in the diagnosis and assessment 
of the disease activity of pSS.1,14,15 However, before making salivary gland ultrasound a 
standard in pSS diagnostics, disease monitoring and treatment evaluation, there are 
several questions that need to be answered first, i.e. the reliability of ultrasound in the 
evaluation of changes that occur in the major salivary glands of pSS patients, and the 
validity of ultrasound to detect the histopathologic changes occurring in the parotid tissue 
of patients (suspected) with pSS in particular (direct comparison of ultrasonographic and 
histhopatologic features). 
Conclusion
From the abovementioned, it may be concluded that our study and the study of Cornec et 
al. differ in some respect,2,3 but do not present contradicting results. Most likely differences 
in assessment of patients’ responsiveness to RTX treatment by using different methods 
and techniques lead to different results and apparent differences (Table 1). Probably, by 
combining theirs and our analyses we might even be able to more efficiently select patients 
at baseline who probably will benefit from RTX treatment.
Table 1 : Comparison of two studies
STUDY Cornec et al., 2015 Delli et al., 2015
Outcome Proportion of B cells Absolute number of CD20+B-cells/mm2 
parenchyma
Software Digital pixel counting software, developed 
by the same team5
HistoQuest software, version 3.5.3.0171, 
Tissuegnostics, Vienna, Austria
Tool for measuring 
response to RTX
SSRI6 ESSDAI4
Salivary gland Minor salivary glands Parotid gland
General features •	 Baseline ESSDAI:10
•	 Median age: 50.4 to 54.8 (± 9.5 & 
±13.8)
•	 Baseline salivary gland biopsy positivity: 
64%
•	 Baseline anti-SSA positivity: 80%
•	 Baseline ESSDAI: 8
•	 Median age: 43 (±11 years)
•	 Baseline salivary gland biopsy positivity: 
100%
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Abatacept treatment of patients 
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results in a decrease of germinal 




Objective: The aim of this study was to assess the histopathological changes in parotid 
gland tissue of primary Sjögren’s syndrome (pSS) patients treated with abatacept.
Methods: In all 15 pSS patients included in the open-label Active Sjögren Abatacept Pilot 
(ASAP, 8 abatacept infusions) study parotid gland biopsies were taken before treatment 
and at 24 weeks of follow up. Biopsies were analysed for pSS-related histopathological 
features and placed in context of clinical responsiveness as assessed with EULAR Sjögren’s 
syndrome disease activity index (ESSDAI). 
Results: Abatacept treatment resulted in a decrease of germinal centres (GCs)/mm2 
(p=0.173). Number of GCs/mm2 at baseline was associated with response in the glandular 
domain of ESSDAI (Spearman ρ=0.644, p=0.009). Abatacept treatment did not reduce 
focus score, lymphoepithelial lesions, area of lymphocytic infiltrate, amount of CD21+ 
networks of follicular dendritic cells, and numbers of CD3+ T-cells or CD20+ B-cells. Number 
of IgM plasma cells/mm2 increased (p=0.041), while numbers of IgA and IgG plasma cells/
mm2 were unaffected during abatacept treatment.
Conclusion: Abatacept affects formation of GCs of pSS patients in parotid glands, which is 
dependent on co-stimulation of activated follicular-helper-T-cells. Herewith local formation 
of (autoreactive) memory B-cells is inhibited. Presence of GCs at baseline predicts 




Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterized by chronic 
inflammation of exocrine glands, histomorphologically seen as periductal infiltrates 
predominantly consisting of T- and B-cells. Lymphocytic infiltration of the epithelium 
of striated ducts leads to formation of lymphoepithelial lesions (LELs) which are more 
pronounced in parotid than in labial glands.1 Besides periductal infiltrates, there is a 
plasmacytosis with an increased number of IgG expressing plasma cells.2 A subset of 
pSS patients develop germinal centers (GCs) in ectopic lymphoid infiltrates of the glands. 
Presence of GCs is associated with more active disease and is considered to be a predictor 
for malignant lymphoma development.3-5
There are no approved therapeutic interventions for pSS yet, but promising results with 
biological disease modifying anti-rheumatic drugs, e.g. abatacept, are reported. Abatacept 
was shown to be effective and safe in open-label studies in pSS.6,7 This fully human biological 
binds to CD80/CD86 on antigen presenting cells and hereby blocks the CD28-mediated co-
stimulation of CD4+ T-cells.8 In pSS patients, systemic disease activity is assessed with the 
EULAR Sjögren’s Syndrome Disease Activity (ESSDAI) score. Abatacept treatment resulted 
in a decrease of ESSDAI with most prominent beneficial clinical effects in the glandular, 
articular, constitutional and biological domains. Saliva production remained stable during 
treatment.6 It is not clear yet what the effect of abatacept treatment is on the inflammatory 
process in salivary glands, in the context of responsiveness to treatment. Therefore, the aim 
of this study was to assess the histopathological changes in parotid gland tissue of early and 
active pSS patients treated with abatacept. This evaluation was performed in a standardized 
fashion that was shown before to identify biomarkers useful for personalized medicine.9 
MATERIALS AND METHODS 
Patients
In all pSS patients (for characteristics see supplementary Table 1) included in the open-
label Active Sjögren Abatacept Pilot (ASAP) study (n=15),6 a parotid gland biopsy was taken 
within 12 months before and 24 weeks after the initiation of abatacept treatment. Patients 
received abatacept infusions (≈10 mg/kg) on days 1, 15, 29 and every 4 weeks thereafter 
(Bristol Myers Squibb, France). ESSDAI scores were used for rating disease activity.10
(Immuno-)histological staining and evaluation of parotid gland biopsies
(Immuno-)histological processing and staining was performed as previously described (see 
also Figure 1).9 Primary antibodies are listed in supplementary Table 2. Staining was performed 
on serial sections, except for CD21. For practical reasons, staining for CD21 was performed on 
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sections from the same paraffin blocks, but sectioned in a separate session. Hematoxylin and 
eosin (HE) stained sections were used to assess FS and number of GCs/mm2. Dual staining 
with CD20 and CK8/18 was used to determine number of LELs/mm2. Severity of LELs was 
scored as previously described.9 Evaluation was performed independently and blinded (B.V., 
E.H.) resolving discrepancies by consensus. Relative area of CD45+ lymphocytic infiltrate and 
CD21+ follicular dendritic cell (FDC) networks was measured using ImageScope v12.0 (Aperio 
Technologies, USA). Numbers of CD20, CD3, IgA, IgG, IgM positive cells were assessed using 
HistoQuest v3.5.3.0171 (Tissuegnostics, Austria).9 The parenchyma of the whole biopsy was 
examined, excluding intraparenchymal connective,- and fat tissue. 
Statistical analysis
Wilcoxon Signed Rank test was used to test differences between groups. Spearman 
correlation coefficient was calculated for correlations (IBM SPSS Statistics V.22).
RESULTS 
Focus score, relative area of CD45+ lymphocytic infiltrate, number of CD20+ B-cells/mm2 
and CD3+ T-cells/mm2, CD21+ FDC networks and total plasma cell population, were all 
unaffected by abatacept (Figure 1, Table 1). Also structure and regeneration of the ductal 
epithelium, as reflected by number and severity of LELs, was not improved (supplementary 
Figure 1). In contrast to these findings, number of GCs/mm2 was reduced by abatacept 
treatment. At baseline, GCs were present in parotid gland biopsies of five patients and 
GCs were absent in all these patients after treatment (Figure 1I). In one patient GCs were 
absent at baseline, but detected after abatacept treatment. This patient was the only 
patient in whom ESSDAI had increased after treatment and thus can be considered as 
non-responder. In all other patients ESSDAI had decreased upon treatment and in these 
patients the decline in GCs/mm2 was statistically significant (p=0.043). The ESSDAI glandular 
domain was higher in patients with GC activity than patients without GC activity at baseline 
(1.2 vs 0.6). The number of GCs/mm2 at baseline was associated with improvement in 
the ESSDAI glandular domain (Spearman ρ=0.644, p=0.009), but not with other ESSDAI 
domains. Numbers of IgA and IgG plasma cells/mm2 remained stable, while numbers of 
IgM plasma cells/mm2 increased (p=0.041, Figure 1J). However, relative proportion of IgM 
plasma cells remained still low after treatment (4.8%).
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Figure 1: (Immuno-)histological analysis of parotid gland tissue of pSS patients treated with abatacept. 
Biopsy from a parotid gland showing A) germinal center (HE), B) LEL (CD20 in brown and CK 8/18 in red), C) CD20+ 
B-cells, D) analysis of sample shown in C with HistoQuest, E) IgM+ plasma cells, F) analysis of sample shown in 
E with HistoQuest, G) CD45+ lymphocytes, H) measurement of relative area of CD45+ lymphocytic infiltrate with 
Aperio ImageScope of sample shown in G, I) Number of GCs in parotid gland tissue decline after treatment with 
abatacept. J) Plasma cells in parotid gland tissue before and after treatment of abatacept. IgM plasma cells/
mm2 increase after abatacept treatment (*Wilcoxon Signed Rank, p=0.041). Values presented in mean and SD.
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Histopathological pSS parameters 
Area of parotid parenchyma 5.3 (4.3-8.1) 6.5 (4.9-8.9) 0.820
Focus score (number of foci of ≥50 
lymphocytes/4 mm2)
3.1 (1.5-5.0) 3.2 (0.9-4.1) 0.173
Germinal centers (#/mm2) 0.06 (0.13)* 0.009 (0.04)* 0.173
Lymphoepithelial lesions (#/mm2) 0.24 (0-0.56) 0.27 (0-0.61) 0.583
Area of CD21+ FDC networks 0.063 (0.006-0.539) 0.030 (0.004-0.244) 0.334
Area of CD45+ lymphocytic infiltrate 9.0 (5.8-38.0) 15.3 (10.4-33.1) 0.649
B-cells (#/mm2) 1187 (687-3128) 752 (268-3677) 0.394
T-cells (#/mm2) 1109 (892-2510) 1119 (425-2971) 0.427
Total plasma cells (#/mm2) 1271 (566-1939) 2161 (1177-2887) 0.125
Values are presented as median (IQR) unless otherwise specified.*Average (SD). P value <0.05 was considered 
statistically significant. 
DISCUSSION
We assessed histopathological changes in parotid gland tissue in relation to abatacept 
treatment in early and active pSS patients. These changes were evaluated in a standardized 
fashion, that was previously shown to be able to identify biomarkers that predict 
responsiveness to rituximab treatment.9 Importantly, we observed that GCs disappeared 
completely in parotid gland tissue of patients with GCs at baseline (33%). Furthermore, 
number of IgM producing plasma cells increased, while other histopathological parameters 
measured did not change upon abatacept treatment. These observations are in line with 
our previous findings that during abatacept therapy secretion of stimulated whole saliva 
did not deteriorate.6
Also Adler et al.7 observed that foci/mm2, CD3+ T-cells, CD20+ B-cells and total number 
of plasma cells in labial (rather than parotid) glands were unaffected by abatacept. 
However, in their study, two major elements of pSS histopathology, namely GCs and 
LELs, were not analyzed. We demonstrated for the first time that abatacept abrogated 
ectopic, histomorphologically-defined, GCs in a human autoimmune disease. Other 
studies had shown in a murine model for rheumatoid arthritis that the proportion of 
flow-cytometry-defined (GL7+Fas+) GC B-cells was reduced by abatacept treatment in 
lymph nodes draining affected joints.11 Abatacept did not decrease the amount of CD21+ 
FDC networks (supplementary Figure 2). Although these networks are a prerequisite for 
GC formation in the foci, presence of these networks does not imply per se that GCs 
are also present.12 Since abatacept does not affect the FDC networks, this observations 
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suggests that absence of GCs cannot be attributed to a disorganized microenvironment. 
For formation and perpetuation of GCs, GC B-cells require co-stimulatory signals from 
T-follicular-helper-cells (Tfh-cells) for their development and maintenance. Tfh-cells are also 
involved in pSS pathogenesis.13 Tfh-cells are elevated in blood from pSS patients and are 
also present in glandular tissue.14 In pSS patients Tfh-cells appear to be in a hyperactivated 
state as reflected by elevated ICOS-levels on circulating Tfh-cells [Verstappen, unpublished 
observations]. We have shown that abatacept selectively reduces the (elevated) proportion 
and number of circulating Tfh-cells in the peripheral blood of pSS patients to levels of healthy 
controls, and also normalizes the ICOS-levels [Verstappen, unpublished obervations]. A 
reduction in Tfh-cell activity after abatacept treatment might lead to decreased GC activity in 
inflamed salivary glands. Presence of GCs in labial glands is associated with higher FS and 
percentages of patients positive for autoantibodies (RF, anti-SSA/SSB).3,4 Whether patients 
with GCs also exhibit higher systemic disease as reflected by higher ESSDAI remains to 
be explored. In our (small) group of pSS patients there was no difference in total ESSDAI 
scores between patients with and without GCs in their biopsy, but there was a difference 
detectable considering the ESSDAI glandular domain. 
The characteristic epitheliotropic autoimmune inflammation in pSS is histologically 
seen as LELs of striated ducts. LELs are composed of proliferative metaplastic epithelial 
cells in association with intra-epithelial lymphocytes and are more pronounced in parotid 
than in labial glands1, making analysis of these structures more easy and reliable in parotid 
tissue. We have shown here that numbers and severity of LELs are not influenced by 
abatacept. This finding indicates that the cross-talk between epithelial cells and intra-
epithelial lymphocytes, thought to be responsible for formation and maintenance of LELs9, 
is independent of CD28-mediated co-stimulation.
Our data showed that numbers of IgG plasma cells/mm2 remained stable in 
parotid gland tissue after abatacept treatment. Part of these IgG plasma cells comprise 
autoantibody producing cells.15 These findings support the notion that (autoreactive) 
plasma cells located at inflamed sites are long-lived cells that are not replaced by newly 
generated plasma cells in a T(fh)-cell dependent fashion. Indeed our previous B-cell 
depletion studies showed that in parotid glands IgG-producing B-cell clones can persist 
for at least one year.16 A small proportion of long-lived plasma cells may express CD28 
which is needed for their maintenance and survival.17 CD28 expressing plasma cells have, 
however, not yet been detected in parotid glands of pSS patients (unpublished data). 
Despite the fact that numbers of IgG (and IgA) producing plasma cells remained constant in 
parotid glands, serum IgG levels and autoantibody (anti-SSA/SSB) titers decreased during 
treatment.6 We suggest that this decrease is due to loss of (autoreactive) IgG producing 
plasma cells located elsewhere in the body. These cells are either CD28-expressing plasma 
cells that require CD28 stimulation for their survival or require T-cell dependent and 
CD28-mediated co-stimulation for their generation. In contrast to isotype switched plasma 
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cells, there was an increase in numbers of IgM plasma cells/mm2 in parotid tissue. IgM 
plasma cells are generally considered to be short-lived and their formation can partially 
occur in a T-cell independent fashion. The increase in IgM plasma cell numbers during 
abatacept treatment is in line with this T-cell independency. Why their numbers increase 
is unclear. We speculate that blocking T-cell help, drives the B-cells towards differentiation 
of unswitched IgM plasma cells, at the expense of IgG or IgA plasma cells. 
To conclude, abatacept treatment results in a reduction of GCs in parotid gland tissue 
of pSS patients, probably due to inhibition of local T-cell dependent B-cell activation. Likely, 
the selective decrease in (activated) Tfh-cells plays an important role in reduction of GCs. 
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Age years, mean (SD) 43 (14)
Female gender, n(%) 12 (80)
Disease duration in months, median (IQR) 11 (7-36)
ESSDAI total, median (IQR) 11 (8-14)
ESSDAI glandular domain ≥1, n(%) 11(73)#
Laboratory assessments 
IgG (g/L), mean ±SD 21.5 ±7.3
RF (kIU/L), mean ±SD 89 ±94
SSA positive, n(%) 15 (100)
SSB positive, n(%) 12 (80)
Values are presented as median (IQR) unless otherwise specified. 
Supplementary Table 2: Antibodies used for immunohistochemistry.
Antigen Clone Host Company
CD20 L-26 Mouse Ventana Roche
CD3 2GV6 Rabbit Ventana Roche
CD45 2B11 + PD7/26 Mouse Ventana Roche
CK8/18 B22.1 + B23.1 Mouse Ventana Roche
CD21 2G9 Mouse Ventana Roche
IgA Polyclonal Rabbit Ventana Roche
IgG Polyclonal Rabbit Ventana Roche
IgM Polyclonal Rabbit Ventana Roche
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Supplementary Figure 1: Severity of LELs in pSS patients treated with abatacept. 
LELs are classified in three stages9 as stained for CD20 + CK8/18. Stage 1: LEL affecting less than 50% of the 
epithelium of the striated duct (partial LEL), Stage 2: LEL affecting between 50% and 100% of the epithelium of the 
striated duct (developed LEL); Stage 3: LEL with fully circumferential affected epithelium without lumen (occluded 
LEL). Y-axis indicates the total number of patients before (open circles) of after (closed circles) treatment, while 
X-axis the presence of different stages of LELs. Of note patients can have various stages of LELs at the same time. 
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Supplementary Figure 2: Network of follicular dendritic cells in parotid glands of pSS patients treated with 
abatacept
A) The proportion (in percentages) of foci containing networks of follicular dendritic cells (FDCs) per patient as 
visualized by CD21 staining. Boxes represent the interquartile range divided by the median with Tukey-style 
whiskers. Of the pSS patients, 87% (13/15) showed a CD21+ FDC network within at least one focus, and 73% 
(11/15) after treatment. B) Relative area of CD21 staining, measured by Aperio ImageScope. C) Example of a 
CD21+ FDC network with a morphologically recognizable germinal center. D) Example of a CD21+ FDC network 
without a morphologically recognizable germinal center.
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Large parts of this chapter are derived from “The role of salivary gland histopathology 
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The formation of lymphomononuclear cell infiltrates organizing as periductal infiltrates 
in the salivary glands of patients with primary Sjögren’s syndrome (pSS) is one of the 
hallmarks of the disease. The clinical role of salivary gland histopathology has been 
confined to the clinical classification and diagnosis of pSS whereby according to the ACR-
EULAR criteria a positive histopathology finding is a requirement for the diagnosis of 
pSS in the absence of either anti-Ro/SSA. In recent years, further understanding of the 
heterogeneity of the immune cell infiltration and organization within the salivary glands 
of pSS patients and its correlation with clinical manifestations of the disease has led to 
propose salivary gland histopathology as a novel tool able to identify patients at higher risk 
of developing more severe extraglandular manifestations and lymphoma. Furthermore, 
recent clinical developments in ongoing randomized clinical trials with novel biologicals 
in pSS have focused on salivary glands histopathology to inform on patients stratification 
based on target validation, proof of drug efficacy and mechanisms of response/resistance 
to therapy. 
In this chapter the promises and the future prospective of salivary gland histopathology 
in pSS patients are discussed. Following a brief introduction on the formation of the 
periductal inflammatory infiltrates in the salivary gland tissue of pSS patients, the focus in 
this chapter will be on three critical aspects of salivary gland histopathology that are of 
important clinical relevance in patients with pSS:
1)   The performance of histopathology as a diagnostic tool discussing the focus score, 
lymphoepithelial lesions (LELs) and relative decrease of IgA+ plasma cells. 
2)  Salivary gland histopathology as predictor of disease severity and lymphomagenesis 
in pSS patients with special emphasis on the role of germinal centers. 
3) The emerging role of salivary gland histopathology in evaluating clinical response in 
clinical trials. 
Formation of the periductal lymphoid infiltrate 
The salivary glands of pSS patients are characterized by chronic inflammation as witnessed 
by the presence of lymphocytic infiltrates (or lymphocytic foci) located around the striated 
ducts (Figure 1A). These so-called periductal foci can be seen in both minor and major 
salivary glands and are present in most pSS patients. The foci are mainly composed of T- 
and B-lymphocytes with few other mononuclear cells, including macrophages, myeloid and 
plasmacytoid dendritic cells, and follicular dendritic cells.1 They may develop to organized 
ectopic lymphoid structures resembling secondary lymphoid organs with segregated 
T- and B-cell areas, and high endothelial venules (HEVs).2 These structures contain all 
components to carry out effectively immune responses. This is reflected by the presence 
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of germinal centers (GCs) in the B-cell areas of the organized periductal infiltrate in roughly 
a quarter of the pSS patients3 and the presence of (IgG) plasma blasts and plasma cells at 
the border of the infiltrate.2 Initially, (activated) lymphocytes and (IgG expressing) plasma 
blasts are thought to be attracted towards the salivary gland tissue by the combined action 
of pro-inflammatory cytokines and chemokines. The triggers for this early event are not 
known, but viruses might well be implicated.4 
A major pro-inflammatory chemokine likely involved in the early formation of the periductal 
infiltrate is the chemokine CXCL10 (IP-10) which is highly expressed by the ductal epithelium.5,6 
Increased levels of CXCL10 are found in saliva, tears and serum from pSS patients. Early pSS 
patients express the highest levels of CXCL10 in their saliva, emphasizing the importance of 
this chemokine in the initial phases of the disease.7,8 CXCL10 binds to its receptor CXCR3, which 
is highly expressed by CD4+ Th1-cells.9 Several other cells, including (activated and memory) 
B-cells, IgG secreting plasmablasts and some plasmacytoid dendritic cells express the CXCR3 
receptor and can also be attracted to the salivary glands.10 The relatively unorganized infiltrates 
may transform towards more organized ectopic lymphoid structures. Triggers essential for 
this transition in human salivary glands are only poorly understood, but a role for lymphoid 
tissue inducer cells and Th17-cells have been suggested.11-13 The lymphoid tissue inducer cells 
and Th17-cells produce cytokines such as lymphotoxin β, RANKL, IL-17 and IL-22 which, in 
turn, promote production of the homeostatic lymphoid chemokines CXCL13, CCL19, CCL21 
and CXCL12 by stromal and other cells.2,12,13 All these chemokines (protein and mRNA) are 
strongly upregulated in salivary glands of pSS patients.14-17 Collectively they are involved in 
attraction of naïve and memory T- and B-lymphocytes, plasmablasts, and other immune cells 
to the inflamed sites, and formation and maintenance of the organized lymphoid structures.2 
Prolonged activation of the glands leads to development of follicular dendritic cell (FDC) 
networks and segregation of the T- and B-cells.18 The FDCs, which characteristically express 
the long isoform of CD21 (complement receptor 2), as well as other stromal cells produce 
CXCL13 and are instrumental in the formation of B-cell rich areas, due to the binding of this 
chemokine to its receptor CXCR5. In conjunction with CXCL12, CXCL13 also supports formation 
and function of GCs.15,19,20 This important role of CXCL13 in pSS histopathogenesis is illustrated 
by the fact that elevated levels of this chemokine are detected in the saliva and blood of pSS 
patients with the highest saliva levels seen in patients with xerostomia.21 Furthermore, high 
expression levels of CXCL13 in the labial gland biopsy are associated with higher number of 
periductal foci and higher disease activity.22 This might indicate that with progression of the 
disease, as indicated by more severe inflammatory lesions in the glandular tissue, the number 
of infiltrating B-lymphocytes increases.1 CXCL12 is also produced in healthy salivary glands 
and is important for migration and survival of (largely IgA+) plasma cells in the proximity of 
the acini.23,24 In pSS patients the production of CXCL12 by acinar and ductal cells is strongly 
enhanced.15,16 CXCL12 forms, together with IL-6 and APRIL, survival niches for long-lived plasma 
cells within the salivary gland tissue.25 Thus, the initial infiltrate, which is rather unorganized, 
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evolves under the influence of homeostatic, lymphoid chemokines towards ectopic lymphoid 
structures characterized by segregated T- and B-cell areas (with FDC networks), in which 
GCs may develop. Whether progression of the disease in individual pSS patients is always 
associated with these sequential stages of histopathology remains to be shown. 
Focus score and its diagnostic role 
The presence of foci is thus a hallmark of the disease. For this reason histopathological 
analysis of the salivary gland is an important item in diagnosis and classification. A biopsy 
can be taken from either the labial or the parotid salivary gland. Although in most centers 
a labial gland biopsy is taken, the parotid gland biopsy is a good alternative and is a 
well-tolerated and safe procedure in experienced hands (chapter 2).26,27 For diagnosis 
and classification of pSS the presence of focal lymphocytic sialadenitis (FLS) in glandular 
biopsies (either labial or parotid) is assessed. The term FLS refers to the histopathological 
pattern of the presence of one or more foci in the biopsies, while the tissue surrounding 
the foci is composed mainly of unaffected parenchyma.28 A focus is defined as an aggregate 
of ≥50 lymphocytes and the focus score (FS) is the total number of foci per 4mm2 salivary 
gland tissue.29,30 In both labial and parotid gland a FS of ≥1 is considered as a positive 
biopsy and used for the classification of pSS. With a high FS of about 10, the foci become 
confluent and an arbitrary maximal score of 12 is given.30,31 
The importance of the calculation of the FS in the salivary gland biopsies is reflected 
by the prominent place of the biopsy in the current ACR-EULAR classification criteria. 
In these criteria a positive biopsy (i.e. FS≥1 per 4 mm2) accounts for 3 points, similar 
to the presence of anti-SSA antibodies. In these criteria, 1 point is attributed to either 
reduced saliva production or reduced tear production (or ocular damage). A total of 4 
or more points in suspected pSS patients (i.e. patients with at least one symptom of 
ocular or oral dryness or positive ESSDAI (European League Against Rheumatism Sjögren’s 
Syndrome Disease Activity Index)) leads to the classification of pSS.32,33 Thus, for fulfillment 
of the criteria a positive biopsy and/or presence of anti-SSA antibodies is required. For 
a correct assessment of the FS, analysis of a glandular surface area of at least 8mm2 is 
recommended.34 The specificity and diagnostic accuracy of the biopsy can be increased 
by multiple cutting levels, especially for pSS patients with a FS of 1.0 to 1.9.35 For the 
diagnosis of pSS, the sensitivity and specificity of the parotid gland biopsy and labial gland 
biopsy are comparable. The sensitivity of the labial gland biopsy ranges from 64% to 94% 
and specificity from 61% to 100%. The parotid gland biopsy has a sensitivity of 78% and 
specificity of 86%.36,37 
Not all pSS patients have a positive salivary gland biopsy. In 18-40% of the pSS patients 
the labial gland biopsy is negative, i.e. have a FS< 1.0.37-39 These patients might be at risk 
to be misclassified as non-pSS according to the ACR-EULAR criteria. The clinical diagnosis 
based upon expert opinion is important in these cases. It is not known whether foci are 
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evenly spread throughout the salivary glands, and there is always a risk for sampling 
errors, in particular in patients with a low number of foci. Multiple sectioning levels in an 
inconclusive biopsy might reduce the possibility of a falsely negative biopsy.34 Foci can 
also be found in healthy individuals: 6-9% of the healthy individuals have a FS of > 1.0 
in a labial gland biopsy and 5% in a parotid gland biopsy.37,40,41 In addition to the FS, two 
scoring systems for salivary glands are in use for diagnosis and classification of pSS (see 
Table 1). These scoring systems are also based on the presence of foci. Grading according 
to Tarpley takes the destruction of acinar tissue and fibrosis into account and Chisholm 
and Mason also the take the presence of diffuse infiltrates into account, when the FS is 
lower than 1.29,42 Since all three scoring systems are in use, it is important to avoid any 
confusion, to indicate which scoring system has been used for the evaluation of the tissue.
Table 1: Grading systems for salivary gland biopsies of Chisholm/Mason and Tarpley.29,42
Chisholm/Mason Tarpley
Grade Lymphocytes per 4 mm2 of salivary 
gland tissue
Grade Description 
0 Absent 0 Normal
1 Slight infiltrate 1 1 or 2 aggregates# (minimal infiltration)
2 Moderate infiltrate or less than one 
focus*
2 >3 aggregates#
3 One focus* 3 Diffuse infiltrate with partial destruction of acinar 
tissue with or without fibrosis
4 More than one focus* 4 Diffuse infiltrate with or without fibrosis destroying 
the lobular architecture completely
*Focus: a cluster of 50 or more lymphocytes and histiocytes.
#Aggregate: approximately 50 cells (lymphocytes, plasma cells, or histiocytes)
Limitations of the focus score 
The FS (and the other scoring systems based upon the number of foci) is a robust 
classification tool in defining biopsies as positive or negative, but it has certain shortcomings. 
Although the definition of the FS should not give rise per se to significant issues with 
interpretation, in reality failure to apply the FS or its miscalculation in clinical diagnostic 
setting is rather the norm. Vivino et al. reported that a second expert evaluation of 58 
labial salivary glands re-analysed by a single center led to revision of the initial diagnosis 
in a staggering 53% of the patients.43 Problems in assessing the FS also arise when other 
histopathological patterns besides focal lymphocytic sialadenitis, such as non-specific 
chronic sialadenitis, sclerosing chronic sialadenitis are present.28 With increasing age of 
healthy individuals, acinar atrophy, fibrosis and increase of fat cells are commonly observed 
in the labial salivary gland tissue.44,45 These age-associated changes result to a reduced 
acinar capacity and may consequently lead to a decrease in saliva production. Compared 
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to healthy controls, labial gland biopsies of pSS patients exhibit more acinar atrophy and 
fibrotic changes.46,47 This is likely the result of the sustained chronic inflammation. There 
is no consensus whether there is an increase in the amount of adipose tissue in labial 
gland biopsies of pSS patients compared to age-matched healthy controls. The study of 
Skarstein et al.48 reported a higher occurrence of fat infiltration in labial gland biopsies 
in pSS patients compared to non-pSS controls. In contrast, Leehan et al.49 showed that 
the increased area of fat tissue in the labial gland biopsy is not specifically associated 
with pSS but is a selective feature of aging. For the calculation of the FS, Fisher et al.34 
recommended to evaluate the whole section of the gland, including, fibrotic areas tissue, 
atrophic areas and adipose tissue. When fibrotic and atrophic changes in the biopsies 
progress, the inflammation is slowly extinguished leading to a “burnt-out” biopsy, even 
resulting in a negative FS.50 How many patients finally evolve to this stage is not known. 
Generally speaking, the FS is thought to be rather stable and only progresses slowly over 
time.50,51 In the study of Shiboski et al. repeated biopsies with a 2 to 3 year time interval 
were taken in 498 participants (Sjögren patients and non-SS sicca patients) from the 
SICCA-cohort. In these patients the result of the labial gland biopsy changed in 7% of the 
patients from FS-negative to FS-positive, in 11% of the patients from positive to negative 
and in 82% of the patients the FS remained unchanged.52 
An important drawback of the FS is that it is only based upon the number of foci and 
does not include the size of these foci. For a better estimation of the level of inflammation 
in the salivary gland biopsy, the area of infiltrate can be evaluated.34,53 This gives a more 
precise indication of how much glandular tissue is involved in the inflammation. Likely, 
such an approach is also more sensitive to change, in case sequential biopsies are 
taken for evaluation of treatment effects, or for follow-up of disease progression. This is 
especially important when foci are confluent and should strictly be considered as a single 
focus. Measurement of the area of infiltrate can be done with a regular HE stain or after 
immunohistological staining for CD45 (staining all leucocytes) (chapter 7a).34,53 Currently, 
there is no cut-off level for the classification/diagnostic use of the area of infiltrate, but in 
clinical trials with pre- and post-treatment biopsies measurement of the infiltrated area 
can give important information (chapter 7a).53
Other histopathological markers besides focus score 
In addition to periductal infiltrates there are also other histopathological features in the 
glands that are associated with pSS and therefore might be indicative for this disease. 
Besides FS, lymphoepithelial lesions (LELs) and a relative decrease of IgA+ plasma cells, 
appear to be characteristic for pSS.54-57 Both features can aid in assessment of the salivary 
gland biopsies for the diagnosis of pSS, especially when the FS in the biopsy is <1. LELs 
are striated ducts, which are infiltrated by lymphocytes with concurrent hyperplasia of the 
epithelial cells (Figure 1B).58 LELs can be found both in labial and in parotid glands, albeit 
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that they seem to be more pronounced within the parotid gland tissue.37 These structures 
are always associated with periductal infiltrates and solitary LELs are not present. In pSS 
patients LELs are present in 58%-93% of the parotid gland biopsy compared to 33%-86% 
of the labial gland biopsies (chapter 4 and 5).58,59
The sensitivity and specificity of LELs in the diagnosis of pSS is not known. The 
current hypothesis in development of LELs is that the infiltrated lymphocytes cause the 
hyperplasia of the epithelium (chapter 5).56,59 This hyperplasia can ultimately result in 
complete occlusion of the striated duct. Based upon the proportion of the hyperplastic 
epithelium we proposed a classification system for the severity of the LELs: stage 1: a 
partial LEL (affecting <50% of the epithelium), stage 2: developed LEL (affecting 50% 
-100% of the epithelium), stage 3: occluded LEL (fully circumferentially affected epithelium 
without lumen) (chapter 5 and 7a).53 The infiltrating lymphocytes comprise both B- and 
T-cells. With progression of the severity of the LELs the relative number of B-cells within 
the lesions increase, suggesting an important role for B-cells in epithelial proliferation 
(chapter 5).58 The vast majority of the B-cells within the LELs of pSS patients express 
FcRL4 (chapter 4).59 Fewer FcRL4+ B-cells are located outside the LELs, but still within the 
foci and the intensity of FcRL4 expression decreases outside the LEL. The FcRL4+ B-cells 
represent a small subset of highly proliferative mucosal memory B-cells.60,61 Most non-
Hodgkin lymphomas associated with pSS are (salivary gland) mucosa-associated lymphoid 
tissue (MALT) B-cell lymphomas and 93%-97% of these MALT lymphomas express FcRL4 
(chapter 4).59,62 We have shown that B-cells in the LELs are also targeted with rituximab 
treatment (chapter  7a).53,63 This results into normalization of the ductal epithelium, 
which strongly argues that factors derived from the FcRL4+ B-cells are responsible for the 
epithelial hyperplasia (chapters 4 and 5). Although LELs are characteristic for pSS, they 
are not specific for the disease as for example patients with an HIV infection may also 
harbor cystic LELs within their salivary glandular tissue.64
Besides LELs the salivary gland of pSS patients also show a relative decrease in IgA+ 
plasma cells, and a relative increase in IgG+ and IgM+ plasma cells compared to control 
individuals (Figure 1C).55 This relative IgA+ plasma cell decrease is largely due to a marked 
increase in numbers of IgG+ and in to a lower extent also IgM+ plasma cells.25,55 The absolute 
number of IgA+ plasma cells remains more or less constant in pSS. The IgG+ and IgM+ 
plasma cells are mostly located in the periphery of the foci and unaffected parenchyma. 
The diagnostic threshold of <70% IgA was set by Bodeutsch et al. based upon labial gland 
biopsies pSS patients compared to the control groups consisting of healthy controls, 
keratoconjunctivitis sicca patients and RA patients.54 In the biopsies of pSS patients the 
relative decrease of <70% IgA has a specificity of 95.4% and a sensitivity of l00%.55 Several 
studies showed that a relative decrease of <70% IgA+ plasma cells (and consequently 
increase in IgG+ and IgM+ plasma cells) was more sensitive and more disease specific 
than the FS.54,57,65 Even without the presence of foci a decrease of <70% IgA+ plasma cells 
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is possible.57 These robust data indicate that the combination of FS and <70% IgA can 
increase the accuracy of the biopsies as indicative for the diagnosis of pSS or not.57
According to the ACR-EULAR classification criteria the salivary gland biopsy has to fulfill 
the criterion of FS≥1 to be considered positive.32,33 In daily clinical practice, however, an 
evaluation of the salivary gland biopsy for the presence of LELs and <70% IgA+ plasma cells 
besides the FS may greatly aid in the correct diagnosis of pSS. Both markers show high 
specificity and sensitivity in the labial and parotid gland biopsy (Haacke et al, manuscript 
in preparation). For instance, if a biopsy with FS<1 but LELs and a decrease of >70% IgA+ 
plasma cells are present, it is reasonable to interpret the biopsy as suggestive for pSS. Vice 
versa, if a biopsy has a FS just above 1 and lacks these additional features, the clinician 
should be aware that there might be a risk of a falsely positive biopsy.
Figure 1: Histopathological changes in parotid gland biopsies of pSS patients 
The examples are all from parotid gland tissue. A) Periductal focus surrounded by unaffected parenchyma. B) 
Centrally located duct forming a lymphoepithelial lesion within a focus. C) Dual staining for IgA and IgG expressing 
plasma cells, showing a decrease of <70%IgA expressing plasma cells.
Salivary gland histopathology as predictor of disease severity and lymphomagenesis: 
the case for and against ectopic GCs
The appreciation of the high heterogeneity of the degree of immune cell infiltration in the 
salivary glands of pSS patients ranging from sparse T-cells to highly organized B-cell-rich 
follicles has prompted the investigation of whether salivary gland histopathology could be 
associated with disease severity and predict disease evolution including lymphomagenesis. 
Approximately 5-10% of patients with pSS will develop a non-Hodgkin B-cell lymphoma, 
most commonly MALT lymphomas which predominantly arises in parotid glands as a 
low grade lymphoproliferative disorder, but can evolve into more aggressive large B-cell 
lymphomas.66 Malignant B-cell clones originate from precursors already infiltrating the 
pSS salivary glands during the polyclonal phase of the local humoral response and are 
progressively enriched during the progression from lymphoepithelial lesions to MALT 
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lymphomas.59,67 Of interest, malignant B-cells often display Ig variable heavy (IgVH) 
gene rearrangement observed in rheumatoid factor producing B-cells suggesting that 
lymphomagenesis in pSS is an (auto)antigen-driven process taking place within the salivary 
gland tissue.68,69 
Antigen-driven B-cell selection normally takes place in GCs within secondary lymphoid 
organs but there is definitive evidence that also ectopic GCs in the salivary glands of pSS 
allow affinity maturation of GC B-cells with somatic Ig gene hypermutation.70 This somatic 
hypermutation is not limited to GCs, but can occur at extrafollicular sites such as the T 
zone-red pulp border.71,72 Somatic hypermutation, but also Ig isotype class switching, is 
dependent on the enzyme activation-induced cytidine deaminase (AID) encoded by the 
AICDA gene which is expressed by GCs in the pSS salivary glands.73,74 Of interest, AICDA 
mRNA expression in MALT lymphomas is strongly associated with the process of aberrant 
somatic hypermutation whereby off-target mutations in important genes regulating B-cell 
proliferations promote genetic instability and malignancy.75 Thus, there is a immunological 
rationale whereby GCs might represent key early pathogenic players in the process of 
B-cell lymphomagenesis and their histopathological detection in the salivary glands might 
help in predicting patients at increased risk of lymphomagenesis; however, conflicting 
evidence on this topic has emerged in the last 10 years. These studies are discussed below 
in chronological order of publication. 
In a first report in a small retrospective cohort of 8 pSS patients with MALT lymphoma 
and matched parotid and labial salivary gland biopsies the prevalence of GCs in labial 
salivary gland tissue prior (average 3.3 years) to lymphoma was reported to be significantly 
higher (75% vs 33%) in SS patients who later developed MALT lymphomas.73 In this work, 
GCs were defined by the presence of CD21+ FDC networks containing AID+ GC B-cells. 
In a retrospective-prospective study of a large Swedish cohort of 174 pSS minor salivary 
gland biopsies Theander et al76 reported the presence of ectopic GCs, determined using 
haematoxylin and eosin as focal lymphocytic foci with features indicative of lymphoid 
organization such as a densely packed dark zone and a light zone, in 32% of the patients. 
Linkage with the national cancer registry identified 7 pSS patients with NHL with a median 
time lapse between salivary gland biopsy and NHL diagnosis of 8 years. Similar to the 
previous report73, the prevalence of GCs in pSS patients who later developed lymphoma 
was significantly increased (86%). The relative risk of developing NHL in pSS patients with 
GC formation calculated using Cox regression analysis and Kaplan Meier statistics/log rank 
test was 15.4-fold higher compared to the GC negative pSS subset with a negative predictive 
value of 99%. Additionally, the presence of GC correlated with anti-SSA/SSB autoantibodies, 
lymphadenopathy and peripheral neuropathy as defined in the relevant ESSDAI domains.76 
These promising data were not confirmed by Johnsen et al77 who conducted a 
retrospective nationwide search in the Cancer Registry of Norway and identified 21 
patients with lymphoma (~50% with salivary gland MALT lymphomas) including 12 with 
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previous, concomitant or subsequent matching labial salivary glands tissue blocks. These 
tissue blocks were analyzed for GCs and compared with 28 labial salivary gland biopsies 
from patients with pSS without lymphoma matched for sex and age. GCs were defined by 
hematoxylin and eosin staining plus immunohistochemistry for IgD/CD21 and IgD/CD38. 
Although pSS patients with lymphoma displayed a significantly higher FS, no significant 
difference in the prevalence of GCs was observed. Somewhat surprisingly, in this study 
ectopic GCs were more frequent in pSS without than with lymphoma (46% vs 33%), a result 
which was also mirrored by a higher prevalence of CD21+ FDC networks (71% vs 58%). 
In a large Greek cohort the presence of GC in the labial salivary gland biopsy were not an 
independent risk factor for NHL development.78 This cohort compromised 92 pSS patients with 
NHL (79% MALT lymphoma) and 381 pSS patient without lymphoma. Of the 92 pSS patients 
with NHL, 49 minor salivary gland biopsies were available and 11 (22%) showed GC. In the 
pSS patients without lymphoma 12/101 (12%) showed GC in the minor salivary gland biopsy 
(p=0.15). In the biopsies of the pSS patients who did develop NHL a FS >1.6, Tarpley score ≥3 
and the presence of monoclonality in the tissue were significantly more frequently observed. 
The manner in which GCs were assessed in the biopsies was not given in the article. 
Similar negative results were reported in the University of Groningen Medical Center cohort 
where 11 labial salivary gland biopsies taken at diagnosis were available from patients who 
later developed a MALT lymphoma (median time lapse 4 years) (chapter 6a).79 A population of 
22 pSS patients with no lymphoma was taken as control. In this cohort, GC identification was 
based on hematoxylin and eosin plus staining for Bcl-6, a marker of GC B-cells. No difference 
in the prevalence of GC was observed (18% in both groups), although pre-lymphomatous LEL 
were observed in 7 out of 11 of the GC+ pSS subset prior to lymphoma (chapter 6a). 
In a recent multicenter French study of 115 minor salivary gland biopsies with 8 
identified cases of subsequent NHL (median time lapse 51 months), Sène et al reported 
a significant increase in the prevalence of GCs comparing pSS patients with and without 
subsequent NHL (37.5% vs 15% with an incidence of GCs of 16.5% in the total pSS 
cohort).80 In this study the definition of the GC was based on hematoxylin and eosin 
staining together with presence of FDC and B-cells with low activity of Bcl-2 and high activity 
of Bcl-6. Of relevance, after Cox multiple regression analysis, but not in univariate analysis, 
the presence of ectopic GCs in the salivary glands remained an independent positive 
predictor of lymphoma with a conferred increase hazard ratio of 7.8. Within this study 
half of the pSS patients developing NHL were male, and all pSS patients who developed 
NHL, had a monoclonal gammopathy (MG). MG is a known risk factor for NHL and in the 
general pSS patients population the presence of MG is 4-2280-82 Most important, MG is, 
just as the presence of GCs in the salivary gland biopsy, associated with higher disease 
activity.82,83 As, both GCs and MG are associated with higher disease status, there is no clear 
indication that presence of ectopic GCs is a prerequisite for MALT lymphoma development 
(chapter 6b). 
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In addition to the above studies, indirect evidence of the potential clinical relevance 
of GCs on lymphomagenesis has been provided by Carubbi et al84 who showed that 
GC+ pSS patients displayed increased prevalence of several clinical and laboratory 
risk factors previously associated with lymphoma including salivary gland swelling, 
hypergammaglobulinemia, RF positivity. Additionally, they reported that pSS patients 
with GC had a higher prevalence of a salivary gland FS >3, which is of significant interest 
considering that a FS ≥3 has been reported in multivariable linear regression analysis as 
an independent risk factor for lymphomagenesis in pSS patients based on a meta-analysis 
by Risselada et al.85 
Reconciling conflicting data on ectopic GCs in pSS: the need for longitudinal studies 
and consensus on standardization 
As emerged from the studies reviewed above, salivary gland histopathology, with 
particular reference to the identification of ectopic GCs, has potential clinical utility in 
the management of pSS by identifying patients with an increased risk of severe clinical 
manifestations with high disease activity and possibly lymphoma. A critical review of the 
evident pitfalls of existing studies would help in further progressing the field thus paving the 
way for more conclusive studies. At least two major criticisms should be made regarding 
existing data; those related to study design and those related to the identification of GCs. 
Regarding the former, the major limitation is the retrospective nature of these studies, 
potentially introducing selection bias, particularly in the control population. Additionally, 
considering the relatively low prevalence of lymphoma in pSS, all the previous studies 
have largely underpowered cohorts with only a handful of cases with lymphoma available 
for analysis. Further confusion is dependent on the inclusion of different subtypes of 
NHL in the different studies, from selected populations of MALT- lymphoma to a mix of 
different lymphoproliferative malignancies underlined by diverse pathogenic mechanisms. 
Furthermore, high variability in the follow up time from labial biopsies to diagnosis of NHL, 
ranging from medians of few months to several years further complicates the comparative 
analysis in different studies. On top of the above limitations which are somewhat intrinsic 
to the complexity of studying a low prevalence clinical manifestation in a relatively low 
prevalence disease such as pSS, there are technical aspects related to the identification of 
GCs which could be overcome with a consensus on standardization of the protocols used 
to define what an ectopic GC is. This aspect should move away from the identification of 
GCs in secondary lymphoid organs such as tonsils or lymph node as ectopic GCs in pSS 
salivary do not necessarily reflect the same physiopathological mechanisms. 
As indicated above, virtually all existing studies on GCs in pSS salivary glands have used 
a different definition of GCs resulting in highly variable incidences of GCs in the different 
cohorts. Simple hematoxylin and eosin staining has intrinsic limitations as a clear separation 
of dark and light zone is frequently absent in ectopic GCs. Furthermore, LEL can sometimes 
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be mistakenly identified as GCs (chapters 3a and 3b). Addition of immunohistochemistry for 
the identification of GCs is certainly of help, however there is no consensus on the markers 
required. Double staining for CD3/CD20 followed by CD21 can help identifying follicles 
with T/B-cell segregation with differentiation of FDC networks; however, CD21 staining can 
potentially overestimate the prevalence of GCs as the non-long isoform of CD21 is also 
expressed by B-cells. More specific staining for GC B-cells such as Bcl-6 and AID display 
variable degrees of sensitivities and risk falling in the opposite direction of underestimating 
GC prevalence. In a recent study we compared Bcl-6 and CD21 stainings in the parotid- and 
labial gland biopsies. This study showed that the number of foci containing CD21+ FDC-
networks was significantly higher that foci harboring Bcl-6+ cell clusters. The foci with CD21+ 
FDC-networks only showed Bcl6+ cell clusters in 18% (9/50) of the labial gland and 32% 
(22/69) of the parotid gland biopsies. This indicates that CD21 as surrogate marker for GCs 
overestimates the number of GCs and that Bcl-6 is a more suitable marker for identification 
of GCs in salivary gland biopsies of pSS patients (chapter 3c). Additionally, there are other 
critical aspects which need to be considered and cannot be critically evaluated in the present 
studies. GCs are “skip lesions” which are variably present in adjacent minor salivary glands, 
thus a minimal number of individual biopsies should be taken in order to cover minimal 
total area of 8mm2, as we recently suggested.34 Additionally, including multiple cutting 
levels would maximize the accuracy of the analysis.35 All these factors combined advocate 
for consensus guidelines to standardize the assessment of ectopic germinal centre-like 
structures in salivary gland tissue of pSS-patients (chapters 3a and 3b).86,87 Furthermore, 
design of prospective multicenter studies with centralised review of labial salivary gland 
biopsies would be required to provide definitive evidence in support of the use of salivary 
gland histopathology in general and ectopic GCs in particular as clinically meaningful 
predictors of disease progression to inform management of pSS patients. 
Role of salivary glands biopsies in clinical trials 
Since xerostomia is one of the major complaints of pSS patients and salivary glands are a 
primary target of the autoimmune process, the histopathological changes in these glands 
are of utmost importance for evaluating (new) treatment options. Currently, most clinical 
trials take the change in ESSDAI scores as primary endpoint, implying that pre- and post-
treatment biopsies are not required.88,89 Nevertheless, post-treatment biopsy evaluation 
may give important information about efficacy of the treatment, mode of action of the 
compound, effect on the glandular tissue and the pathogenic mechanism of the disease 
(chapter 7a and 8). 
The inclusion of pSS patients in clinical trials is usually based upon the latest 
classification criteria for pSS. Hence also patients without a salivary gland biopsy, or with 
a “negative” biopsy (i.e. FS<1.0) may enter these trials. In these negative biopsies, in which 
lymphoid infiltrates may even be complete absent, the possible effect of treatment on the 
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lymphocytic inflammation cannot be assessed in their post-treatment biopsies. Only few 
clinical trials used a positive salivary gland biopsy as additional inclusion criterion (chapter 
7a and 8).90,91 The disadvantage is that fewer pSS patients qualify for inclusion into the 
study and that there might be a patient bias. 
Although repeated biopsies can be taken from both minor and major salivary 
glands, taking biopsies from the parotid glands has certain advantages (chapter 2). The 
major advantage of parotid glands over labial glands is that post-treatment biopsies can 
repeatable be taken from the same gland as the initial (diagnostic) biopsy to evaluate 
treatment efficacy, while in case of labial salivary biopsies for every post-treatment 
assessment a new series of glands has to be removed for histopathologic review.37,92 Also 
disease recurrence or progression can be monitored. Another advantage of the parotid 
biopsy is that histopathological results can be directly correlated with other clinical and 
laboratory findings from the same gland such as parotid salivary flow, composition of the 
saliva and ultrasound (chapter 2).27,93 Fisher et al34 published consensus guidelines for 
assessing salivary gland biopsies in clinical trials (Table 2). The evaluation of the biopsies 
encompasses the same aspects as for diagnostic biopsies and includes FS, percentage 
of CD45+ infiltrate presence of GCs and LELs. In this guideline CD21 is proposed to 
assess GCs, but as mentioned before, new data indicate that Bcl-6 is the most suitable 
marker for GC identification (chapter 3c). Furthermore, features like fibrosis, atrophy, fat 
infiltration and sialadenitis patterns besides FLS, should be reported. In addition to these 
general aspects, specific analysis should be performed, depending upon the drug used 
for treatment. 
Response of salivary gland biopsies to biological DMARDs therapy 
There are no approved biological DMARDs yet for the treatment of pSS, but there are a 
number or trials that have been performed or are currently running. In Table 3 the major 
findings have been summarized of the trials that also analyzed the effect of treatment 
on the salivary gland biopsy. Timing of the post treatment biopsies varies between the 
different trials and the histopathological items that were assessed are diverse. Obviously 
there is a need for standardization, in order to allow a proper comparison between the 
various studies. Most biologicals tested in pSS patients target the B-cells or signaling 
pathways leading to the formation, activation and expansion of (auto-reactive) B-cells.
BAFF (BLyS) plays an important role in the pathogenesis of pSS and elevated levels are 
present in the salivary glands.94 Belimumab blocks the binding of soluble BAFF (BLyS) to its 
receptors on B-cells. In this manner the survival of (autoreactive) B-cells, their maturation 
and differentiation towards immunoglobulin secreting plasma cells are thought to be 
hampered.94,95 The efficacy of belimumab was first shown in an open label (BELISS) study 
of Mariette et al96 in which 18/30 (60%) of the pSS patients responded based upon the 
SSRI-30 (Sjögren’s Syndrome Responder Index-30) and 15/30 (50%) upon ESSDAI ≥3 points 
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at week 28. Seror et al97 showed in a sub-study of 15 pSS patients of the BELISS trial 
that after 28 weeks of belimumab treatment the FS in the post-treatment labial gland 
biopsies tended to decline with a significant decrease in the Chisholm grading (see table 
1). Furthermore, belimumab decreased the proportion of BAFF-positive cells and the B/T-
cell ratio in the foci. Although this study was rather small, belimumab did seem to alter the 
composition of the infiltrates in the glandular tissue and a clinical response in ESSDAI of 
≥3 was seen in 6/15 (40%) of pSS patients. In biopsies taken after continuous treatment 
up to 52 weeks, no significant difference in the FS was seen compared to baseline levels. 
Although FS and salivary function did not change after 52 weeks of treatment, the clinical 
response as measured by ESSDAI, continued to be lower than baseline levels.98 
Abatacept (CTLA4-Ig), which blocks the CD28-mediated co-stimulation of T-cells, has 
shown efficacy with respect to the ESSDAI in a phase II trial of pSS.91 Treatment with 
abatacept resulted in a significant decline in ESSDAI, whereas unstimulated and stimulated 
whole saliva flow did not increase. Abatacept treatment did not alter FS or the number 
of B-cells and T-cells in the parotid gland or the labial gland biopsy (chapter 8).99,100 The 
amount of CD45+ infiltrate and number or severity of LELs did also not change in the 
parotid gland biopsy. However, the number of GCs declined, and there was an increase in 
the number of IgM+ plasma cells.100 Likely this reduction of GC activity is the consequence 
of a reduced CD28-mediated activation of Tfh-cells (chapter 8).
101 In the labial gland 
biopsy, Adler et al found decreased numbers of Foxp3+ regulatory T-cells in the foci after 
abatacept treatment.99 
Rituximab is directed to CD20 and treatment of pSS patients leads to a near complete 
depletion of B-cells in the blood at 12 weeks. Rituximab is also able to affect the glandular 
infiltrates in both labial and parotid glands, as reflected by lower FS or reduced surface 
area of CD45+ staining (chapter 7a).53,63,102-106 This effect is the direct result of a decline 
in B-cell numbers within the infiltrate, since T-cell numbers were unaffected. In addition 
there is a decrease in the number of GCs, within the infiltrates.53,102 Not only B-cells 
that constitute the infiltrate, but also intra-epithelial (FcRL4+) B-cells within the LELs 
were depleted by rituximab (chapters 4 and 7a).59 This depletion of the intra-epithelial 
B-cells of the striated ducts was associated with a normalization/restoration of the ductal 
epithelium,53,63 which illustrates the importance of the interaction between intra-epithelial 
B-cells and formation of LELs (chapter 4 and 7a), These changes in parotid gland tissue 
after rituximab treatment, in particular the reduction in infiltrate size and normalization 
of LELs, is partially reflected in the glandular function. Three studies reported that the 
salivary flow increased after rituximab treatment53,63,90,102 Other clinical studies showed 
no change in the salivary function upon rituximab treatment.105,107-110 All together these 
studies indicate that the salivary gland function (measured by whole salivary flow) did 
not further deteriorate but remained stable or even improved after rituximab treatment.
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Table 2: Guidelines for assessing salivary gland biopsies in general and for in clinical trials. 
Table from publication of Fisher et al.34
1 The minimum number of minor salivary glands is suggested to be four (six if small), and should be 
surgically separated
2 The minimum surface area of gland sections examined should be 8 mm2
3 If the first cutting level is inconclusive, or in the context of a clinical trial, consideration should be given 
to including two additional cutting levels at 200 µm intervals (typical focus diameter is <50 μm) in order 
to increase the surface area
4 Care should be given to preparation of paraffin blocks, with smaller glands set higher to allow 
midspecimen sampling during cutting
5 Histological examination should determine whether there is FLS present. Attribution of FLS, or possible 
FLS, should be followed by calculation of a focus score
6 The extent (absent, mild, moderate, severe) of atrophy, fibrosis, duct dilatation and non-specific chronic 
sialadenitis, in addition to the presence or absence of FLS, should be reported
7 Calculation of the focus score should include the whole of the glandular surface area in the denominator, 
to avoid introduction of bias
8 The presence or absence of germinal centre-like structures and lymphoepithelial lesions should be 
reported
Guidance relevant to clinical trials
1 The focus score should be recorded, and the area of individual foci should also be summed and divided 
by glandular area to give a more quantitative indication of the extent of glandular infiltration
2 Once FLS has been confirmed, all foci should be included in the focus score and in area of foci calculations, 
even when adjacent to abnormal acini or ducts, to avoid introduction of bias
3 Staining for CD3, CD20 and CD21 should be included, and the presence of germinal centre-like structures 
should be reported as the proportion of foci with both T/B-cell segregation and follicular dendritic cell 
networks. Consideration should be given to reporting the mean B/T-cell ratio in foci
4 Scoring should be undertaken by two trained observers who have reviewed a reference slide set, and 
with reporting of intraobserver and interobserver variability
5 Samples should be scored blind to subject and order
6 High-resolution image morphometry of each sample should be stored
7 Given the stable or slowly progressive nature of the histological features, baseline biopsies may be 
substituted with prior biopsies to reduce the number of biopsies required. However, given the limited 
evidence available, these should have been acquired no longer than 1 year prior to baseline
8 The optimal period of time for rebiopsy has not been established and will depend on the agent employed.
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Biopsies for stratification of patients 
The various histopathological features might also be used for patient stratification for 
treatment, and precision medicine. For example, we showed (chapter 7a) that high absolute 
number of B-cells in the baseline parotid gland biopsy predicts better responsiveness 
of patients with pSS to rituximab treatment.53 Response to rituximab was defined as a 
decline in ESSDAI of ≥3 points in this study, which is considered a clinically meaningful 
improvement.113 This response to rituximab seems to be in contrast with studies of Cornec 
et al104,114 which showed that pSS patients with a high proportion of B-cells and higher FS in 
the labial salivary gland predicted the absence of a clinical response to rituximab. In these 
studies responders were defined by the SSRI-30, a composite endpoint.115 As discussed 
extensively,116,117 differences in assessing B-cells in sections (numbers versus proportions) 
and differences in how clinical response were measured (ESSDAI versus SSRI-30), may 
contribute to explain the apparent differences in outcome (chapter 7b). 
For belimumab, Seror et al97 showed that low numbers of NK-cells, mainly located in 
the periphery of the foci of the labial gland biopsy are associated with a better response 
to treatment. In this study response was also defined as an decrease in ESSDAI of ≥3 
points. Remarkably, the baseline number of BAFF+ cells in the biopsy could not predict 
response to belimumab. 
Even when treatment with (biological) DMARDs leads to (complete) resolution of the 
inflammation of the glandular tissue, it is questionable whether this will result in a salivary 
gland that is fully restored and saliva production that has been returned to normal. The 
inflammation in the glandular tissue is likely to cause irreversible damage in the form 
of fibrosis and loss of acinar cells leading to sustained reduced saliva production46,47 
Furthermore, in pSS patients the salivary gland stem cells responsible for the production 
of new epithelial and acinar cells are decreased in number and functional ability and 
exhausted as compared to healthy controls.118 This implies that after resolution of the 
inflammation, the gland cannot fully restore to the level of healthy individuals, and 
consequently saliva production might still be suboptimal. 
In summary, in clinical trials with pSS patients, repeated biopsies give important 
information about treatment efficacy, the mode of action of the drug and the pathogenic 
mechanism of the inflammation within the salivary gland tissue. Treatment with biologicals 
such as rituximab and belimumab appear to have a positive effect on the salivary glands 
with at least stabilization of the salivary flow. Results from studies combining these two 
biologicals are eagerly awaited. Further studies for stratification of patients and studies to 
evaluate glandular function when the salivary infiltrates are fully diminished are needed. 
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Table 3: Overview of studies assessing histopathological salivary gland tissue before and after treatment with 
biologicals in pSS patients 
Biological Target Trial Study 
design
Number biopsies Gland Time of biopsy Histopathological evaluation 
Etanercept TNF-α Zandbelt111 Open label N=10 Etanercept Labial Baseline + week 12 FS = , %IgA =
Abatacept CD28-mediated 
co-stimulation
Adler99 Open label N=10 Abatacept Labial Baseline + week 28 Foci/mm2 =, Number of foci ↓, CD20 =, CD3 =, CD4 =, CD8 =, 




Open label N=15 Abatacept (Verstappen 
N=14)
Parotid Baseline + week 24 FS =, CD45 =, GCs (HE) ↓, LELs (HE) =, CD20 =, CD3 =, IgA =, IgG =, 
IgM ↑, CD21 =, FcRL4+ B-cells =, ICOS ↓, IL21+CD4+ cells =
Infliximab TNF-α Mariette112 RDBPCT N=57 (Infliximab + controls) Labial Baseline + week 10 FS =
Rituximab CD20+ B-cells Delli53 Haacke59 RDBPCT N=16 RTX, (Haacke N=18) N=9 
placebo
Parotid Baseline + week 12 FS =, CD45 ↓, GCs (HE) ↓, LELs (HE) ↓, CD20 ↓, CD3 =, FcRL4+ 
B-cells ↓
Ciccia103 Open label N=10 RTX Labial Baseline + week 48 Chisholm grading =to↓, IL22+ infiltrating cells ↓, IL22+ 
myoepithelial cells ↓
Cornec104 Open label 
and RDBPCT
N=14 low dose RTX (open label)
N=17 high dose RTX (RDBPCT)
N=14 placebo (RDBPCT)
Labial Low dose RTX: baseline + 
week 12
High dose RTX and placebo: 
baseline + week 24
Low dose RTX week 12: proportion B-cells ↓, high dose RTX week 
24: proportion B-cells =. Note: patients with persistent blood 
B-cell depletion at week 24: ↓ or = of tissue B-cells. Patients with 
blood B-cell repopulation before week 24: ↑ proportion of tissue 
B-cells at week 24.104 
Pijpe63 Open label N= 5 RTX Parotid Baseline + week 12 %acinar parenchyma =, %lymphocytic infiltrate ↓, %fat =, 
germinal centres ↓, LELs ↓, proliferation of acinar parenchyma 
(%Ki-67) ↓, B:T lymphocyte ratio in the infiltrate ↓ 
Pers106 Open label N= 15 RTX Labial Baseline + 4 months (N=15), 
12 months (N=3), 24 months 
(N=2)
B-cells ↓ (repopulation at 24 months), CD3 =, CD4 =, CD8 =
Devauchelle-
Pensec109
Open label N=16 RTX Labial Baseline + week 12 FS =, B-cells ↓ 
Carubbi102 Open label N=19 RTX
N=22 DMARDs
Labial Baseline + week 120 RTX: FS ↓, GCs (CD21) ↓, CXCR4+ and CXCR5+ cells in the 
mononuclear cell infiltrate ↓
Belimumab BAFF/BLyS Seror97 Open label N=15 Belimumab Labial Baseline + week 28 Chisholm grading ↓, FS =to↓, B-cell/T-cell ratio in the foci ↓, % 
BAFF-positive cells in foci ↓, NK infiltrate inside and outside the 
foci =
De Vita98 Open label N=12 Belimumab Labial Baseline + week 52 FS =
Abbreviations: TNF-α: tumor necrosis factor- α, BAFF: B-cell activating factor, BlyS: B-lymphocyte stimulator, 
RDBPCT: randomized double-blind placebo controlled trial, RTX: rituximab, DMARDs: disease modifying anti-
rheumatic drugs, FS: focus score, GCs: germinal centers, IgA / IgG / IgM: IgA / IgG / IgM expressing plasma cells, 
HE: hematoxylin and eosin, LELs: lymphoepithelial lesions, ↑: increased, ↓: decreased, =: no significant change.
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Abbreviations: TNF-α: tumor necrosis factor- α, BAFF: B-cell activating factor, BlyS: B-lymphocyte stimulator, 
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Concluding remarks 
There is little doubt that salivary gland histopathology is a cornerstone of the diagnostic 
algorithm in pSS, although the accuracy of the evaluation of FLS and FS calculations 
could be significantly improved by standardization. Besides solely focusing on the 
FS, adding the histopathological markers LELs and a relative decrease of ≤70% IgA 
expressing plasma cells in the routine evaluation of the salivary gland biopsy may 
contribute to the correct diagnosis of pSS. Standardization of the identification of 
GCs in the glandular biopsies is essential to further evaluate the relevance of these 
structures. Larger, international, prospective studies, should provide more insights 
in clinical and laboratory characteristics of pSS patients with GCs in their salivary 
gland biopsy and whether their disease progression differs (e.g. towards lymphoma 
development) from patients without GCs in the biopsy. Furthermore, detailed studies, 
incorporating the histopathological parameters LELs and a relative decrease of ≤70% 
IgA expressing plasma cells in the diagnosis of pSS are needed to establish the 
additional value of these markers besides the FS. 
Currently, the University Medical Center of Groningen follows pSS patients for 10 years 
within the so-called REgistry of Sjögren syndrome in UMCG - LongiTudinal (RESULT) cohort. 
These patients are subjected to a full diagnostic work-up including a salivary gland biopsy 
in which, amongst others, the FS, proportion of CD45 infiltrate, presence of GCs, LELs and 
ratio between IgA and IgG expressing plasma cells are assessed. This RESULT cohort of pSS 
patients might provide insights in the correlation of these histopathological parameters of 
the salivary gland biopsy taken at time of pSS-diagnosis with a wide variety of biomarkers 
in blood, saliva and tears, salivary gland ultrasonography and clinical outcome during the 
progression of the disease. 
Besides the glandular histopathology, the involvement of the salivary glands in 
pSS can be examined by salivary gland ultrasonography (SGUS). This is a well-tolerated 
non-invasive procedure which can be performed repeatedly. The SGUS evaluates the 
parotid and submandibular gland and are graded by the Hocevar score. Five domains are 
incorporated in the Hocevar scoring system: clearness of salivary gland borders, presence 
of hyperechogenic reflections, presence of hypoechogenic areas, the homogeneity 
of the gland, and the parenchymal echogeneity.119 The SGUS is considered positive if 
the Hocevar score is ≥15.120 The absolute agreement between SGUS and the salivary 
gland biopsy is good,120 and studies incorporating the SGUS in the ACR-EULAR criteria 
are promising.121,122 Of note, a negative SGUS showed a positive labial biopsy in 26% of 
patients and 22% of patients with a positive SGUS had a negative parotid gland biopsy.120 
It is, however, currently not fully elucidated how the echographic images correspond 
with the histopathology of the glandular biopsies. Although SGUS is a valuable diagnostic 
instrument, especially in the follow-up of pSS patients, it is not likely to replace the biopsy 
soon. The SGUS is currently not specific enough to differentiate salivary gland changes 
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related to pSS from changes occurring in other auto-immune diseases such as sarcoidosis, 
amyloidosis and IgG4 related disease.123,124 Furthermore, the diagnosis of a (developing) 
salivary gland MALT-lymphoma cannot be made based upon SGUS. 
The combination of salivary gland histopathology with molecular biology will provide 
interesting data in the future. With the use of spatial transcriptomics the expression levels 
of different genes in different areas in the salivary gland biopsies can determined. This 
will allow to visualize, amongst the other endless possibilities, the differences in gene 
expression of epithelial cells from ducts with LELs and ducts without LELs, differences in 
gene expression of foci in different stages of organization and the effect of treatment on 
gene expression in different cells of the biopsy. Currently pubmed.com gives no hits for 
the terms “spatial transcriptomics” combined with “Sjögren’s syndrome”, indicating that 
the initial work on the gene expression profile of salivary gland biopsies from healthy 
controls, sicca non-pSS patients and pSS patients has yet to be performed and published. 
Finally, with the new era of biological therapies coming to fruition in pSS, although 
currently still limited to the clinical trial phase, this thesis showed that salivary gland 
histopathology may assist in patient stratification regarding efficacy of the treatment, 
mode of action of the drug and unraveling immunopathological mechanism of pSS. 
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Sjögren’s syndrome is a systemic autoimmune disease primarily affecting the salivary 
and lacrimal glands. The chronic inflammatory process in these glands is involved in the 
characteristic complaints of dry mouth and dry eyes. Many other organ systems, such as 
lung, kidneys and skin can be affected as well. For the diagnosis of pSS, a salivary gland 
biopsy is often taken. This biopsy takes a prominent place in the current American College 
of Rheumatology – European League against Rheumatism (ACR-EULAR) classification 
criteria. In these criteria a glandular biopsy is considered positive if the focus score (FS), 
calculated as the number of foci per 4 mm2 glandular parenchyma, is ≥1. The presence 
of lymphoepithelial lesions (LELs) and a relative decrease of ≤70% IgA expressing plasma 
cells are other characteristic histopathological features of the glandular tissue, although 
they are not taken into account in the ACR-EULAR criteria. Furthermore, germinal centers 
(GCs) can be found in the salivary tissue of about a quarter of the pSS patients and is 
associated with more severe and active disease. In most centres a labial salivary gland 
biopsy is taken, but a parotid salivary gland biopsy can be used as an alternative. Besides 
its use in diagnosis and classification of pSS, salivary gland biopsies are increasingly used as 
an outcome measure in clinical trials. Pre-treatment and post-treatment biopsies give new 
insights in the pathogenesis of the disease. Although the importance of the salivary gland 
biopsy is recognized, the accurate assessment of these biopsies requires a standardized 
histopathological evaluation. 
The cause of pSS is currently not fully known. It is thought that an initial trigger (e.g., a 
viral infection) leads to a breach of tolerance resulting in an inflammatory response in the 
salivary/lacrimal glands. The early inflammatory response in the salivary gland is dominated 
by T-cells followed by the influx of B-cells. Besides T- and B-cells, also other non-lymphoid 
cells are attracted to the inflamed salivary glands. Finally, all components for the formation 
of ectopic lymphoid are present even allowing the local generation of germinal centres. In 
5-10% of the pSS patients, the hyperactivity of B-cells is reflected by the development of 
malignant non-Hodgkin’s lymphomas (NHL). These lymphomas mostly occur in the parotid 
gland and are predominantly of the mucosa-associated lymphoid tissue (MALT) type.
Treatment of pSS is primarily symptomatic, relieving dryness complaints. With the 
emergence of disease-modifying anti-rheumatic drugs (DMARDs), treatment options have 
been extended. These DMARDs aim not only to relieve symptoms, but also to provide 
a (long lasting) systemic effect. Since not all pSS patients benefit from treatment with 
the same DMARD, it is crucial to find biomarkers to identify patients which will profit 
from treatment. This personalized medicine might aid in relieving pSS related complaints 
and preventing further disease progression. In this thesis the value of salivary gland 
histopathology in pSS patients for diagnosis and stratification, and as an outcome measure 
in treatment studies was described.
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Thesis part 1: Salivary gland histopathology 
In chapter 2 the applicability of the parotid gland biopsy is compared to the labial gland 
biopsy as well as that the chirurgical procedures for both biopsies are described. The 
current surgical procedure of a biopsy from the superficial lobe of the parotid gland 
has no reports of development of sialoceles or fistula. After this biopsy procedure, 
no permanent complications were observed and the level of post-operative pain is 
comparable to that of the labial gland biopsy. The histopathological evaluation of the 
biopsies is similar, and the diagnostic sensitivity and specificity of the biopsies are 
comparable. The parotid gland biopsy has certain advantages over the labial gland 
biopsy. It is possible to take more than once biopsies from the same gland. In this 
manner, disease progression can be monitored and treatment efficacy can be assessed. 
Furthermore, parotid gland biopsies make a direct comparison with other diagnostic 
results such as salivary flow, salivary scintigraphy and salivary gland ultrasound possible. 
Also, in the parotid gland biopsy an early, clinically not suspected, MALT lymphoma is 
fairly regular found in contrast to the labial gland biopsy. 
In chapter 3a, we described that the manner in which GCs are histologically assessed 
differs greatly amongst studies. Detection of GCs is in need of a clear histological definition. 
Correct assessment of these structures is clinically relevant as the presence of GCs is linked 
to higher disease activity. In haematoxylin-eosin (H&E) stained sections, the presence of 
GCs may be overlooked due to small size or LELs may incorrectly be classified as GCs. 
Therefore, in chapters 3a and 3b we argue to stain for the transcription factor B-cell 
lymphoma (Bcl)-6 for the easy and proper identification of germinal centres in salivary 
glands of pSS patients. This transcription factor is expressed at high levels by germinal 
centre B-cells. In the study described in chapter 3c, we subsequently show that Bcl6 
is indeed the most appropriated marker for correctly identifying GCs. On the contrary, 
assessment of GCs with CD21 leads to an overestimation of the number of GCs. 
Thesis part 2: Germinal centres and MALT lymphoma in biopsies of primary Sjögren’s 
syndrome patients
In the study described in chapter 4, the presence of FcRL4 expressing B-cells in the labial 
gland biopsies, parotid gland biopsies, and parotid gland MALT lymphoma of pSS patients 
was examined. First, we showed that almost all (97%) of the pSS associated parotid MALT 
lymphomas express FcRL4. FcRL4 expressing B-cells were also found in the salivary gland 
tissue of non-lymphoma pSS patients. Importantly, virtually all B-cells located between 
the epithelial cells of the striated ducts express FcRL4+, whereas only a small fraction of 
the periductal B-cells express this protein. Second, the study showed that these FcRL4+ 
B-cells are highly proliferative, are in close association with LELs. Third,their numbers 
are significantly higher in the parotid gland tissue compared to labial gland tissue. Their 
enrichment in the parotid glands may explain why MALT lymphomas in pSS patients 
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preferentially develop at this specific location. Last, this population of FcRL4+ B-cells can 
be targeted by rituximab which leads to restoration of the glandular striated ducts as 
demonstrated by the reduction and the severity of LELs after rituximab treatment. 
In chapter 5 it is described that there is an association between presence of 
intraepithelial B-cells and formation of LELs in salivary gland tissue of pSS patients. In 
simultaneously taken labial and parotid gland biopsies, the presence and severity of LELs, 
and the number of B- and T-cells within the striated ducts were assessed. Within the 
striated ducts of non-SS sicca patients, T-cells were found, but B-cells (and LELs) were 
completely absent. In contrast, B-cells were found in the striated ducts of pSS patients, 
even in a low proportion of ducts without hyperplasia. When LELs are present, B-cells are 
usually present and they were concentrated in the areas of epithelial hyperplasia. The 
B-cell/T-cell ratio increased significantly with higher severity of LELs. These results are 
indicative for a cross-talk between B-cells and ductal epithelial cells in salivary gland tissue 
of pSS patients, leading to LEL formation. 
In chapter 6a, a study is described in which retrospectively pre-lymphoma biopsies of 
pSS MALT lymphoma patients were compared with a matched control group with a long 
lymphoma free follow-up. Presence of GCs in biopsies, taken for the initial diagnosis of 
pSS, did not differ between these groups. Also the percentage of pre-lymphoma biopsies 
containing GCs was similar to the percentage of salivary gland biopsies with GCs of the 
general pSS population. Therefore, it was concluded that the presence of GCs in the labial 
gland biopsy of pSS patients is not predictive for parotid MALT lymphoma development. In 
chapter 6b, it was further argued that presence of GCs in labial gland biopsies is a reflection 
of high disease activity (EULAR Sjögren’s Syndrome Disease Activity Index: ESSDAI) and not 
a prerequisite for MALT lymphoma development because many pSS patients with GCs 
in the salivary gland biopsy will not develop malignant lymphomas. Another indication of 
high disease activity is a monoclonal gammopathy. In 4-22% of pSS patients, a monoclonal 
gammopathy is present. Moreover, monoclonal gammopathy is a known risk factor for 
lymphoma development. Finally, disease activity in pSS patients varies over time, possibly 
influencing the change of finding GCs in the salivary gland biopsy.
Thesis part 3: Histopathological changes after biological treatment
In chapter 7a, the histopathological changes in parotid gland biopsies of pSS patients after 
treatment with rituximab are presented. After rituximab treatment, the total number of 
lymphocytes (CD45+), the number of B-cells, severity and number/mm2 of LELs and GCs /
mm2 in the parotid gland parenchyma declined as compared to the placebo treated group. 
The number of T-cells/mm2 parotid gland parenchyma did, however, not change. Besides 
the number of LELs, the severity of LELs was also reduced. This indicates that elimination 
of B-cells from the parotid gland allows striated ducts to restore. Furthermore, comparing 
the pre-treatment characteristics of clinical responders (defined as decrease in ESSDAI 
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≥3 points) with non-responders, the median number of CD20+ B-cells/mm2 parenchyma 
at baseline was significantly higher in responders. In other words, the baseline number 
of B-cells/mm2 may serve an indicator of the response to rituximab treatment. This allows 
for identification of patients who can benefit from rituximab treatment (personalized 
treatment). In the study described in chapter 7b, the proportion of B-cells (B-cell/B- + T-cell 
ratio) was calculated instead of the number of B-cells/mm2 parotid gland parenchyma. The 
results showed that clinical responders (ESSDAI ≥3 points) also had a significantly higher 
B-cell proportion than non-responders. In others words, B-cell proportions presumably 
also predict responsiveness to rituximab treatment. Using the SSRI (Sjögren’s Syndrome 
Response Index) instead of the ESSDAI, the number of baseline B-cells/mm2 did not differ 
between responders and non-responders. 
In chapter 8, we showed that treatment of pSS patients with abatacept results in a 
decrease of the number of GCs/mm2 parotid gland parenchyma and in an increase in 
the number of IgM positive plasma cells/mm2 parotid gland. The FS, LELs/ mm2, area of 
lymphocytic (CD45+) infiltrate, amount of CD21+ networks of FDCs, and numbers of CD3+ 
T-cells or CD20+ B-cells did not change. The reduction of GCs in parotid gland tissue of 
pSS patients is probably due to inhibition of local T-cell dependent B-cell activation and a 
diminished generation of (activated) follicular helper T-cells. The increase of (short-lived) 
IgM positive plasma cells might occur in a T-cell independent manner. The numbers of IgA 
and IgG expressing plasma cells did not change after abatacept treatment.
To conclude, salivary gland biopsies play an important role in the diagnosis and 
classification of pSS as well as in predicting disease severity, assessing treatment efficacy 
and stratification of patients. More accurate, standardized and preferably digitized 
analyses of salivary gland histopathology in treatment studies could aid in understanding 















Het primaire syndroom van Sjögren (pSS) is een systemische auto-immuunziekte waarbij 
vooral de speekselklieren en traanklieren worden aangetast met een droog gevoel van 
de mond en ogen als gevolg. Een andere veel voorkomende klacht is moeheid. Daarnaast 
kunnen in tal van andere orgaansystemen klachten ontstaan, zoals in de longen, nieren 
en huid. 
Het chronische ontstekingsinfiltraat in de speekselklieren is betrokken bij de 
karakteristieke droogheidsklachten van de mond en ogen. In de speekselklieren 
zijn de ontstekingsinfiltraten gelokaliseerd rondom de afvoergangen. Een dergelijk 
ontstekingsinfiltraat wordt een focale lymfocytaire sialoadenitis genoemd. Hierbij zijn er 
meerdere foci (groepen van ≥50 lymfocyten) aanwezig. De infiltratie van deze lymfocyten 
in het epitheel van de afvoergangen leidt tot hyperplasie van dit epitheel en vorming van 
lymfo-epitheliale laesies (LELs). 
Voor de diagnose van pSS wordt vaak een speekselklierbiopt genomen. Dit biopt 
neemt een belangrijke positie in binnen de American College of Rheumatology – European 
League against Rheumatism (ACR-EULAR) classificatie criteria. In deze criteria wordt 
een speekselklierbiopt als positief beschouwd wanneer de focusscore (FS), welke wordt 
berekend door het aantal foci per 4 mm2 speekselklierparenchym, groter of gelijk is aan 1. 
De aanwezigheid van LELs en een relatieve afname van ≤70% IgA positieve plasmacellen 
in het speekselklierweefsel zijn andere karakteristieke histopathologische kenmerken van 
pSS. Deze laatste twee kenmerken zijn momenteel niet geïncorporeerd in de ACR-EULAR 
classificatie criteria. Daarnaast worden kiemcentra (KC) gevonden in het speekselklierweefsel 
van ongeveer een kwart van de pSS patiënten. De aanwezigheid van KC is geassocieerd met 
een ernstiger en actievere ziektestatus van pSS. In de meeste ziekenhuizen wordt een biopt 
van de lipspeekselklieren genomen. Een biopt van de glandula parotis (oorspeekselklier) 
vormt een goed alternatief. Naast de rol van het speekselklierbiopt in de diagnose en 
classificatie van pSS patiënten kunnen speekselklierbiopten worden gebruikt als (secundaire) 
uitkomstmaat in klinische studies. Het vergelijken van biopten voor en na de behandeling 
geeft nieuwe inzichten in de pathogenese van de ziekte. 
Het belang van speekselklierbiopten wordt erkend, maar de histopathologische 
beoordeling van de biopten behoeft standaardisatie. Ondanks dat de definitie van de FS 
helder is, blijkt de manier waarop de FS wordt beoordeeld te verschillen tussen laboratoria. 
Een gevolg hiervan is dat de interpretatie of een speekselklierbiopt als positief of negatief 
moet worden beschouwd, kan verschillen.
De oorzaak van pSS is momenteel niet precies bekend. Er wordt gedacht dat een 
initiële trigger (zoals bijvoorbeeld een virale infectie) kan leiden tot een verlies van 
immunologische tolerantie resulterend in een ontstekingsreactie in de speekselklieren en 
traanklieren. De beginnende ontstekingsreactie in de speekselklieren wordt gedomineerd 
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door T-cellen, gevolgd door een influx van B-cellen. Naast deze T-cellen en B-cellen worden 
ook andere non-lymfoïde cellen aangetrokken naar de ontstoken klier. Uiteindelijk zijn 
alle componenten in de speekselklier aanwezig voor de vorming van ectopische KC. Bij 
pSS zijn de B-cellen hyperactief. Deze hyperactiviteit van B-cellen leidt in 5-10% van de 
pSS patiënten tot de ontwikkeling van een maligne non-Hodgkin’s lymfoom (NHL). Deze 
lymfomen komen met name voor in de parotis en zijn overwegend van het slijmvlies-
geassocieerd lymfoïde weefsel (MALT) subtype. 
De behandeling van pSS is momenteel nog steeds primair symptomatisch. Met 
de komst van ‘disease-modifying anti-rheumatic drugs’ (ziekteverloop beïnvloedende 
geneesmiddelen tegen reuma) of DMARDs komen er meer behandelopties. Met name 
biologische DMARDs worden steeds meer ontwikkeld. DMARDs zijn niet alleen gericht 
op het verlichten van de symptomen, maar tevens om een langdurig systemisch effect 
te bewerkstelligen. Aangezien niet alle pSS patiënten baat hebben bij behandeling met 
dezelfde DMARD is het van groot belang om biomarkers te vinden om patiënten te kunnen 
identificeren die baat hebben bij behandeling. Deze zogenaamde gepersonaliseerde 
geneeskunde kan helpen in het verlichten van pSS gerelateerde klachten en bij het 
voorkomen van verdere ziekteprogressie. 
In dit proefschrift wordt de waarde van de histopathologie van speekselklierbiopten 
bij pSS patiënten voor 1) de diagnose, 2) stratificatie van patiënten en 3) uitkomstmaat bij 
klinische studies beschreven.
Deel 1: Histopathologie van het speekselklierbiopt 
In het review van hoofdstuk 2 wordt het parotisbiopt vergeleken met het lipbiopt en 
worden de chirurgische procedures voor het nemen van beide biopten beschreven. In de 
meeste ziekenhuizen wordt een lipbiopt genomen. Het parotisbiopt vormt echter een goed 
alternatief. Na het nemen van het parotisbiopt zijn, in tegenstelling tot na het nemen van 
een lipbiopt, geen permanente complicaties (sensibiliteitsstoornissen) gedocumenteerd. 
De door de patiënt ervaren postoperatieve pijn bij een parotisbiopt is vergelijkbaar met de 
postoperatieve pijn van het lipbiopt. De histopathologische evaluatie en de specificiteit van 
beide speekselklierbiopten zijn gelijk. Het parotisbiopt heeft echter enkele voordelen ten 
opzichte van het lipbiopt. Van de glandula parotis kunnen herhaalde biopten uit dezelfde 
speekselklier worden genomen, terwijl in geval van een biopt van de lipspeekselklieren 
telkens nieuwe speekselkliertjes uit de lip moeten worden verwijderd. Hierdoor kan, bij 
een parotisbiopt, het ziekteverloop nauwkeuriger worden gemonitord en de effectiviteit 
van behandelingen worden onderzocht. Tevens maakt het parotisbiopt het mogelijk om 
een directe vergelijking met andere diagnostische testen van dezelfde speekselklier te 
maken, zoals speekselvloed, speekselklierscintigrafie en echografie van de speekselklier. 
Als laatste, in het parotisbiopt wordt met enige regelmaat een MALT lymfoom aangetroffen, 
zonder dat hiervoor een klinische verdenking was. Dit in tegenstelling tot het lipbiopt. 
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In hoofdstuk 3a wordt beschreven dat de histopathologische manier waarmee 
KC worden aangetoond in de speekselklierbiopten sterk verschilt tussen studies. 
Helaas worden ook incorrecte methodes toegepast, waardoor de betrouwbaarheid en 
vergelijkbaarheid van studies wordt verlaagd. Voor de detectie van KC is er zodoende 
internationaal behoefte aan een duidelijke histopathologische definitie. De correcte 
beoordeling van deze structuren is klinisch relevant aangezien de aanwezigheid van KC is 
geassocieerd met een hogere ziekteactiviteit. In coupes van speekselklierbiopten gekleurd 
met haematoxyline-eosine (HE) kan de aanwezigheid van kleine KC gemakkelijk worden 
gemist en kunnen LELs foutief geïnterpreteerd worden als KC. Daarom wordt in hoofdstuk 
3a en 3b beargumenteerd om naast de standaard HE kleuring tevens te kleuren voor 
de transcriptiefactor B-cel lymfoom -6 (Bcl-6). De transcriptiefactor Bcl-6 komt sterk tot 
expressie in kiemcentrum B-cellen. Kleuring met Bcl-6 zorgt voor een makkelijke en juiste 
identificatie van KC in de speekselklieren van pSS patiënten. In de studie beschreven in 
hoofdstuk 3c wordt bevestigd dat Bcl-6 de meest geschikte marker is voor het correct 
identificeren van KC. Tevens wordt in dit hoofdstuk aangetoond dat identificatie van KC 
door middel van een CD21 kleuring leidt tot een overschatting van het aantal KC. Dit komt 
omdat CD21 niet alleen op kiemcentrum B-cellen tot expressie gebracht wordt, maar ook 
door folliculair dendritische cellen. Een netwerk van deze folliculair dendritische cellen kan 
in de foci aanwezig zijn zonder dat er daadwerkelijk sprake is van een (Bcl6+) KC. 
Deel 2: Kiemcentra en MALT lymfomen in speekselklierbiopten van patiënten met 
het primaire syndroom van Sjögren 
MALT lymfomen in het algemeen brengen het eiwit FcRL4 tot expressie, net als een klein 
aantal B-cellen die geassocieerd zijn met slijmvliezen. Om die reden hebben we onderzocht 
of dergelijke B-cellen ook aanwezig zijn in de MALT lymfomen in de glandula parotis van 
pSS patiënten. Daarnaast bekeken we of deze FcRL4+ B-cellen aanwezig waren in de 
speekselklierbiopten van pSS patiënten. In de in hoofdstuk 4 beschreven studie wordt 
de aanwezigheid van FcRL4+ B-cellen in zowel het parotis MALT lymfoom als parotisbiopt 
en lipbiopt van pSS patiënten bevestigd. Als eerste lieten we zien dat bijna alle (97%) 
van de pSS geassocieerde MALT lymfomen FcRL4 tot expressie brengen. FcRL4+ B-cellen 
werden ook gevonden in het speekselklierweefsel van pSS patiënten zonder lymfoom. 
Hierbij lagen vrijwel alle FcRL4+ B-cellen tussen de epitheliale cellen van de uitvoergangen 
die LELs vormen. Slechts een kleine fractie van de B-cellen in de periductale foci bracht 
dit eiwit tot expressie. De studie toonde aan dat FcRL4+ B-cellen een hoge delingsactiviteit 
hebben en sterk geassocieerd zijn met LELs in het speekselklierweefsel. Omdat MALT 
lymfomen bij pSS ook FcRL4 tot expressie brengen en vrijwel altijd geassocieerd zijn met 
LELs, zou het goed kunnen dat de MALT lymfomen afkomstig zijn van deze FcRL4+ B-cellen. 
Het aantal FcRL4+ B-cellen in het parotisklierweefsel is significant hoger dan het aantal 
FcRL4+ B-cellen in het lipbiopt. Deze verrijking in het parotisklierweefsel kan verklaren 
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waarom MALT lymfomen in pSS patiënten zich bij voorkeur ontwikkelen in de glandula 
parotis. De populatie FcRL4+ B-cellen reageert op behandeling met rituximab waardoor de 
uitvoergangen in het klierweefsel kunnen herstellen. Dit herstel is zichtbaar in de reductie 
van het aantal LELs en de afname van de ernst van de LELs na rituximab behandeling. 
In hoofdstuk 5 wordt de associatie tussen B-cellen die in het epitheel liggen van de 
uitvoergangen en de formatie van LELs in het speekselklierweefsel van pSS patiënten 
beschreven. In gelijktijdig genomen biopten van de lipspeekselklieren en de glandula 
parotis werd de aanwezigheid van LELs, de ernst van de LELs en het aantal T- en B-cellen in 
de dwarsgestreepte ducten onderzocht. Dit werd onderzocht in zowel gezonde controles, 
patiënten met sicca klachten die niet volledig aan de diagnose pSS voldoen (non-SS sicca 
patiënten) en pSS patiënten. In de uitvoergangen van non-SS sicca patiënten werden 
wel T-cellen gevonden, maar geen B-cellen en ook geen LELs. In tegenstelling daarmee 
werden er wel B-cellen gevonden in de uitvoergangen van pSS patiënten, zelfs in een 
gering aantal ducten zonder proliferatie van het epitheel. Als er LELs aanwezig waren in 
het biopt, dan waren er meestal ook B-cellen aanwezig in de uitvoergangen, met name in 
de gebieden waar proliferatie van de epitheelcellen van de uitvoergangen is. De B/T-cel 
ratio werd significant hoger (meer B-cellen) met de ernst van de LELs. Deze resultaten 
geven een indicatie dat er een ‘crosstalk’ bestaat tussen intra-epitheliale B-cellen en de 
epitheelcellen van de uitvoergangen in het speekselklierweefsel van pSS patiënten. Deze 
crosstalk kan leiden tot de formatie van LELs. 
Eerder werd er gepubliceerd dat KC in het lipbiopt een risicofactor zijn voor het 
ontwikkelen van lymfomen bij pSS patiënten. Zodoende wordt in hoofdstuk 6a een 
retrospectieve studie gepresenteerd waarin pre-lymfoom lipbiopten van pSS MALT 
lymfoom patiënten werden vergeleken met lipbiopten van een gematchte controle groep 
van pSS patiënten met een lange lymfoomvrije follow-up. De aanwezigheid van KC in 
de lipbiopten, welke waren genomen voor de initiële diagnose van pSS, verschilde niet 
tussen deze twee groepen. Het percentage van de pre-lymfoom lipbiopten waarin KC 
werden gevonden was tevens vergelijkbaar met het percentage van lipbiopten met KC in 
de algemene populatie pSS patiënten. Daarom werd geconcludeerd dat de aanwezigheid 
van KC in de lipbiopten van pSS patiënten niet voorspellend is of er in de toekomst een 
MALT lymfoom zal ontwikkelen. In hoofdstuk 6b wordt vervolgens beargumenteerd dat 
de aanwezigheid van KC in de lipbiopten een reflectie is van een hoge ziekteactiviteit 
(EULAR Sjögren’s Syndrome Disease Activity Index: ESSDAI) en niet per se leidt tot het 
ontwikkelen van een MALT-lymfoom. Ongeveer een kwart van de pSS patiënten heeft KC 
in het lipbiopt. Dit percentage is veel hoger dan het percentage patiënten (5-10%) dat 
een maligne lymfoom ontwikkeld. Als laatste, de ziekteactiviteit in pSS patiënten varieert 
met de tijd, waardoor de kans op het vinden van een KC in het speekselklierbiopt wordt 
beïnvloed. De ziekte kan (tijdelijk) opvlammen waarbij de ziekteactiviteit hoog is. De kans 
op het vinden van KC in het speekselklierbiopt kan op zo’n moment hoger zijn. 
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Deel 3: histopathologische veranderingen na behandeling met biologicals. 
Hyperactiviteit van B-cellen speelt een belangrijke rol in pSS. Het uitschakelen van B-cellen 
door middel van rituximab vormt gezien deze hyperactiviteit een logische behandelstap 
bij pSS patiënten. Rituximab grijpt aan op het eiwit CD20 dat op B-cellen zit. De binding 
van rituximab aan dit eiwit resulteert in de celdood van de B-cellen. In hoofdstuk 7a 
worden de histopathologische veranderingen in het parotisbiopt van pSS patiënten na 
behandeling met rituximab gepresenteerd. Na behandeling met rituximab neemt het 
totaal aantal van lymfocyten (CD45+), het aantal B-cellen/mm2, en de ernst en het aantal 
LELs/mm2 en KC/mm2 in het parotisparenchym af in vergelijking met de placebo groep. 
Het aantal T-cellen/mm2 parotisparenchym veranderde echter niet. Naast het aantal LELs 
nam ook de ernst van de LELs af. Dit impliceert dat de uitvoergangen in de glandula parotis 
herstellen na eliminatie van de B-cellen door rituximab. Verder was aantal CD20+ B-cellen/
mm2 parotisparenchym voor de behandeling (baseline) significant hoger in responders 
op rituximab in vergelijking met non-responders. Een responder is gedefinieerd als een 
afname in ESSDAI ≥3 punten. Met andere woorden, het aantal aanwezige B-cellen/mm2 
parotisweefsel, voorafgaand aan de behandeling, kan fungeren als indicator voor de 
respons op rituximab behandeling. Dit geeft mogelijkheden om te identificeren welke 
pSS patiënten baat hebben bij een behandeling met rituximab en welke patiënten niet. In 
de studie beschreven in hoofdstuk 7b wordt de proportie van B-cellen (B-cellen/ B-cellen 
+ T-cellen ratio) berekend in plaats van het aantal B-cellen/mm2 parotisparenchym. De 
resultaten toonden dat de klinische responders tevens significant hogere B-cel proporties 
hadden in vergelijking met de placebogroep. Met andere woorden, ook B-cel proporties 
kunnen mogelijk worden gebruikt om de respons op rituximab te voorspellen. Het gebruik 
van de SSRI (Sjögren’s Syndrome Response Index) in plaats van de ESSDAI, om responders 
van niet-responders te onderscheiden, resulteerde in een vergelijkbaar aantal B-cellen/
mm2 parenchym bij responders en non-responders. Het gebruik van verschillende 
meetmethoden (SSRI of ESSDAI) om de respons op een behandeling te meten kan 
zodoende leiden tot verschillen in uitkomsten.
Abatacept is een biologische DMARD welke de T-cel activatie remt. In hoofdstuk 8 
laten we zien dat de behandeling van pSS patiënten met abatacept resulteert in een 
afname van het aantal KC/mm2 parotisparenchym. Daarnaast was er een stijging zichtbaar 
in het aantal IgM+ plasmacellen/mm2 parotisparenchym. De focusscore, het aantal LELs/
mm2, de oppervlakte van het lymfocytaire (CD45+) infiltraat, het aantal CD21+ netwerken 
van folliculair dendritische cellen en het aantal van T-cellen en B-cellen veranderde niet. De 
afname van KC in het parotisweefsel na behandeling kan komen door de inhibitie van T-cel 
afhankelijke B-cel activatie (welke nodig is voor KC vorming). De toename in (kortlevende) 
IgM+ plasmacellen kan voortvloeien uit een T-cel onafhankelijke activatie van de B-cellen. 
De aantallen van IgA+ en IgG+ plasmacellen veranderde niet na behandeling met abatacept, 
aangezien deze cellen voor het grootste gedeelte langlevend zijn.
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Samenvattend, speekselklierbiopten spelen een belangrijke rol in het diagnosticeren en 
classificeren van pSS patiënten. Speekselklierbiopten zijn bruikbaar in het voorspellen van 
de ernst van de ziekte, het beoordelen van de effectiviteit van de gegeven behandeling 
en de stratificatie van pSS patiënten. Preciezere gestandaardiseerde en bij voorkeur 
gedigitaliseerde analyses van het speekselklierbiopt in behandelstudies kunnen tevens 
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Prof. dr. A. Vissink, beste Arjan. Binnen een paar dagen had jij gegarandeerd een 
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beoordeeld te hebben, durf ik te stellen dat wij het best gekalibreerde stel pathologen 
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